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Executive Summary 
Background  
Data holds the potential to drive rapid response and informed decision-making during public health 
emergencies. There is a need for timely and accurate collection, reporting and sharing of data within and 
between research communities, public health practitioners, clinicians and policymakers. Accurate and 
rapid availability of data will inform assessment of the severity, spread and impact of a pandemic to 
implement efficient and effective response strategies. 
The availability of efficient information and communication technology has improved the global capacity 
to implement systems to share data during a pandemic. However, the harmonisation across these 
sophisticated yet diverse systems combined with the timeliness of accessing data across information 
systems are currently major roadblocks. The World Health Organization’s (WHO) statement on data 
sharing during public health emergencies clearly summarises the need for timely sharing of preliminary 
results and research data. There is also strong support for recognising open research data as a key 
component of pandemic preparedness and response, evidenced by the 117 cross-sectoral signatories to 
the Wellcome Trust statement on 31st January 2020, and the further agreement by 30 leading publishers 
on immediate open access to COVID-19 publications and underlying data. 
The Research Data Alliance (RDA) COVID-19 Working Group (CWG) members bring varied global expertise 
to develop a body of work that comprises how data from multiple disciplines inform response to a 
pandemic combined with guidelines and recommendations on data sharing under the present COVID-19 
circumstances. This extends to research software sharing, in recognition of the key role played by software 
in analysing data. The work has been divided into four research areas (Clinical, Omics, Epidemiology, Social 
Sciences) with four cross-cutting themes (Community Participation, Indigenous Data, Legal and Ethical 
Considerations, Research Software), as a way to focus the conversations and provide an initial set of 
guidelines in a tight timeframe. The detailed guidelines are aimed to help stakeholders follow best 
practices to maximise the efficiency of their work, and to act as a blueprint for future emergencies. The 
recommendations in the document are aimed at helping policymakers and funders to maximise timely, 
quality data sharing and appropriate responses in such health emergencies.  
The CWG addressed the development of such detailed guidelines on the deposit of different data sources 
in any common data hub or platform. The guidelines aim at developing a system for data sharing in public 
health emergencies that supports scientific research and policymaking, including an overarching 
framework, common tools and processes, and principles that can be embedded in research practice. 
The guidelines address general aspects of data practice, for example the FAIR principles (that research 
outputs should be Findable, Accessible, Interoperable, and Reusable), or the adoption of research-domain 
community standards.  
There are foundational overarching challenges and recommendations that appear across the four 
research sub-groups as well as the cross-cutting themes. These foundational elements are presented in 
the summary before the area-specific challenges, recommendations and guidelines are articulated.  
Challenges  
The unprecedented spread of the virus has prompted a rapid and massive research response with a 
diversity of outputs that pose a challenge to interoperability. To make the most of global research efforts, 
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findings and data need to be shared equally rapidly, in a way that is useful and comprehensible. The 
challenge here is the trade-off between timeliness and precision. The speed of data collection and sharing 
needs to be balanced with accuracy, which takes time.  
Lack of pre-approved data sharing agreements and archaic information systems hinder rapid detection 
of emerging threats and development of an evidence-based response. While the research and data are 
abundant, multi-faceted, and globally produced, there is no universally adopted system or standard for 
collecting, documenting, and disseminating COVID-19 research outputs. Furthermore, many outputs are 
not reusable by, or useful to, different communities if they have not been sufficiently documented and 
contextualised, or appropriately licensed. Correspondingly, research software is developed and 
maintained in an ad hoc fashion. Access information for the software developed for analysis is not noted 
consistently in papers and, if the software is available, it is often placed in arbitrary locations with no 
guarantee of its persistence.  
Recommendations 
Governments, research funders, and research or research-supporting institutions around the world must 
coordinate with one another, and support and promote Open Science through policy and investment to 
streamline the flow of data between local entities, and across international jurisdictions.  
There are motivational barriers to making data outputs available rapidly. There is a need for incentivising 
the early publication/release of data outputs and the software used to produce them during a public 
health emergency. The early publication/release of data outputs and the tools used to create them should 
be encouraged by building trust, providing incentives for sharing data and providing appropriate 
governance.  
There is a need to invest in state-of-the-art information technology (IT) and data management systems 
infrastructure. The investment should also be directed towards people and skills to fully utilise the 
potential of large-scale infrastructure. The minimum required infrastructure for pandemic response in 
terms of technology, skills, people and frameworks should be accessible to all jurisdictions/sectors.  
The consensus in this series of guidelines is that research outputs should align with the FAIR principles, 
meaning that data, software, models and other outputs should be Findable, Accessible, Interoperable and 
Reusable. A balance between achieving ‘perfectly’ FAIR outputs and timely sharing is necessary with the 
key goal of immediate and open sharing as a driver. Data management plans (DMPs) should be created 
early in the research process and updated regularly to prepare for data deposit and reuse. 
The key to finding and using digital assets is metadata. COVID-19 research requires access to different 
assets for different communities. Within a given community, the commonly used metadata standards are 
well known, but a researcher working across communities has more difficulty in locating relevant assets. 
In this case a ‘metadata element set’ that is generally applicable is required to be associated with each 
asset so that they can be used under the FAIR principles. 
Research outputs need to be documented, which includes documentation of methodologies used to 
collect, define and construct data, data cleaning, data imputation, data provenance and so on. The recent 
joint statement on the Duty to Document underlines how crucial it is, especially during this time of rapid 
and unprecedented decision-making, to document decisions, and secure and preserve records and data 
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To facilitate data quality control, timely sharing and sustained access, data should be deposited in data 
repositories. Whenever possible, these should be trustworthy data repositories (TDRs) that have been 
certified, subject to rigorous governance, and committed to longer-term preservation of their data 
holdings. By providing persistent identifiers, requiring preferred formats, rich metadata, etc., certified 
trustworthy repositories already guarantee a baseline FAIRness of and sustained access to the data, as 
well as citation. 
Pre-print journals should undergo an expedited review process to balance the need to publish findings 
rapidly with the requirement to publish relevant and reliable findings. Full reports should be made 
available immediately upon communication of results, e.g. through a press release. Peer-reviewed data 
articles should be treated as first-class research outputs equal in value to traditional peer-reviewed 
articles. In order to expedite reuse, data that could be used to advance research on pandemics should be 
given top priority in the data publication process, fast-tracked by repositories, institutions, and other data 
publishers. 
The ethical and privacy considerations around participant and patient data are significant in this crisis, 
and several guidelines note the need to find a balance that takes into account individual, community and 
societal interests and benefits whilst addressing public health concerns and objectives. Access to 
individual participant data and trial documents should be as open as possible and as closed as necessary, 
to protect participant privacy and reduce the risk of data misuse.  
Technical solutions that ensure anonymisation, encryption, privacy protection, and data de-identification 
will increase trust in data sharing. The implementation of legal frameworks that promote sharing of 
surveillance data across jurisdictions and sectors would be a key strategy to address legal challenges. 
Emergency data related legislations activated during a pandemic need to clearly outline data 
custodianship/ownership, publication rights and arrangements, consent models, and permissions around 
sharing data and exemptions. 
The sub-groups and cross-cutting themes have each articulated the challenges facing researchers working 
on COVID-19, as well as recommendations/guidelines for improving data sharing (Table 1). These sub-
group guidelines and recommendations should be considered directly depending on the relevant area of 
COVID-19 research as well as policy/decision-making. 
Table 1 - Summary of challenges, guidelines and recommendations 
Sub-groups/cross 
cutting themes 




Promotion of clinical data 
sharing is important due 
to many studies and trials 
being performed under 
enormous time pressure 
Standardised clinical 
terminologies should be used 
and a fair balance achieved 
between timely data sharing 
and protecting privacy and 
confidentiality   
Measures should be 
taken in order to organise 
the sharing of data and 
trial documents in a 
suitable, trustworthy and 
secure data repository 
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Omics 
An increased need of 
rapid openness for omics 
data to gain early insights 
into molecular biology of 
the processes at cellular 
level  
Omics research should be a 
collaborative effort to learn 
the genetic determinants of 
COVID-19 susceptibility, 
severity and outcomes 
Promote use of domain-
specific repositories to 
enable standardisation of 
terms and enforce 
metadata standards  
Epidemiology 
Data and models are 
frequently incomplete, 
provisional, and subject to 
correction under changing 
conditions 
Data models must include 
clinical data, disease 
milestones, indicators and 
reporting data, contact 
tracing and personal risk 
factors 
Incentivise the publication 
of situational data, 
analytical models, 
scientific findings, and 
reports used in decision-
making  
Social Sciences 
Require equal inclusion of 
social and economic 
context with health-
related information to 
enable evidence-based 
decision-making   
Enable interoperable cross-
disciplinary and cross-
cultural data collection, data 
use and collaboration for 
managing social sciences 
data during pandemics  
Ensure robust funding 
streams for social 
sciences research for 
understanding and 
managing the human 
aspects of pandemics  
Community 
Need specific guidelines 
for enabling citizen 
scientists undertaking 
research to contribute to 
a common body of 
knowledge  
Encourage public and patient 
involvement (PPI) 
throughout the data 
management lifecycle from 
research question to final 
data sharing and usage 
Balance between timely 
testing and contact 
tracing, emergency 
response, community 




Indigenous data rights, 
priorities and interests 
must be recognised in all 
COVID-19 research and 
surveillance activities 
Indigenous governance of 
data collection, ownership, 
sharing and use priorities is 
the central principle of 
Indigenous data sovereignty 
CARE Principles of 
Indigenous Data 
Governance set minimum 
standards for collectors, 
users and stewards of 
data 
Legal and Ethical 
Considerations 
Achieve a balance 
between rights of people 
and interests of 
researchers and 
policymakers  
Ethical instruments should 
be interpreted with the law, 
and can guide the 
interpretation of the law if 
the law does not address a 
particular issue 
During a pandemic, 
ethical review and 
approval for legally 




Need systems in place for 
sharing of research 
software and accelerated 
and reproducible research 
during a pandemic 
It is critical for software that 
is used in data analysis to 
produce results that can, if 
necessary, be reproduced 
Funders must allocate 
financial resources to 
support the development 
and maintenance of new 
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1. Objectives and Use of This Document 
The objectives of the RDA COVID-19 Working Group (CWG) are: 
1. to clearly define detailed guidelines on data and software sharing under the present COVID-19 
circumstances to help stakeholders follow best practices to maximise the efficiency of their work, 
and to act as a blueprint for future emergencies; 
2. to develop recommendations for policymakers to maximise timely, quality data and software 
sharing and appropriate responses in such health emergencies; 
3. to address the interests of researchers, policymakers, funders, publishers, and providers of data 
sharing infrastructures. 
It is important to note that in this document the terms guidelines and recommendations are distinguished 
as follows. A guideline provides detailed advice pertaining to the practice of research data and software 
sharing. As a consequence, guidelines are aimed at researchers, data stewards, research software 
engineers and public health officials. A recommendation provides higher level and more generic advice. 
As a consequence, recommendations are aimed at other important stakeholder groups such as 
policymakers, funders, publishers and infrastructure providers. 
 
Figure 1 - RDA COVID-19 WG sub-groups including research areas and cross-cutting themes 
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The CWG is addressing the development of detailed guidelines on the deposit of different data sources in 
any common data hub or platform. The guidelines aim at developing a system for data sharing in public 
health emergencies that supports scientific research and policymaking, including an overarching 
framework, common tools and processes, and principles that can be embedded in research practice. The 
guidelines contained herein address general aspects that data should adhere to, for example the FAIR 
principles (that research outputs should be Findable, Accessible, Interoperable, and Reusable), or the 
adoption of research domain community standards. At the same time, they also provide a tool which 
could help researchers and data stewards to determine the standards for what is ‘good enough’ when 
there is significant value to sharing research outputs as quickly as possible.  
These detailed guidelines are supplemented with higher level recommendations aimed at the other 
stakeholder groups who need to work together with researchers, data stewards and research software 
engineers to realise the timely and open sharing of research data and software as a key component of 
pandemic preparedness and response. 
The work has been divided into four research areas with four cross-cutting themes, as a way to focus the 
conversations, and provide an initial set of guidelines in a tight timeframe.  
The RDA COVID-19 WG was initiated after a conversation between the RDA and the European 
Commission. The first meeting of the CWG to determine the work was held in March 2020. As of June 
2020, the CWG counted over 440 members spread across the different sub-groups. This effort also reflects 
the work of a host of other RDA Working Groups, as well as external stakeholder organisations, including 
the Global Indigenous Data Alliance and the Research Software Alliance.  
The CWG and the sub-groups operate according to the RDA guiding principles of Openness, Consensus, 
Balance, Harmonisation, Community-driven, Non-profit, and Technology-neutral, and are open to all. 
The aims of the CWG align with recent statements made by other international organisations promoting 
rapid and efficient sharing of data during the pandemic. The World Health Organization’s (WHO) 
statement on data sharing during public health emergencies clearly summarises the need for timely 
sharing of preliminary results and research data. There is also strong support for recognising open 
research data as a key component of pandemic preparedness and response, evidenced by the 117 cross-
sectoral signatories to the Wellcome Trust statement on 31st January 2020, and the further agreement 
by 30 leading publishers on immediate open access to COVID-19 publications and underlying data. There 
are many initiatives developing in different communities to facilitate COVID-19 data sharing. For example, 
one could look to CoronaWhy - a globally distributed, volunteer-powered research community aimed at  
answering key questions related to COVID-19. CoronaWhy is applying recent advances in natural language 
processing, data mining, machine learning and other Artificial Intelligence technologies, building a 
horizontal data management platform following the best FAIR practices and facilitating the collaboration 
between different research communities from various countries.  
This document starts in Section 2 with an overview of foundational, overarching elements that emerged 
across the different research areas. These recommendations touch upon a number of topics well known 
to those working in research data sharing. The focus of Sections 3 to 6 is on the COVID-19 related research 
areas. Each section starts with a description of the area and the focus and scope of the work, followed by 
the actual recommendations and guidelines. In sections 7 to 10 this same structure is used for the four 
cross-cutting themes. The document contains an extended glossary of terms and acronyms to support the 
reader (Sections 11 and 12, respectively), an overview of useful additional resources (Section 13) and a 
list of references (Section 14). Note as well that the RDA-COVID19 working group Zotero Library has been 
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published to support these Recommendations and Guidelines. Section 15 lists the contributors to this 
work. 
The Research Data Alliance understands that this document is lengthy and may well challenge busy 
researchers to find the specifics that most apply to them. Please see the working group page for an 
Executive Summary, and visual aids for navigating the document.  Please cite this document if you find it 
useful, as this will help to disseminate the recommendations and guidelines: RDA COVID-19 Working 
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2. Foundational Elements 
Specific challenges facing researchers working on COVID-19 from different research areas have been 
articulated throughout this document, as well as recommendations and guidelines for improving data 
sharing in these areas. These recommendations and guidelines should be considered directly depending 
on the relevant area of COVID-19 research. However, certain common or key aspects appear across 
different research areas. These are presented here as foundational elements.  
2.1 Challenges 
The availability of research data is a key component of pandemic preparedness and response. The 
timeliness of accessing data and the harmonisation across information systems are currently major 
roadblocks. 
Critical Need for Data Sharing 
The unprecedented spread of the virus has prompted a rapid and massive research response. To make 
the most of global research efforts, findings and data need to be shared equally rapidly, in a way that is 
useful and comprehensible. Raw data, algorithms, workflows, models, software and so on are required 
inputs to research studies and are essential to the scientific discovery process itself. New findings and 
understandings need to be disseminated and built upon at a pace that is faster than usual; due to decisions 
being taken by healthcare practitioners and governments on a daily basis, it is crucial that they are well-
informed. 
The rapid pace of the disease and the immense and rapid mobilisation of resources could create an 
environment for inaccurate or low-quality data, which could have considerable implications. Shortcuts 
with the interpretation of data can, for example, create issues such as the early debate on the severity, 
transmissibility and global spread of COVID-19.  
The obligation to share data could orient at least some institutions to reduce testing (only confirmed, not 
suspected, cases “count” and hence reducing testing allows for a lower number of confirmed cases, 
creating the illusion that the epidemic is under control).  
And in some cases, a lack of transparency and publication of false or unchecked numbers is perhaps worse 
than no publication at all. 
The COVID-19 pandemic has revealed how interconnected we are globally, and how interdependent we 
are in terms of research, public health and economy. Data in relation to this pandemic is being collected 
and created at a high velocity, and it is critical that we can share this data across cultural, sectorial, 
jurisdictional, and disciplinary boundaries.  
The challenge here is the trade-off between timeliness and precision. The speed of data collection and 
sharing needs to be balanced with accuracy, which takes time. The pressure to interpret results, turn 
studies around quickly and update statistics in almost real-time must not compromise quality and 
reliability. There is no overarching formula for finding that balance, but documented transparency in the 
research process and decisions taken can help to mitigate the dangers associated with working at hyper 
speed. 
Lack of Harmonised Standards and Context 
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Emerging infections are largely unpredictable in nature and there are limited data to support disease 
investigation. The evidence base generated from early outbreak data is critical to inform rapid response 
during an emerging pandemic. Lack of pre-approved data sharing agreements and archaic information 
systems hinder rapid detection of emerging threats and development of an evidence-based response. 
While the research and data are abundant, multi-faceted, and globally produced, there is no universally 
adopted system, or standard, for collecting, documenting and disseminating COVID-19 research outputs. 
Furthermore, many outputs are not reusable by, or useful to, different communities if they have not been 
sufficiently documented and contextualised, or appropriately licensed. There is an urgent need for data 
to be shared with minimal contextual information and harmonised metadata so that they can be reused 
and built upon (see the OECD Open Science Policy Brief). 
2.2 Recommendations 
2.2.1 Coordinated, Cross-jurisdictional Efforts to Foster Global Open Science 
The COVID-19 pandemic has had, in a very short time, an unprecedented global impact on health, 
economies, and daily life. It has underlined the importance of open science practices and demonstrated 
clearly how different jurisdictions require the policies and support to collaborate with and build research 
efforts across political, geographical, and disciplinary boundaries. In addition to sharing the response 
effort, effective cross-national comparisons can provide useful insights for the development of future 
global emergency preparedness programmes.  
Governments, research funders, and research or research-supporting institutions around the world must 
coordinate with one another, support and promote Open Science through policy and investment to 
streamline the flow of data between local entities, and across international jurisdictions. Systemic 
investment in and support for Open Science must be developed rapidly and sustainably to face both our 
current pandemic and future public health emergencies. 
Coordination includes such efforts as urgently updating data sharing policies and Memoranda of 
Understanding (MOUs) across all domains in government, healthcare systems, and research institutions 
to support Open Data, Open Science, scientific data modernisation, and linked data life cycles that will 
enable rapid and credible scientific discovery, and fast-track decision-making. International organisations 
and alliances such as the World Health Organization, the OECD, the International Science Council, UNESCO 
and the Research Data Alliance, to name a few, provide avenues for this coordination. We also call on the 
international Open Government Partnership (OGP) to add “Open Science” as one of its Policy Areas (OGP, 
2020a). 
Similarly, governments, funders and policymakers should engage with big technology companies, mobile 
network operators, social network companies and others in the private sector who hold data that can 
better help understand the pandemic and population behaviour. Data sharing policies should be adopted 
to encourage and facilitate data flows from data holders to the research community with the goal of 
protecting citizens' rights and health (de Pedraza et al., 2019; Askitas, 2018). 
There is a need for incentivising the early publication/release of data outputs during a public health 
emergency, because there are motivational barriers to making data outputs available rapidly and before 
primary papers have been written or published. Data publication should be encouraged by building trust 
and providing incentives and credit for preparing and sharing data and providing appropriate governance. 
It is important to foster collaboration under agreements that clearly describe how the data will be used 
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(e.g. only for early investigation of pandemic, surveillance or research and not for publication without 
consent and/or credit), with whom the data will be shared, and the value of sharing data for informing 
response during an emergency. Initiatives to support rewards and credits for data sharing should be 
strengthened. See RDA Sharing Rewards and Credit (SHARC) IG (Research Data Alliance) and FORCE 11 
“Joint declaration of data citation principles” (Data Citation Synthesis Group, 2014). Correspondingly, 
research software should be made available in code repositories that enable feedback from the research 
community, and archival repositories which can then be referenced with persistent identifiers. 
Research institutions and funding agencies can incentivise data stewardship, research software 
engineering data and software sharing by creating structures for researchers to get credit for this work 
and by providing support for publishing data and software as valid research outputs. This can include 
developing research assessment systems that reward data and software outputs alongside publications 
and other research objects. Policymakers should put guidelines into place that give researchers ease of 
mind when licensing/sharing their data. All research data based on public research funding should be 
made available and exploitable in a timely manner, in particular for those of critical interest during an 
emergency situation. From a funding agency perspective, this could mean that increased weighting is 
given in the grant review process to researchers who demonstrate best practice in open data and data 
reproducibility with respect to their research outputs. 
2.2.2 Infrastructure Investment & Economies of Scale 
Support for Open Science requires investment in infrastructure so governments, funders and institutions 
should therefore fund state-of-the-art information technology (IT) and data management infrastructure, 
which includes hardware, networks, and the development and maintenance of critical research software. 
Investment should also be directed towards the human resources required to maintain the infrastructure, 
and the training and support required to fully utilise the potential of large-scale infrastructure.   
In general, new infrastructure should harness the value of existing infrastructure, building on what is 
already working well. Economies of scale should be considered when planning institutional, disciplinary, 
sector-wide, or regional/national infrastructure to reduce overlap, encourage collaboration, and 
maximise return on investment. In the case of limited resource settings, the use of existing data 
management infrastructure should be leveraged to prioritise and support pandemic research response. 
Research institutions can provide granular, tiered access to restricted data by appropriately authorised 
and credentialed users and machines, based on roles and needs. Data storage policies should follow 
recommendations regarding regular backup in multiple locations. There should be priority access to 
resources for researchers/practitioners working on response during a public health emergency. The 
research community’s ability to apply best practices for research software, including training in software 
development concepts is to be encouraged. 
The investment in infrastructure, analytical skills and resources for data management should be carried 
out in an equitable manner. Some jurisdictions/sectors making significant contributions towards the 
evidence base for pandemic response may not have access to state-of-the art information technology and 
resources. The minimum required infrastructure for pandemic response in terms of technology, 
interoperability, skills, people and frameworks should be accessible to all jurisdictions/sectors. 
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2.2.3 FAIR and Timely  
The consensus in this series of guidelines and recommendations is that research outputs should align with 
the FAIR principles, meaning that data, software, models and other outputs should be Findable, 
Accessible, Interoperable and Reusable. The FAIR principles (Wilkinson et al., 2016) address a primary 
concern that has led to the formation of the group writing these guidelines: availability and reusability of 
research data on COVID-19 in order to prevent unnecessary duplication of work. Many of the specific 
guidelines in this document address what can be done to make the data as FAIR as possible with a 
reasonable time investment. 
However, there is also consensus that outputs need to be shared as quickly as possible in order to have a 
direct impact on the progress of the pandemic. A balance between achieving perfect outputs and timely 
sharing is necessary, with the key goal of immediate and open sharing as a driver. Researchers should be 
paired with data stewards to facilitate FAIR sharing, and data management should be considered at the 
start of a study or trial. FAIRifying data saves valuable time, as it facilitates a level of trustworthiness in 
research outputs. 
Researchers should also be encouraged to share what they have as-is without fear of it being insufficient, 
and signal that help is needed. The reusability of data can be increased with consistent preprocessing: to 
increase the availability of data ready for analysis and integration, it may be prudent to agree on a 
consistent approach to preprocessing data. This would be a second-phase step that should not 
unnecessarily slow down researchers collecting data. 
In the COVID-19 situation access to data should be as open as possible. This does not necessarily mean 
completely open access, as data must also be protected as necessary, but measures to control and 
manage risk (e.g. encryption, anonymisation, de-identification, aggregation, data use agreements) can be 
used to ease authorised access as much as possible, while still offering adequate protections. If a Data 
Access Board or a similar third-party mechanism is involved in decisions about data sharing, there is a 
need for a transparent and fast track process. Immediate access with licences that are as open as possible 
is desirable, but effort should be put into the quality and documentation of the dataset. 
Finally, it is important to note that a lot of data that are very relevant to the pandemic are kept exclusively 
on websites and are therefore extremely fragile. This data should be deposited in TDRs, but to address 
existing gaps, the websites should be web-archived systematically (and permit doing so by way of their 
robots.txt), so as to ensure persistent availability of the information and to facilitate retrospective 
analyses. Preference should be given to public web archives that are created and stored by archival 
organisations. 
2.2.4 Data Management Planning 
Sharing data in a FAIR and timely way requires planning for data management early in the process of any 
research undertaking. As funding agencies make use of rapid funding mechanisms (e.g. administrative 
supplements, fast-track projects), it should not be at the expense of requiring Data Management Plans 
and ensuring data are sharable.  
Researchers should create a Data Management Plan (DMP) at the beginning of the research process so 
that it can be included in the work plan and the budget. The DMP is a “living” document, which may 
change over the course of a project, and it should be updated regularly to ensure data are managed 
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throughout the research lifecycle. Projects already underway that might contribute data to address 
COVID-19 should update their DMPs to ensure alignment with current recommendations.  
DMPs devise how existing data will be used, how new data will be stored, documented and quality 
controlled, (and any issues around the handling of sensitive data, legal and ethical issues), and how and 
where the data will be shared and preserved. DMPs should also identify the human and financial resources 
required for data management activities.  
Researchers should contact, where possible, institutional support services (e.g. library staff), the 
repository of their choice, or other research infrastructure providers which may offer guidelines for the 
DMPs in advance of deposit. Working with a dedicated data steward can significantly affect the maturity 
of this process, and funders and institutions should be encouraged to provide support and recognition for 
data stewardship roles and contributions. 
All parties with responsibility for activities across the research lifecycle - not just the researcher - have a 
part to play in ensuring good quality data that are safeguarded so they can be located, understood, and 
effectively used and reused. Roles and responsibilities should be considered early (ideally at the data 
planning phase) and be clearly defined and documented in the DMP. A common understanding of how 
data will be managed is particularly important in collaborative projects that involve many researchers, 
institutions and groups with different ways of working.  
2.2.5 Metadata 
The key to finding and using digital assets is metadata. Several of the FAIR principles also call for rich 
metadata. COVID-19 research requires access to different assets for different communities. Within a given 
community, the commonly used metadata standards are well-known, but a researcher working across 
communities has more difficulty in locating relevant assets.  
In this case, a generally applicable ‘metadata element set’ is required to be associated with each asset so 
that they can be used under the FAIR principles. A proposed metadata element set is available on the RDA 
Metadata Interest Group page. At present there are four generic metadata standards that are used widely: 
Dublin Core (DC), Data Catalog Vocabulary (DCAT), DataCite and Schema.org. The latter has a 
specialisation called Bioschemas which provides a way to add semantic markup to web pages for improved 
findability of data in the life sciences, and is currently updating profiles to aid in discovery of COVID-19 
data. A simple but key recommendation, noted in the COAR recommendations for COVID-19 resources in 
repositories, is to add the keyword tag “COVID-19” under subject. Metadata for research software is also 
essential for its reuse and to enable reproducibility.  
Providing FAIR access to assets would be much enhanced if assets had metadata encoded in one of these 
standards – as well as in the metadata standard(s) used by the particular community. It is to be hoped 
that in the future, richer generic metadata standards will be used. For a longer registry of metadata 
standards, see the Metadata Standards Catalog or the RDA-endorsed FAIRsharing (in the ‘Standards’ 
section). 
Especially where data about human subjects is concerned, it is not always possible to share such metadata 
in an open catalogue. Specifics can be found in guidelines for the individual data types as well as in the 
section on legal and ethical considerations. 
Providers of data sharing infrastructures should perform validation that data complies to recommended 
metadata/annotation standards in order to help researchers make their data as FAIR as possible. 
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The use of these standards for machine-to-machine communication depends on how they are 
implemented. Many DC implementations are in text, HTML or XML form and used more easily by human 
readability than machine understandability. More recent implementations use Resource Description 
Framework (RDF) which does provide machine-to-machine capability. Earlier DCAT implementations used 
XML, more recent implementations use RDF. DataCite uses XML but also schema.org metadata format 
and JSON-LD, while Schema.org uses RDF and JSON-LD. Thus, these metadata standards encourage 
machine-to-machine interoperation. 
Metadata has two aspects: syntax and semantics. The syntax defines the structure of the metadata 
information and should conform to a formal grammar. The semantics defines the meaning of strings of 
characters – usually through an associated ontology – and should be declared. Again, there are generic 
ontologies (or vocabularies which have less detail on relationships between the terms) and community-
specific ontologies (or vocabularies). 
Critical in the current situation is to have datasets easily findable. Resolvable persistent identifiers like 
Digital Object Identifiers (DOIs), e.g. linking to a repository or network of repositories, would play a large 
part in making the data available. Persistent identifiers for primary data sources should be included as a 
rule in secondary analyses to recognise primary data providers, and this should be requested by publishers 
and editors. 
2.2.6 Documentation 
Research outputs need to be well documented, which includes documenting the following: research 
context, methodologies used to define, construct, and compile data, data cleaning and quality checks, 
data imputation, data provenance and so on. 
When sharing datasets, other relevant outputs (or documents) should also be made available, such as 
codebooks, lab journals, or informed consent form templates, so that data can be understood and 
potentially linked with other data sources. Reusability of data requires documented provenance: when 
sharing any secondary data, the generation of which involves comparison against other resources, both 
the public availability of these used resources and unambiguous referencing of the used resources, 
including version numbers, should be ensured. It is also useful to document the computing time and 
resources required for data processing. This could help other researchers to assess the resources required 
for the computation and help them to decide whether it is feasible to proceed with the local resources 
available. 
Software should provide documentation that describes at least the libraries, algorithms, assumptions and 
parameters used and software licences or other terms of use. 
The recent joint statement on the Duty to Document underlines how crucial it is, especially during this 
time of rapid and unprecedented decision-making, to document decisions, and secure and preserve 
records and data for the future (International Council on Archives et al., 2020). 
2.2.7 Use of Trustworthy Data Repositories 
To facilitate data quality control, timely sharing and sustained access, data should be deposited in data 
repositories. Whenever possible, these should be trustworthy data repositories (TDRs) that have been 
certified, subject to rigorous governance, and committed to the long-term preservation and sustained 
access of their data holdings. Software should be made available in appropriate repositories.  
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Examples of widely adopted certifications are CoreTrustSeal (CoreTrustSeal), nestor Seal for Trustworthy 
Digital Archives (nestor) and ISO 16363 (PTAB). Repositories certified by CoreTrustSeal, a result of the RDA 
Repository Audit and Certification DSA–WDS Partnership WG are listed here. The underlying community-
based TRUST principles (Lin et al., 2020) should also be considered.   
As the first choice, widely used disciplinary repositories are recommended for maximum accessibility and 
assessability of the data, as well as repositories that are part of research infrastructures (e.g. CESSDA, 
ELIXIR, and others), as this also ensures maximum cross-border visibility. These are followed by general 
or institutional repositories. Using existing open repositories is better than starting new resources.  
Making data available in existing and certified repositories will increase the FAIRness of the data. 
Trustworthy data repositories provide key metadata associated with its datasets, optimally utilising a 
metadata standard that allows for interoperability. They also employ tools such as persistent identifiers 
for discovering and citing the data, as well as mechanisms for linking data and other research objects. The 
re3data.org and the RDA-endorsed FAIRsharing registries can be consulted to find an appropriate 
repository.  
Finally, it is important that policymakers, funders and publishers also promote the use of trustworthy data 
repositories in their national and institutional policies, calls and data availability policies. 
2.2.8 Publications / Data Publications 
Rapid publication, i.e. via pre-print repositories or before peer review is possible, along with other forms 
of knowledge sharing and exchange should be encouraged. Similarly, journals should undergo an 
expedited review process for pandemic related research. There remains of course the need to balance 
the rapid dissemination of findings with the dissemination of reliable findings. Full reports should be made 
openly available immediately upon communication of results, e.g. through a press release. 
Research funders and policymakers should implement a “data/software first” publication policy by 
encouraging the publication of data and software articles in “open” peer-reviewed data journals, or 
mandating and supporting the deposit of data and associated software in a trustworthy data repository 
in tandem with the publication of articles. Curated datasets and software, peer-reviewed data and 
software articles should be treated as first-class research outputs equal in value to traditional peer-
reviewed articles.  
Funders need to make sure that calls for projects clearly state that for COVID-19 data “timely” publication 
means “as soon as possible after it has been collected” and not “as soon as the publication has been 
accepted by the journal”. Publishers need to require publishing of the data, software and code underlying 
a study, in an even more timely manner than usual. Publishers should actively recommend publishing of 
data in trustworthy domain-specific repositories where findability is better than in generic or institutional 
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3. Data Sharing in Clinical Medicine 
3.1 Focus and Description 
Health care measures and clinical research are at the forefront of combating the COVID-19 pandemic. 
Promotion of clinical data sharing is of utmost importance because many studies and trials are performed 
under enormous time pressure, with weaknesses in the methodology (e.g. no control) and preliminary 
results published without any review. Sharing of data, and related documentation (e.g. protocols) will 
reduce duplication of effort and improve trial design, when many similar studies are being planned or 
implemented in different countries (Sharing and re-use of individual participant data from clinical trials: 
principles and recommendations, BMJ Open 2017). Clinical data outside clinical trials (e.g. case studies, 
descriptive cohorts of patients, etc.) may also be of high value and should be reported.   
3.2 Scope 
The work highlighted in the Clinical section centres on obtaining consent to address future use of data, 
conducting clinical trials, sharing the different types of clinical information (personal and health data), and 
ensuring that results are shared and reused in a trustworthy and efficient manner. Ethics, legal and equity 
related recommendations are fundamental and applicable to clinical data. However, they can be found in 
the section on legal and ethical considerations and in other parts of this document. 
3.3 Policy Recommendations 
3.3.1 Trustworthy Sources of Clinical Data 
During a pandemic like COVID-19, it is important to concentrate efforts on scrutinising reliable data 
sources that provide data and metadata of high quality and guarantee the authenticity and integrity of 
the information. The recommendations are: 
1. Measures should be taken in order to organise the transferral of data and trial documents to a 
suitable and secure data repository to help ensure that the data are properly prepared, available 
in the longer term, stored securely (with respect to access control, confidentiality, and integrity) 
and subject to rigorous governance. Repositories that explicitly support data sharing for COVID-
19 trials should be announced. 
2. Trustworthy repositories should be leveraged as a vital resource for providing access to and 
supporting the depositing of research data. However, as an emerging and evolving area in 
biomedical domains, trustworthiness assessment should not be limited to certification or 
accreditation (Consultative Committee for Space Data Systems, 2011; CoreTrustSeal Standards 
and Certification Board, 2019). A wide range of community-based standardised quality criteria, 
best practices, and principles (e.g. TRUST Principles (Lin et al., 2020)) should also be considered.   
3. If analysis environments that allow in situ analysis of datasets are available, but prevent 
downloads, they should be provided to the end-user researchers in a pandemic situation, without 
fees if possible. 
4. Tools allowing different datasets from different repositories to be analysed together on a 
temporary basis should be provided. 
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5. Adequate tools should be implemented for collection and analysis of reliable real-world data on 
drugs approved for the treatment of COVID-19. 
6. Sharing of preclinical data would speed-up the validation of new tools, leading to an update of 
the current preclinical testing standards used by the pharmaceutical industry. However the 
reproducibility of preclinical data is a matter of concern (Raimondi et al., 2020). 
Data Standards 
Using relevant data and metadata standards for clinical data will allow and support the consistent access 
to and reliable exchange of data from COVID-19 clinical research and case reporting. 
1. More support is needed for academic researchers to apply the relevant standards (a 'simplified 
CDISC' for COVID-19 may be useful); this should be a priority for funders and institutions. 
2. In the current situation, standards related to data sharing around COVID-19 clinical research and 
case reporting should be made accessible without licensing fees. Openness should become the 
rule in pandemic situations. 
3. Multi-centre and/or multi-country studies, including a sample size calculation according to the 
primary objective, should be recommended to generate sound evidence on COVID-19 treatments. 
Policymakers and funders should act so that priority is given to such trials for quickly achieving 
results. Collaborative trials and multi-arm studies comparing different interventions are advisable. 
4. Heterogeneity between registries regarding the number of studies listed and the information 
available for individual studies should be overcome through a dialogue among different platforms. 
FAIR Data 
Discoverability and metadata are important elements to optimise sharing and accelerate data use.  
1. Tools should be developed to enable regular harvesting of metadata objects from clinical trials, 
allowing identification of trials and all related data objects (e.g. protocol, dataset, a summary of 
results, publication, data management plan) through one portal (e.g. ECRIN: Clinical Research 
Metadata Repository (European Clinical Research Infrastructure Network). 
2. For COVID-19 a variety of study designs is applied, covering interventional trials, observational 
studies, cohorts and registries. Metadata schemas between these study types should be aligned 
to improve discoverability of studies and associated data objects. 
Protection of Trial Participants 
1. Due to the pressure to rapidly publish and make data available, there may be a greater risk of data 
not being properly prepared prior to data sharing. Regardless of the pressure, measures to protect 
privacy and prevent the risk of re-identification is paramount (e.g. specific data use agreements). 
For public health emergency situations, some legislation (e.g. GDPR Article 9 (Vollmer, 2018)) 
contains emergency provisions on processing of sensitive personal information in the area of 
public health, but even in this situation, the standard of protection of this data still requires 
safeguarding the rights and freedoms of the data subjects. This information should be available 
centrally on a government web page with explicit authority. 
Informed Consent for Data Sharing 
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1. Data and clinical trial information should be made available for broad sharing when possible. 
2. Where real-world data are collected from patient registries or similar data sources not involving 
specific consent to participate, patients’ privacy must be adequately protected (Access Now, 
2020). 
Publications and Other Formats 
Availability for timely publication of results - even for negative and withdrawn studies - and for data 
underlying a publication should be declared by investigators and sponsors at the time of study registration 
and included in the study documents (e.g. protocol, patient information and consent form). However, in 
the COVID-19 crisis, publication cannot be the criterion for data sharing. Timely data sharing should be 
performed as soon as the study is completed (Birney et al., 2009). 
Biological Samples as Data Sources       
1. In the context of a pandemic, access to biological samples that are data sources might be of high 
interest and policies should be in place for facilitating their access; they should be developed in 
full respect of legal and safety regulations, protection of patients, and with recognition of the 
value of the work performed to constitute such collections with relevant metadata and in line 
with the General Data Protection Regulation (GDPR) provisions on biobanking (Staunton et al., 
2019). 
2. Main principles are delineated in the Access policy of BBMRI-ERIC, the European Research 
Infrastructure Consortium for Biobanking and Biomolecular Resources (BBMRI-ERIC, 2020).  
Rights, Types and Management of Access 
In order to expedite the process of data sharing, standardised agreements for sharing of data between 
data providers, repositories and data requestors for COVID-19 clinical trials should be developed and 
implemented (e.g. data transfer agreements, data access and data use agreements). 
3.4 Guidelines 
3.4.1 Data and Metadata Standards for Clinical Data 
1. Widely accepted data and metadata standards should be applied in COVID-19 studies and case 
reporting. Among the various standards for consistently defining, coding and reporting data from 
clinical research and case reports, those from the Clinical Data Interchange Standards Consortium 
(CDISC, 2020a) and, especially for exchanging electronic health records (EHR), HL7 FHIR (Fast 
Healthcare Interoperability Resources) are particularly encouraged to be considered for ensuring 
data interoperability. Clinical trials, case reports and public health studies should put the CDISC 
Interim User Guide for COVID-19 (CDISC, 2020b) into consideration. For computational tools used 
in the clinical research and case reporting, the application of COVID-19 specific FHIR profiles are 
recommended, if available. For cases where CDISC and HL7 standards are not applicable or 
feasible, there are alternatives, especially for academic teams. Standardised clinical terminologies 
and ontologies should be used to describe the semantic content of the data and corresponding 
metadata, e.g. International Classification of Diseases (ICD) (World Health Organization, 2018),  
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Systematised Nomenclature of Medicine Clinical Terms (SNOMED CT) and LOINC (Logical 
Observation Identifiers Names and Codes). This ensures unambiguous interpretation (by both 
humans and computer algorithms) of the used terms describing the data and its elements. 
SNOMED CT and ICD-10 were both extended by specific terms corresponding to COVID-19 and 
special use codes were developed for LOINC that can be accessed as pre-release terms.  
3.4.2 Clinical Trials on COVID-19 
Clinical trials are an important research area to discover and make available safe and effective treatments 
for COVID-19. International, national, and regional networks exist for clinical trials. Specific resources were 
also made available to guide clinical trials in COVID-19. Specific recommendations on registering, 
performing, and sharing ongoing clinical research are the following: 
1. Lawful fast track approval procedures of clinical trials in cases of public health emergencies exist 
that speed up processes while adequately protecting individual rights. Platforms that point to 
them in the various national and international institutions should be further developed and 
administrations should apply them diligently and transparently.  
2. Clinical trials in COVID-19 should be registered at or before the time of first patient enrolment 
and protocols published in order to favour harmonisation of studies, collaboration among centres, 
as well as to avoid duplication of efforts. 
3. Individual participant data sharing should be based on broad consent by trial participants (or if 
applicable by their legal representatives) to the sharing and secondary reuse of their data for 
scientific purposes, according to applicable laws, regulations, and policies. 
4. Procedures on data sharing specific for COVID-19 in the informed consent for clinical trials should 
be in accordance with standards and recommendations (e.g. ISO/TS 17975:2015 Health 
informatics: Principles and data requirements for consent in the Collection, Use or Disclosure of 
personal health information) (International Organization for Standardization, 2015) or the Global 
Alliance for Genomics and Health (GA4GH) Consent Policy (Global Alliance for Genomics and 
Health, 2019). 
5. Clinical data and clinical trial information should be done using appropriate reporting guidelines 
(see EQUATOR Network guidelines and FAIR Sharing Registry). 
6. Multi-centre and/or multi-country studies, including a sample size calculation according to the 
primary objective, should be performed to generate sound evidence on COVID-19 treatments. 
Collaborative trials and multi-arm studies comparing different interventions are advisable. 
7. Protocols should follow standard criteria for data collection, stratification of the randomised 
population, type of intervention and comparator, a minimal set of primary outcome measures 
(e.g. SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials) and adhere to 
FAIR data principles. 
8. When regulatory bodies allow compassionate use of approved repurposed drugs, such a use 
should be reported; if a fast track for approval of proved COVID-19 drugs exists, it is also useful to 
report it. Adaptive study designs and post-authorisation efficacy and safety studies, after 
exceptional or conditional approval, should be planned with sponsors in order to favour early 
access of severe patients to promising medicines. 
9. Pre-print publishing and other forms of knowledge sharing and exchange are important to 
accelerate timely circulation of information. 
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3.4.3 Immunological, Imaging and Healthcare Data 
COVID-19 clinical trials and clinical data of patients infected by SARS-CoV-2 represent valuable information 
for better knowledge and management of this pandemic. The important elements of such data are clinical 
presentation and evolution, diagnostic and prognostic data including immunological data, virology test 
results and imaging, especially lung scan in case of respiratory distress.  
All values for metadata and assay results should be defined with the use of domain specific controlled 
vocabularies. These data standards are recommended for the following data types: 
1. Flow Cytometry (FACS) and Mass Cytometry (CyTOF) Experiments for ImmunoPhenotyping 
Minimal information on flow cytometric data should be provided via the MiFlowCyt minimal standard (Lee 
et al., 2008). Raw data should be provided in the standardised .fcs format (Spidlen et al., 2010). The 
primary cytometry data in .fcs format is greatly enhanced by the inclusion of interpreted data (e.g. the 
cell population name, definition and frequency) (Dunn, 2020a).  
Cell population names should be the standard name from a curated reference source (e.g. Cell Ontology).  
Use of standardised cell population names in flow cytometry and CyTOF experiments improves the ability 
to compare datasets. 
Cell population definitions are based on the biomarker expression pattern or ‘gating strategy’. Biomarker 
names, when the biomarker is a monoclonal antibody, should use the antibody’s antigen name from 
Protein Ontology, UniProt, or ChEBI. Cell population frequency units should be defined.  Inclusion of the 
monoclonal antibody’s clone name enhances the confidence that this crucial assay reagent is the same 
across datasets. Gating information should be provided using Gating-ML (Spidlen et al., 2015). 
2. Chemokine and Cytokine Measurements (e.g. ELISA, Luminex xMAP, MBAA) 
Chemokine and cytokine assay methods are often based on monoclonal antibodies and findability and 
interoperability is facilitated by standardised naming of the antibody’s antigen (e.g. Protein Ontology, 
UniProt, ChEBI), the antibody detector, the antibody’s clone name and the vendor. Data standards and 
deposition guides are available (Dunn, 2020b). 
3. Neutralising Antibody Titer 
Standardised names for viral targets using reference sources (e.g. National Center for Biotechnology 
Information [NCBI] Taxonomy) is recommended.  Description of the neutralising antibody type (e.g. IgM,  
IgG) and detector enhances interoperability. 
4. Virus Presence and Titer 
Standardised names using reference sources (e.g. NCBI Taxonomy) for measurement of virus presence is 
recommended. 
5. Imaging Data 
Standards for medical images and interoperability protocols such as those described in the work of 
(Persons et al., 2020) should be applied.  Digital Imaging and Communications in Medicine (DICOM) 
(DICOM Standards Committee)— is the international standard for medical images and related information 
that is universally adopted by almost all of the leading vendors of medical imaging equipment and 
software. Most relevant to COVID-19 is that virtually all clinical chest X-ray, lung CT, and brain/neuro MRI, 
and many ultrasound imaging systems follow the DICOM standard, which defines the formats for medical 
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images that can be exchanged with the data and quality necessary for clinical use.  A DICOM Tag serves 
as a unique identifier for an element of information which is used to identify Attributes and corresponding 
Data Elements.  Supplement 142 of the DICOM Standard (DICOM Standards Committee, 2011) offers a 
framework for de-identification of clinical imaging data for use in research studies (Freymann, 2012).  
DICOMweb, a DICOM standard for web-based medical imaging, and HL7 FHIR are complementary 
standards to service the needs of imaging in healthcare.  HL7 and FHIR provide the information model for 
health information, whereas DICOM and DICOMweb provide the information for imaging (DICOM 
Standards Committee).  
6. Genomics Data and Health-related Data 
Sharing genomic and health-related data should follow recommendations modeled after the “Global 
Alliance for Genomics and Health (GA4GH) Consent Policy” (Global Alliance for Genomics and Health, 
2019). Access to sensitive personal data (e.g. genetic data, health-related data) should be outlined in Data 
Access Agreements (DAAs) between the data holder and secondary data users, and data requests should 
be reviewed and managed by Data Access Committees to determine whether future data uses are 
consistent with data use limitations. In addition, data should be shared in accordance with applicable laws, 
regulations, and policies. More information on the ethical and legal bases can be found in the legal and 
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4. Data Sharing in Omics Practices 
4.1 Focus and Description 
The understanding of the ways in which the SARS-CoV-2 virus causes the COVID-19 disease is based on 
research into the molecular biology of the processes at cellular and subcellular level. The data of this style 
are the focus of this section.  
4.2 Scope 
For the purpose of this initiative, Omics are defined as data from cell and molecular biology. For most of 
the data modalities, data can be deposited in existing database resources. Many of these resources are 
now supporting specific COVID-19 subsets. 
Within this scope, recommendations on data that are already frequently associated with biological 
research on SARS-CoV-2 and COVID-19 are prioritised. 
4.3 Policy Recommendations 
4.3.1 Researchers Producing Data 
The FAIR data principles address a primary concern that has led to the formation of the group writing 
these guidelines: availability and re-usability of research data on COVID-19 in order to prevent 
unnecessary duplication of work. Considerations for Omics during the COVID-19 pandemic are: 
1. Reusability of data requires documented provenance: When sharing any secondary data, the 
generation of which involved comparison against other resources (examples for Omics data are: 
reference sequences for mapping, GO annotations for expression analysis, pre-trained models for 
gene annotation), both the public availability of these used resources and unambiguous 
referencing of the used resources, including version numbers, should be ensured.  
2. Increase the reusability of data with consistent preprocessing: To increase the availability of data 
ready for analysis and integration, it may be prudent to agree on a consistent approach to 
preprocessing Omics data. This would be a second-phase step that should not unnecessarily slow 
down researchers collecting data. 
3. If you have any existing SARS-CoV, MERS-CoV or EBOV data that have not yet been made public, 
consider publishing that data now as it can be a useful reference. 
4.3.2 Policymakers & Funders 
Due to the high costs involved with high-throughput genomics, few data are available from low- 
and middle-income countries (LMIC) and from minority ethnic populations in high income 
countries, thus leading to improper extrapolation of results to unrepresented population groups. 
Research that improves the coverage could be worth preferential treatment for funding.   
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4.4 Guidelines 
4.4.1 Guidelines for Virus Genomics Data 
4.4.1.1 Repositories 
There are several genomics resources that can be used to make virus genomics sequences available for 
further research. A curated list can be found in FAIRsharing. Some specific examples are: 
1. We suggest that raw virus sequence data are stored in one of the International Nucleotide 
Sequence Database Collaboration (INSDC) archives, as each of these is well known and openly 
accessible for immediate reuse without undue delays: 
1.1. DNA Data Bank of Japan (DDBJ) (Ogasawara et al., 2020) Sequence Read Archive (SRA) 
1.2. ENA (European Nucleotide Archive at EMBL-EBI), for submission documentation see 
ENA Documentation (ENA-Docs, 2020) 
1.3. NCBI SRA  for submission documentation see SRA Submission documentation (NIH-
NCBI, 2020) 
2. For assembled and annotated genomes we suggest deposition in one or more of these archives: 
2.1. NCBI GenBank  accessible through NCBI Virus (Hatcher et al., 2017), for submission 
documentation see Viral sequence submission documentation (NIH-NCBI, 2020) 
2.2. DDBJ Annotated/Assembled Sequences (DDBJ, 2020) 
2.3. ENA (EMBL-EBI, 2008) 
3. Virus data submitted to GenBank (NCBI, 2013; Benson et al., 2013; Clark et al., 2016) and RefSeq 
(NCBI, 2013; Pruitt et al., 2012) will be available for reuse through NCBI Virus (NCBI, 2013; Hatcher 
et al., 2017). 
4. There are other archives suitable for genome data that are more restrictive in their data access; 
submission to such resources is not discouraged, but such archives should not be the only place 
where a sequence is made available. 
5. Before submission of raw sequence data (e.g. shotgun sequencing) to INSDC archives, it is 
necessary to remove contaminating human reads. 
4.4.1.2 Data and Metadata Standards 
A list of relevant genomics data and metadata standards can be found in FAIRsharing, some specific 
examples are: 
1. We suggest that data are preferentially stored in the following formats, in order to maximise the 
interoperability with each other and with standard analysis pipelines: 
1.1. Raw sequences: .fastq (Cock et al., 2009); optionally compress with gzip 
1.2. Genome contigs: .fastq (Cock et al., 2009); if uncertainties of the assembler can be 
captured, .fasta (Pearson et al., 1988) otherwise; optionally compress with gzip 
1.3. De novo aligned sequences: .afa 
1.4. Gene Structure: .gtf 
1.5. Gene Features: .gff 
1.6. Sequences mapped to a genome: .sam (Li et al., 2009) or the compressed formats .bam 
or .cram (Fritz et al., 2011). Please ensure that the used reference sequence is also 
 
29 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
publicly available and that the @SQ header is present and unambiguously describes the 
used reference sequence. 
1.7. Variant calling: .vcf; please ensure that the used reference sequence is also publicly 
available and that it is unambiguously referenced in the header of the .vcf file, e.g. 
using the URL field of the ##contig field. 
1.8. Browser: .bed 
2. Consider annotating virus genomes using the ENA virus pathogen reporting standard checklist 
(ENA, 2020), which is a minimal information standard under development right now and the more 
general Viral Genome Annotation System (VGAS) (Zhang et al., 2019). 
3. For a viral sequence derived from a non-Human host, the viral (if known) and host binomial name 
should be recorded with the sequence. If that viral sequence was derived from a museum 
specimen, then the host specimen ID (catalogue number) and specimen holding institution should 
be recorded, preferably via a PID. 
4. For submitting data and metadata relating to phylogenetic relationships (including topology, 
branch lengths, and support values) consider using widely accepted formats such as: 
4.1. Newick (Felsenstein, 1986) 
4.2. NEXUS (Maddison et al., 1997) 
4.3. PhyloXML (Han et al., 2009; Stoltzfus et al., 2012)  
4.4. The Minimum Information About a Phylogenetic Analysis (MIAPA) checklist provides a 
reference list of useful tree annotations (Leebens-Mack et al., 2006; Lapp et al., 2017). 
4.4.2 Guidelines for Host Genomics Data 
Host genomics data are often coupled to human subjects. This comes with many ethical and legal 
obligations that are documented in the section on Legal and Ethical Considerations and not repeated here. 
The COVID-19 host genetics initiative is a bottom-up collaborative effort to generate, share and analyse 
data to learn the genetic determinants of COVID-19 susceptibility, severity and outcomes.  
4.4.2.1 Generic Recommendations 
1. Data sharing of not only summary statistics (or significant data) but also raw data (individual-level 
data) will foster a build-up of larger datasets. This will eventually allow identifying the 
determinants of phenotype more accurately.  
2. Especially for raw sequencing and genotyping data make sure to include Quality Control (QC) 
results and details of the sequencing platform used. 
3. Common terminologies for reporting statistical tests, e.g. with StatO  enable reuse and 
reproducibility. 




1The lists of repositories here are sorted alphabetically within each section. The order should not be interpreted as any kind of 
preference or recommendation 
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Several different types of host genomics data are being collected for COVID-19 research. Some suitable 
repositories for these are:  
1. Gene expression data should in general be retrieved from or deposited in the repositories listed 
below (Blaxter et al., 2016). To achieve load balancing, it is recommended to choose the 
respective regional repository. It should be noted that INSDC resources (i.e., DDBJ, ENA and NCBI) 
synchronise most of their datasets daily2.  
1.1. Transcriptomics of human subjects (requiring authorised access): 
1.1.1. Database of Genotypes and Phenotypes (dbGaP) (Mailman et al., 2007) 
1.1.2. European Genome-Phenome Archive (EGA) (Lappalainen et al., 2015); the 
corresponding non-sensitive metadata will be available through EBI ArrayExpress 
(Athar et al., 2019) 
1.1.3. Japanese Genotype-phenotype Archive (JGA) (Kodama et al., 2015) 
1.2. Transcriptomics (from cell lines/animals): 
1.2.1. ArrayExpress (Athar et al., 2019) 
1.2.2. Gene Expression Omnibus (Barrett et al., 2013) 
1.2.3. Genomic Expression Archive 
1.3. Underlying reads can be retrieved from/will automatically be deposited to the corresponding 
read archive: 
1.3.1. DDBJ Sequence Read Archive (DRA) (Kodama et al., 2012), for submission 
documentation see here 
1.3.2. European Nucleotide Archive  for submission documentation see here 
1.3.3. NCBI Sequence Read Archive (SRA)  for submission documentation see here 
1.4. Microarray-based gene expression data: 
1.4.1. ArrayExpress (Athar et al., 2019) 
1.4.2. Gene Expression Omnibus (Barrett et al., 2013) 
1.4.3. Genomic Expression Archive 
1.5. Data on the originating sample can be retrieved from/will automatically be deposited to the 
corresponding sample archive: 
1.5.1. DDBJ BioSample  
1.5.2. EBI BioSamples 
1.5.3. NCBI BioSample 
1.6. For specialised use cases, additional domain-specific repositories might exist, a curated list 
of which can be found in FAIRsharing. Data depositors are encouraged to submit their data 
to these specialised resources in addition to one of the resources mentioned above. 
2. Genome-Wide Association Studies (GWAS): 
2.1. GWAS Catalog 
2.2. EGA (Lappalainen et al., 2015) 
2.3. GWAS Central  
 
2This does not include the sections for restricted access data (dbGaP, EGA, JGA) and for gene expression (ArrayExpress/GEA/GEO) 
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3. Adaptive Immune Receptor Repertoire Sequencing (AIRR-seq)3 data: It is recommended that 
data be deposited using AIRR Community compliant processes and standards, in either of the 
following repositories. 
3.1. AIRR-seq specific repositories that are part of the AIRR Data Commons, for example the 
iReceptor Public Archive (Corrie et al., 2018) or VDJServer (Christley et al., 2018). 
3.2. INSDC repositories via NCBI SRA/Genbank, following the AIRR Community 
recommended NCBI submission processes. 
4.4.2.3 Data and Metadata Standards 
1. Gene Expression Data 
1.1. Transcriptomics 
1.1.1. Preferred minimal metadata standard MINSEQE 
1.1.2. Preferred file formats (sequencing-based): 
1.1.2.1. Raw sequences: .fastq (Cock et al., 2010), optional compression with gzip 
or bzip2 
1.1.2.2. Mapped sequences: .sam  compression with .bam or .cram (Fritz et al., 
2011) 
1.1.2.3. Transcripts per million (TPM): .csv 
1.1.3. Also see FAIRsharing using the query ‘transcriptomics’ 
1.2. Microarray-based gene expression data 
1.2.1. Preferred minimal metadata standard: MIAME (Brazma et al., 2001) 
1.2.2. Preferred file formats: tab-delimited text, e.g. MAGE-TAB and ISA-TAB  and raw 
data file formats from commercial microarray platforms (Annotare accepted 
formats; Athar et al., 2019) 
2. Genome-wide association studies (GWAS): 
2.1. Preferred minimal metadata standard: MIxS (Yilmaz et al., 2011) 
2.2. Preferred file formats: 
2.2.1. Binary files: .bim, .fam and .bed (Chang et al., 2015) 
2.2.2. Text-format files: .ped and .map (Chang et al., 2015) 
3. Adaptive Immune Receptor Repertoire sequencing (AIRR-seq): 
3.1. Preferred minimal metadata standards: MiAIRR (Rubelt et al., 2017) 
3.2. Preferred file formats: 
3.2.1. AIRR repertoire metadata, formatted as .json or .yaml (Vander Heiden et al., 
2018) 
3.2.2. AIRR rearrangements, formatted as .tsv (Vander Heiden et al., 2018) 
4.4.3 Guidelines for Structural Data 
4.4.3.1 Repositories 
 
3 Adaptive Immune Receptor Repertoire sequencing (AIRR-seq) samples the diversity of the immunoglobulins/antibodies and T 
cell receptors present in a host. The respective gene loci undergo random and irreversible rearrangement during lymphocyte 
development, therefore these data are fundamentally distinct from conventional genome sequencing. 
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Several different types of structural data are being collected for COVID-19 research. Some suitable 
repositories for these are:  
1. Structural data on proteins acquired using any experimental technique should be deposited in the 
wwPDB: Worldwide Protein Data Bank (Burley et al., 2019); a collaborating cluster of three 
regional centres at (i) for Europe: EBI PDBe (PDBe-KB consortium, 2020) and the Electron 
Microscopy Data Bank EMDB (Lawson et al., 2011), (ii) for the USA: RCSB PDB (Berman et al., 2000) 
and (iii) for Japan: PDBj (Kinjo et al., 2017). Data submitted to either of these resources will be 
available through each of them.  
2. A public information sharing portal and data repository for the drug discovery community, 
initiated by the Global Health Drug Discovery Institute of China (GHDDI) is the GHDDI Info Sharing 
Portal and includes the following: 
2.1. Compound libraries including the ReFRAME compound library (Janes et al., 2018) (the 
world’s largest collection of its kind, containing over 12,000 known drugs), a diversity-based 
synthetic compound library, a natural product library, a traditional Chinese medicine extract 
library 
2.2. Drug Discovery Cloud Computing System on Alibaba Cloud 
2.3. Data mining and integration of historical drug discovery efforts against coronavirus (e.g. 
SARS/MERS) using artificial intelligence (AI) and big data 
2.4. Molecular chemical modelling and simulation data using computational tools. 
4.4.3.2 Locating Existing Data 
1. The COVID-19 Molecular Structure and Therapeutics Hub community data repository and curation 
service for structure, models, therapeutics, simulations and related computations for research 
into the COVID-19 pandemic is maintained by The Molecular Sciences Software Institute (MolSSI) 
and BioExcel.  
4.4.3.3 Data and Metadata Standards 
1. X-ray diffraction 
1.1. There are no widely accepted standards for X-ray raw diffraction data files. Generally these 
are stored and archived in the vendor’s native formats. Metadata are stored in CBF/imgCIF 
format (in Catalogue of Metadata Resources for Crystallographic Applications). 
1.2. Processed structural information is submitted to structural databases in the PDBx/mmCIF 
format (Fitzgerald et al., 2006). 
2. Electron microscopy 
2.1. Data archiving and validation standards for cryo-EM maps and models are coordinated 
internationally by EMDataResource (EMDR). 
2.2. Cryo-EM structures (map, experimental metadata, and optionally coordinate model) are 
deposited and processed through the wwPDB OneDep system (wwPDB Consortium, 2020), 
following the same annotation and validation workflow also used for X-ray crystallography 
and nuclear magnetic resonance (NMR) structures. EMDB holds all workflow metadata while 
PDB holds a subset of the metadata. 
2.3. Most electron microscopy data are stored in either raw data formats (binary, bitmap images, 
tiff, etc.) or proprietary formats developed by vendors (dm3, emispec, etc.). 
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2.4. Processed structural information is submitted to structural resources as PDBx/mmCIF 
(Fitzgerald et al., 2006). 
2.5. Experimental metadata are described in EMDR, see also (Lawson et al., 2020). 
3. NMR 
3.1. There are no widely accepted standards for NMR raw data files. Generally these are stored 
and archived in single FID/SER files. 
3.2. One effort for the standardisation of NMR parameters extracted from 1D and 2D spectra of 
organic compounds to the proposed chemical structure is the NMReDATA initiative and the 
NMReDATA format (Pupier et al., 2018). 
3.3. There is no universally accepted format for FID-associated metadata. NMR-STAR (Ulrich et 
al., 2019) and its NMR-STAR Dictionary (Ulrich et al., 2019) is the archival format used by the 
Biological Nuclear Magnetic Resonance data Bank (BMRB), the international repository of 
biomolecular NMR data and an archive of the Worldwide Protein Data Bank (Burley et al., 
2019). 
3.4. The nmrML format specification (XML Schema Definition (XSD) and an accompanying 
controlled vocabulary called nmrCV) are an open mark-up language and an ontology for NMR 
data (PhenoMeNal H2020 project, 2019). 
3.5. Processed structural information is submitted in the PDBx/mmCIF format (Fitzgerald et al., 
2006). 
4.  Neutron scattering 
4.1. ENDF/B-VI of Cross-Section Evaluation Working Group (CSEWG) and JEFF of OECD/NEA have 
been widely utilised in the nuclear community. The latest versions of the two nuclear 
reaction data libraries are JEFF-3.3 (Cabellos et al., 2017) and ENDF/B-VIII.0 (Brown et al., 
2018) with a significant upgrade in data for a number of nuclides (Carlson et al., 2018). 
4.2. Neutron scattering data are stored in the internationally-adopted ENDF-6 format (Brown et 
al., 2018) maintained by CSEWG. 
4.3. Processed structural information is submitted in the PDBx/mmCIF format (Fitzgerald et al., 
2006). 
5.  Molecular Dynamics (MD) simulations 
5.1. Raw trajectory files containing all the coordinates, velocities, forces and energies of the 
simulation are stored as binary files: .trr, .dcd, .xtc and .netCDF; see also (Goni et al., 2013). 
5.2. Refined structural models from experimental structural data using MD simulations are 
stored in .pdb format (Bernstein et al., 1977). 
6.  Computer-aided drug design data 
6.1. Virtual screening results are stored in 3D chemical data formats, such as .pdb (Bernstein et 
al., 1977). 
6.2. Structural formulas either in SMILES (Anderson et al., 1987) or IUPAC International Chemical 
Identifier (InChI), and identified through InChIKey, a non-proprietary identifier for chemical 
substances (Heller et al., 2015). 
4.4.4 Guidelines for Proteomics 
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1. For a curated list of relevant repositories see FAIRsharing using the query ’proteomics’. The 
ProteomeXchange Consortium enables searches across the following deposition databases, 
following common standards. 
1.1. For shotgun proteomics one of: 
1.1.1. PRIDE (Perez-Riverol et al., 2019) 
1.1.2. MassIVE (Wang et al., 2018) 
1.1.3. jPOST (Japan Proteome Standard Repository) (Okuda et al., 2017) 
1.1.4. iProX (integrated Proteome resources) (Ma et al., 2019) 
1.2. For targeted proteomics one of: 
1.2.1. PASSEL (Farrah et al., 2012; Kusebauch et al., 2014) 
1.2.2. Panorama (Sharma et al., 2018; Sharma et al., 2014) 
1.3. For repossessed results one of: 
1.3.1. PeptideAtlas (Deutsch et al., 2009) 
1.3.2. MassIVE (Wang et al., 2018) 
2. For recommendations regarding non-mass spectrometry based protein-oriented data (e.g. ELISA, 
neutralising antibody titers, flow/mass cytometry) see the respective sub-section of the Clinical 
WG. 
4.4.4.2 Data and Metadata Standards 
1. For a curated list of relevant standards see FAIRsharing using the query ’proteomics’. Specific 
examples: 
1.1. Use the minimal information model specified in MIAPE by the HUPO Proteomics Standards 
Initiative (HUPO PSI) (Taylor et al., 2007; HUPO PSI, 2007) and these are filled using the 
controlled vocabularies specified by the Proteomics Standards Initiative, PSI CVs.  
1.2. Recommended formats are:  
1.2.1. For gel electrophoresis: gelML (HUPO PSI, 2010) 
1.2.2. For transition lists: TraML (HUPO PSI, 2013)  
1.2.3. For raw spectrometer output: mzML (HUPO PSI, 2017)  
1.2.4. For reporting: mzTab (HUPO PSI, 2014)  
1.2.5. For protein quantisation data: mzQuantML (HUPO PSI, 2017)  
1.2.6. For protein identification data: mzIdentML (HUPO PSI, 2017)  
1.2.7. For metadata ISA-TAB with conversion to PRIDE format 
4.4.5 Guidelines for Metabolomics 
Metabolomics studies are used to find biomarkers for disease and susceptibility. Lipidomics is a special 
form of metabolomics but is also described in more detail in a separate section below because of its 
special relevance to COVID-19 research. 
4.4.5.1 Repositories 
1. For a curated list of relevant repositories see FAIRsharing using the query ‘metabolomics’.  
2. Metabolomics data can be submitted to: 
2.1. MetaboLights (in Europe) (Haug et al., 2020) 
2.2. Metabolomics Workbench (in the USA) (Sud et al., 2016) 
2.3. Massbank (in Japan) (Horai et al., 2010) 
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4.4.5.2 Data and Metadata Standards 
1. For a curated list of relevant standards see FAIRsharing using the query ‘metabolomics’. Specific 
examples: 
1.1. Core Information for Metabolomics Reporting, CIMR standard  
1.2. For identifying chemical compounds use SMILES (Anderson et al., 1987) or InChI (Heller et 
al., 2015) 
1.3. To document Investigation/Study/Assay data, use the ISA Abstract Model, also implemented 
as a tabular format, ISA-TAB in MetaboLights (Haug et al., 2020) and in the Metabolomics 
Workbench (Sud et al., 2016). For an introduction to ISA, see (Sansone S-A et al., 2012). 
1.4. Recommended formats are: 
1.4.1. For LC-MS data use: ANDI-MS specification (ASTM International, 2014), an 
analytical data interchange protocol for chromatographic data representation 
and/or mzML (HUPO PSI, 2017)  
1.4.2. For NMR data: nmrCV, nmrML (PhenoMeNal H2020 Project, 2019) 
4.4.6 Guidelines for Lipidomics 
Lipidomics revealed an altered lipid composition in infected cells and serum lipid levels in patients with 
pre-existing conditions. Lipid rafts (lipid microdomains) play a critical role in viral infections facilitating 
virus entry, replication, assembly and budding. Lipid rafts are enriched in glycosphingolipids, 
sphingomyelin and cholesterol. It is likely that SARS-CoV-2 enters the cell via angiotensin-converting 
enzyme-2 (ACE2) that depends on the integrity of lipid rafts in the infected cell membrane.  
4.4.6.1 Generic Recommendations for Researchers 
Lipidomics analysis should follow the guidelines of the Lipidomic Standards Initiative. 
4.4.6.2 Repositories 
The recommended repository for lipidomics data is MetaboLights (Haug et al., 2020). 
4.4.6.3 Data and Metadata Standards 
1. Metadata should follow recommendations from the CIMR standard by the Metabolomics 
Standards Initiative. It should be made available as tab or comma separated files (.tsv or .csv). 
2. Data standards: Data can be stored in LC-MS file, in tab (.tsv) or comma (.csv) separated formats. 
3. Data analysis 
3.1. Most of the analysis is usually performed using the software delivered by the suppliers of 
the instrumentation. In line with generic software recommendations it should be made sure 
that the process and parameters are well described, and that the output is converted to a 
standard format. 
3.2. Workflow for Metabolomics (W4M) is a collaborative portal dedicated to metabolomics data 
processing, analysis and annotation for Metabolomics community. 
3.3. Data processing using R software and associated packages from Bioconductor (xcms, 
camera, mixOmics) is a flexible and reproducible way for lipidomic data analysis. 
4. Compound identification: After data processing, potential biomarkers should be annotated. This 
could be done either by manual (Lipid Maps tools) or automated identification against templates 
 
36 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
(Library templates for compounds identification) with the help of software such as LipidBlast, 
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5. Data Sharing in Epidemiology  
5.1 Focus and Description 
An immediate understanding of the COVID-19 disease epidemiology is crucial to slowing infections, 
minimising deaths, and making informed decisions about when, and to what extent, to impose mitigation 
measures, and when and how to reopen society.  
Despite our need for evidence-based policies and medical decision-making, there is no international 
standard or coordinated system for collecting, documenting, and disseminating COVID-19 related data 
and metadata, making their use and reuse for timely epidemiological analysis challenging due to issues 
with documentation, interoperability, completeness, methodological heterogeneity, and data quality. 
The intended audience for the epidemiology recommendations and guidelines are government and 
international agencies, policy and decision-makers, epidemiologists and public health experts, disaster 
preparedness and response experts, funders, data providers, teachers, researchers, clinicians, and other 
potential users. 
5.2 Scope 
Epidemiology underpins COVID-19 response strategies and public health measures. The 
recommendations and guidelines support development of an internationally harmonised specification to 
enable rapid reporting and integration of epidemiology and related data across domains and between 
jurisdictions. 
The guidelines outline a data driven, coordinated global system that encompasses preparedness, early 
detection, and rapid response to newly emergent threats such as SARS-CoV-2 virus and the COVID-19 
disease that it causes. 
5.2.1 Supporting Output 
The supporting output (doi.org/10.15497/rda00049) provides supplemental resources, and further 
develops the global data-driven vision described in the guidelines. This includes a proposed computable 
framework to support system responses for emerging pathogens. It offers compatible and reliable data 
models, protocols, and action plans for newly identified threats such as COVID-19. 
5.3 Policy Recommendations 
5.3.1 Information Technology and Data Management 
Properly funded state of the art infrastructure is required to support advanced research, and to support 
the  data management and data sharing required for rapid response and collaboration (See Infrastructure 
Investment). For epidemiology in particular: 
1. Ensure an appropriate semantic annotation of data to facilitate its comparability across studies and 
countries, using as much as possible established standards (e.g. LOINC, UMLS). 
2. Rapidly develop standardised tools for aggregating microdata to a harmonised format(s) that can be 
shared and used while minimising the re-identification risk for individual records. 
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3. Develop machine readable citations and micro-citations for dynamic data. Rapid development of: (a) 
Resolvable Persistent Identifiers, rather than Uniform Resource Locators (URLs); (b) Machine readable 
citations; (c) Micro-citations that refer to the specific data used from large datasets; and, (d) Date and 
Time Access citations for dynamic data (ESIP, 2019). 
5.3.2 COVID-19 Epidemiological Data, Analysis and Modelling 
1) Implement a global system for early detection and rapid response to emerging zoonoses, integrated 
across systems for reporting human and animal diseases as well as their vectors (CDC 2020; CGH 2019; 
eCDC 2019; GLEWS 2006; NASEM 2008, 2009a,b; WHO 2017; WHO, FAO and OIE 2019). 
2) Catalogue and document all zoonotic diseases with associated reservoir species and vectors to 
establish and maintain a global database with potential risks related to humans. 
3) Rapidly develop a consensus standard for COVID-19 surveillance data: 
a) Definition of and reporting criteria for COVID-19 testing, reporting on testing, and testing 
turnaround times. 
b) Policies and definitions: interventions, contact tracing, reporting of cases, deaths, 
hospitalisations and length of stay, ICU admissions, recoveries, reinfections, time from contact 
if known, symptoms onset and detection, through clinical course and interventions, to death 
or recovery, comorbidities, long-term effects in recovered cases, sequelae and immunity, 
location, demographic, socioeconomic information, and outcome of resolved cases. 
c) Uniform standard daily reporting cut-off time. 
4) Rapidly develop an internationally harmonised specification to enable the export/import/integration 
of epidemiologic data across different levels of data generation (e.g. clinical systems, population-
based surveillance/research data, data from biomarker and omics studies, death certification, health 
insurance data), and successful record-linkage.  
5) Develop systems that support workflows to link and share data between different domains, while 
protecting privacy and security. Use domain specific, time stamped, encrypted person identifiers for 
this purpose based on industry-standard encryption and cryptographic constructions. 
6) Implement internationally harmonised COVID-19 intervention protocols based on peer-reviewed 
empirical modelling and epidemiological evidence, considering local conditions. 
7) Publish situational data, analytical models, scientific findings, and reports used in decision-making and 
justification of decisions (OGP, 2020b). 
8) Account for public health decision-making demands in COVID-19 studies. 
9) Harmonise approaches to comparably assess and quantify side-effects of pandemic containment and 
mitigation measures. 
10) Report underlying assumptions and quantify effects of uncertainties on all reported parameters and 
conclusions for all model predictions etc. 
11) Implement a data-driven approach for early identification of hotspots. 
5.4 Guidelines 
These guidelines highlight current system challenges and offer solutions to help support a larger 
framework designed to coordinate and structure the collection and use of COVID-19 related data. Six focus 
areas, described in the guidelines and supporting output (data sources, instruments, privacy, 
epidemiological data model, computable framework, and an epi-stack architecture), progressively 
develop a data driven global vision for managing novel biological threats such as COVID-19. We begin with 
population level data sources that drive the public health strategy and response at all stages of the COVID-
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19 threat, from emergence through containment, mitigation, and reopening of society. We then survey 
clinical and population-based instruments that collect data and discuss preservation of individuals’ privacy 
in shared COVID-19 related data. A full spectrum data model is presented encompassing hospital specific 
surveillance and electronic health records together with field-based demographic and epidemiological 
surveillance. We propose Epi-TRACS, a computable framework for emerging pathogen action plans, and 
an epi-stack that uses the Common Data Model with COVID-19 to integrate clinical data and 
epidemiological data. 
5.4.1 COVID-19 Population Level Data Sources 
Although jurisdictions within countries send COVID-19 population level data to the national level, and 
member countries send data to the WHO, other organisations also collect COVID-19 surveillance data 
from various sources for a variety of reasons (Table 2). Epidemiologists are thus faced with a situation 
where it is difficult to assess which datasets are the most up-to-date, complete, and reliable.    
See Appendix 1 in supporting output for further details and discussion. 
Table 2 - COVID-19 population level data sources 
SOURCE DATA 
Allen Institute for AI COVID-19 Open Research Dataset (CORD-19) 
Apple Inc COVID-19-Mobility Trends Reports 
European Centre for Disease Control Geographic distribution of COVID-19 cases worldwide 
European Centre for Disease Control The European Surveillance System (TESSy). 
Institute for Health Metrics and Evaluation (IHME) Global Health Data Exchange (GHDx) 
Google Inc.  COVID-19 Community Mobility Report 
Johns Hopkins University COVID19 dataset 
Kieren Healy Rpackage Rpackage - COVID19 Case and Mortality Time Series 
University of Oxford COVID19 dataset 
The Atlantic Tracking Project 
The New York Times Covid-19 Data in the United States 
U.N. Humanitarian Data Exchange (HDX) 
U.S. Centre for Disease Control Cases of COVID19 in the U.S. 
University of Washington Be Outbreak Prepared 
World Bank Understanding the Coronavirus (COVID-19) pandemic 
through data 
World Health Organization (WHO) Novel Coronavirus (2019-nCoV) situation reports 
Worldometer COVID19 data 
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5.4.2 Interoperable COVID-19 Epidemiological Surveillance: Clinical and Population-based 
Instruments 
International efforts are currently underway to create COVID-19 instruments/ questionnaires (Tables 3-
4). These COVID-specific tools are concentrated at person-level for clinic/hospital surveillance (e.g. Case 
Report Forms-CRFs), or community surveillance (e.g. questionnaire for general population), and do not 
necessarily collect the same data. Adherence of new studies to already introduced instruments will 
strongly enhance the comparability of results.  
Table 3 - Questionnaire instruments: Reference studies 
 COUNTRY QUESTIONNAIRE 
CLINICAL 
Australia NSW Case questionnaire 
Austria EMS 
Europe TESSy 
Germany Covid-19 research dataset 
Uganda Perinatal COVID-19 Uganda 
US Human Infection with 2019 Novel CoronavirusPerson Under Investigation (PUI) 
and Case Report Form 
Worldwide 
(WHO member states) 
Global COVID-19: clinical platform: novel coronavius (COVID-19): rapid version 
POPULATION BASED 
Brazil Brazil Prevalence of Infection Survey 
Europe Questionnaire by WHO Europe 
Germany GESIS Panel Special Survey on the Coronavirus SARS-CoV-2 Outbreak in 
Germany 
Germany NAKO COVID-19 Survey tool 
Israel One-minute population wide survey 
LMICs LMIC Covid Questionnaire 
South Africa South African Population Research Infrastructure (SAPRIN) COVID-19 Screening 
Form 
South Asian Countries National Institute for Health Research (NIHR) Global Health Research Unit 
UK UK COVID-19 Questionnaire 
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Worldwide (WHO) Population-based age-stratified sero-epidemiological investigation protocol for 
COVID-19 virus infection 
 
Table 4 - Questionnaire instruments: Resources 
NIH Public Health Emergency and Disaster Research Response (DR2)  
NIH COVID-19OBSSR Research Tools 
PhenX PhenX COVID-19 Toolkit 
 
Some of the questionnaire initiatives shown in Tables 3 and 4 are currently feeding into the construction 
of a COVID-19 demographic and epidemiological surveillance question bank that can be used to form 
locality specific surveys with both common and distinct questions by domains and cohorts (Wellcome 
Trust). Some, such as the UK COVID-19 Questionnaire, or the Covid-19 research dataset are now being 
funded. Question banks, once they become operational can be queried and filtered by domain, cohort, 
question text, etc. Based on such queries, new questionnaire products can be developed that are more or 
less interoperable, depending on the questions selected and the capture of “localisation” information in 
the question metadata when questions are reused from one survey to the next. 
See Appendix 2 in supporting output for further details and discussion. 
5.4.3 Preservation of Individuals’ Privacy in Shared COVID-19 Related Data 
Data sharing is essential to improve epidemiological analysis, cross-border pandemic modelling, and 
coordinated policy development between countries. To ensure privacy, both pseudo-anonymisation of 
direct identifiers (e.g. patient specific ID’s) and anonymisation of indirect identifiers (e.g. socio-
demographic information on individuals) must be applied. In addition, it is necessary to control statistical 
disclosure risk to prevent identification of individuals and their health status using a combination of 
indirect identifiers such as education level, sex, age, and clinical condition, among others (Duncan et al., 
2011; Templ et al., 2015; Templ, 2017). Using synthetic data may be an option to lower re-identification 
risks while retaining properties of the original datasets.  
See Appendix 3 in supporting output for further details and discussion. 
5.4.4 Full Spectrum View of the COVID-19 Data Domain: An Epidemiological Data 
Model  
The COVID-19 epidemiology that guides public health decisions is dependent on interoperable input data 
from across a wide variety of domains that include not only clinical, surveillance, research, and modelling 
data, but also administrative, demographic, socioeconomic, cultural practices and lifestyle, and 
environmental data, amongst others. 
An epidemiological surveillance data model must include the primary data domains that need to be 
integrated to understand COVID-19, and to improve surveillance and follow-up: (a) clinical event history 
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and disease milestones; (b) epidemiological indicators and reporting data; (c) contact tracing; (d) personal 
risk factors. 
Standardisation challenges within each of these domains remain to be solved before data can be 
effectively integrated across domains for epidemiology studies. For example, on the clinical side, the U.S. 
Clinical Data Interchange Standards Consortium (CDISC) new specification (Interim User Guide for COVID-
19), and the WHO Core and Rapid COVID-19 Case Reporting Forms used in low- and middle-income 
countries (LMIC) require additional harmonisation. 
See Appendix 4 in supporting output for further details and discussion. 
5.4.5 Epi-TRACS: Rapid Detection and Whole System Response for Emerging 
Pathogens  
WHO’s Global Influenza Surveillance Response System (GISRS) is a well-established network of more than 
150 national public health laboratories in 125 countries that monitors the epidemiology and virologic 
evolution of influenza disease and viruses (WHO, 2020). 
Prior to the COVID-19 outbreak, WHO was already engaged in re-examining GISRS’s long-term fitness-for-
purpose. In line with these short-term considerations, and with GISRS long-term aspirations, we are 
recommending a real time, adaptable, rapid response system that supports developing countries, and 
that employs new technology to combat pandemics and other emerging diseases. The RDA-COVID19-
Epidemiology group recommends the creation of a WHO-led EPIdemiological Translational Research 
Action Coordination System (Epi-TRACS) to add an implementation layer to the existing WHO policies, 
guidelines, partnerships, and information exchange stack adapted to country-specific contexts.  
See Appendix 5 in supporting output for further details and discussion. 
5.4.6 COVID-19 Emergency Public Health and Economic Measures Causal Loops: A 
Computable Framework 
Causal loop modeling may be valuable in assessing system sustainability and system resiliency (Bahri 2020; 
Ricciardi et al. 2020; Wicher 2020). A computable framework in which the actions taken in response to 
COVID-19 sentinel surveillance can be simulated and assessed both retrospectively and prospectively 
based on a causal loop diagram may help inform decision making.   
See Appendix 6 in supporting output for further details and discussion. 
5.4.7 Common Data Models and Full Spectrum Epidemiology: Epi-STACK 
Architecture for COVID-19 Epidemiology Datasets 
Common Data Model (CDM) 
Data models may make use of the broad ecosystem of surveillance and clinical data that can also include 
contact tracing apps, biospecimens, and environmental sample data collected in the 
community/population or clinic/hospitals.  
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An emulated trials approach may enable assessment of various risk and prognostic factors (Hernán et.al., 
2016). Application of a Common Data Model (CDM) for COVID-19 would facilitate comparing clinical 
burden and patient outcomes in the context of previous environmental and exposures and comorbidities.  
Another possible use case is decision support following an early warning system alert of emergence of a 
novel pathogen such as SARS-CoV-2. The CDM provides a framework for making public health policy 
decisions, using partial information about the pandemic that leverages population-level population and 
health information, person-level epidemiological surveillance information collected in the field and, at the 
same time or alternatively, person-level patient care information collected in a clinic or hospital setting.  
Epi-Stack 
The WHO has established the Information Network for Epidemics (Epi-WIN) covering four strategic areas: 
(a) Identify; (b) Simplify; (c) Amplify; and, (d) Quantify. Evidence is gathered, appraised, and assessed to 
help form recommendations and policies that have an impact on the health of individuals and population. 
The RDA Epi subWG proposes an expanded Epi-Stack feeding into Epi-WIN. This would bring together in 
a managed system a common data model, the epidemiological surveillance data model, clinical and 
questionnaire data, population level indicators, and core use cases (Epi-TRACS early warning and response 
system, decision support research, and patient care research). It is critical that resiliency be built into the 
system, from the standpoint of how the system functions under stress. When the degree of complexity 
and interdependencies increase in human made systems, there is always the risk of collapse if not enough 
balance is built into the system (both the IT infrastructure, data governance, and the "people" part). 
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6. Data Sharing in Social Sciences 
6.1 Focus and Description 
Data from the social sciences is essential for all domains (including omics, clinical and epidemiology, 
among others) that seek to better plan for effective management of the COVID-19 pandemic and its 
consequences. Social scientists are collecting new information and reusing existing data sources to better 
inform leaders and policymakers about pressing social and economic issues regarding COVID-19, to enable 
evidence-based decision-making, as this pandemic is as much a social as it is a medical phenomenon. 
Social sciences research, involving a predominance of observational methods, produces unique data that 
cannot be recreated in the future. Furthermore, key social sciences data, such as demographics, are 
valuable tools for all disciplines to be able to understand context and link datasets.  Data types in the 
social sciences include qualitative; quantitative; geospatial; audio, image, and video; and non-designed 
data (also referred to as digital trace data). Recommendations made in these guidelines will help ensure 
that research data management is expedient--but not hasty--and that data contributions from the social 
sciences are shared and preserved in ways that allow them to be leveraged long-term for the broadest 
impact and reused across all domains. 
6.2 Scope 
Social sciences disciplines include economics, sociology, political science, education, demography, social 
anthropology, geography, and psychology, among others. The current health crisis is influenced by the 
way political leaders, health expert panels, social communities and individual citizens have reacted to the 
challenges presented by the virus. Social sciences data have significant value for tracking and altering the 
social, political, cultural, psychological and economic impact of COVID-19 as well as future health 
emergencies. Such knowledge can facilitate preparation and mitigation measures, ameliorate negative 
impacts, improve social and economic wellbeing, and inform decision-making processes. These 
recommendations are shaped by the need for rapid and long-term access to social sciences data in the 
following areas, among others:  
1. Social Isolation and Social Distancing  
2. Family and Intergenerational Relationships 
3. Quality of Life and Wellbeing 
4. Health Behaviours and Behaviour Change 
5. Health Disparities  
6. Impact on Vulnerable Populations (including immigrants, minority groups) 
7. Community Impact and Neighbourhood Effects  
8. Transportation; Food Security 
9. Beliefs, Attitudes, Misinformation, Public Opinion  
10. Technology-Mediated Communication (public information campaigns; social media use) 
11. Economic Impacts (including industry, work, unemployment)  
12. Organisational Change 
13. Social Inequalities and Discrimination 
14. Education Impacts (including online learning) 
15. Political Dynamics, Policy Approaches, and Government Expenditure 
16. Criminal Justice (including domestic violence, prison populations, cybercrime) 
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17. Human Mobility and Migration (including dislocation) 
Ensuring data produced across such areas of research are readily accessible and properly documented will 
(1) advance the social sciences research agenda around COVID-19; (2) promote interoperable cross-
disciplinary and cross-cultural data use, collaboration, and understanding; (3) build a foundation for 
managing social sciences data during pandemics and health emergencies more generally, ensuring that 
social sciences research can be leveraged for the public good.  
6.3 Policy Recommendations 
In formulating policies on pressing questions in times of emergency, policymakers require access to social 
science research based on data. Because the COVID-19 crisis is taking place in the context of a data-
intensive economy, data plays a crucial role and has value across many stakeholders (e.g. scientists, 
citizens, governments, private corporations). Data generated from publicly funded projects should be 
made quickly available to the research community. The following recommendations are aimed at ensuring 
the policies and practices across the wide array of organisations supporting research during COVID-19 
require and ensure high quality, social sciences data in line with FAIR principles.    
1. Ensure robust funding streams for social sciences research, which is essential to the work in all 
other research domains and important itself for understanding and managing the social, 
behavioural, and economic aspects of pandemics. This is necessary to avoid increasing health and 
social disparities due to COVID-19 and other health emergencies.  
2. Funding decisions should prioritise projects where the social sciences data being produced can be 
used across domains and are linkable and interoperable.  
3. Social sciences funding should require data sharing and provide support for infrastructure for data 
archiving and preservation. This includes striving for funding models that are applied equitably 
across projects, researchers, and countries. This is also a mandate for covering costs for 
infrastructure in the broadest sense (e.g. ensuring open access to data, curation services, research 
data management costs across the lifecycle, and long-term preservation, among others).  
4. Despite rapid needs for data and research, basic human subject protections must be upheld by all 
institutions engaged in research. All human subjects are equal and should be treated as such; 
every single human subject should be treated fairly.  
5. All stakeholders (researchers, research institutions, institutional ethics review boards/ethics 
committees, healthcare organisations, funding agencies and policymakers) should consider 
COVID-19 data sharing needs while reviewing the ethics standards, finding balance between the 
community good and the individual rights of the participants. 
6. Official statistical agencies and other official data providers should ensure that there are uniform 
recommendations about the minimal number of metadata variables shared that will allow linking 
the different types of data produced around COVID-19 (e.g. geospatial codes and time stamping 
using controlled vocabularies, ideally international standards such as NUTS (eurostat) and ISO 
(ISO)). 
7. Social sciences journals should require COVID-19 related articles to provide data statements on 
data availability that point to access in a publicly available repository.  
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6.4 Guidelines 
The overall principle appropriate in times of public crises like COVID-19 is to allow the sharing of as much 
data as openly as possible and in a timely fashion, maintaining public trust. The following 
recommendations in relation to data management and sharing, ethical and legal issues, metadata, 
storage, should be referenced in making decisions which necessarily balance individual and public rights 
and benefits. 
6.4.1 Data Management Responsibilities and Resources  
Data management and planning are key, and recommendations Section 2.2.4 should be noted. To ensure 
broad reuse, a Data Management Plan (DMP) constructed for social sciences data collections should guide 
the handling of the data over time and help all disciplines (e.g. clinical, epidemiology) understand the data.  
Social scientists should consult a list of data management resources in Data Management Expert Guide 
(CESSDA Training Team, 2019) and associated DMP template. Use one of the DMP tools for your country, 
funder, and preferred language: DMPonline (DCC; DMPTool (University of California); DMP assistant 
(Portage); ARGOS (OpenAIRE); DMP OPIDoR (OPIDoR) and Plan de Gestión de Datos (PGD) (Vilches) and 
address the relevant aspects of making the data FAIR (Wilkinson et al., 2016) in a DMP. 
6.4.2 Documentation, Standards, and Data Quality 
Social sciences data producers should provide thorough documentation about the data themselves, the 
research context, methods used to collect, store, and treat data, and quality-assurance steps taken. 
Consider the needs of the future data user when developing and creating documentation. The 
documentation serves multiple purposes, supporting reproducibility, linkage, quality checking, 
understandability and transparency of the collection and storage process.  
Social sciences researchers should be aware of metadata standards used in the social sciences and deposit 
data into repositories using Data Documentation Initiative (DDI), the Dublin Core Metadata Initiative 
(DCMI) Scheme, QuDEx, ISO 19115, and SDMX.  
Social sciences researchers should be aware of controlled vocabularies and ontologies for the social 
sciences including Humanities and Social Science Electronic Thesaurus (HASSET), the European Language 
Social Science Thesaurus (ELSST) which is multilingual, the CESSDA Vocabulary for describing data 
elements (e.g. analysis unit, data type, mode of collection, etc.), and the DDI set of controlled 
vocabularies.  
Documentation for data elements (e.g. geography, time period, demographics) that are useful for linking 
to other sources of data around COVID-19 should allow full understanding of context, method, and 
limitations).  
Use standardised codes for places to reduce data consistency challenges that come from the use of textual 
entity names. We strongly encourage the use of ISO-3166 for countries or administrative subdivisions, 
ANSI (American National Standards Institute) and FIPS (Federal Information Processing Standards) for U.S. 
States and counties, and standard identifiers for organisational entities such as companies (Coffey; 
INSEAD). This set of actions will facilitate data analysis, harmonisation, linking, visualisation, and 
integration in applications. 
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To encourage interdisciplinary research, social scientists should be mindful of commonly accepted 
professional codes or norms for documentation needs when producing documentation according to their 
own particular disciplinary norms. This allows for all domains to be able to ensure the research integrity 
of social sciences data it accesses or reuses. For example, the use of readme files to orient a user to a set 
of files are common in some professions.  
Data should be stored in at least one non-proprietary format that is well-documented. Many repositories 
publish lists of recommended, preferred, or acceptable formats that are useful for social scientists to 
consult. Two sources for recommended formats are UKDA Recommended Formats (UK Data Service) and 
Library of Congress Recommended Formats Statement (Library of Congress).  The social sciences benefit 
from the use of many common formats used across disciplines, enabling broader interoperability. 
6.4.3 Storage and Backup 
Where possible, researchers should avoid using personal storage, and instead use the official storage 
provisions available from their institution, including when working remotely, as they are more likely to 
provide robust backup and data protection features.  
Researchers with sensitive data or data with disclosure risk should seek a storage solution for their data 
which offers flexibility and protection, such as a solution offering remote access work (German Data 
Forum (RatSWD), 2020). 
Social sciences data, as is true for human subject data in other domains, may have particular requirements 
as to how it can be stored and accessed, based on laws and regulations, research ethics protocols, or 
secondary data licences that often vary by country. 
Data access while data collection is active should be limited to those with authorisation to use the data. 
To speed access to COVID-related data, we encourage authorising external user groups where possible. 
Sensitive data and human subject data containing personally identifiable information (PII) or protected 
health information (PHI) should be adequately protected and encrypted when at rest or in transit, and no 
matter where or how it is stored.  
Where possible, best practice is to store data (including participant consent files) without direct identifiers 
and replace personal identifiers with a randomly assigned identifier.  Researchers should create a separate 
file, to be kept apart from the rest of the data, which provides the linking relationship between any 
personal identifiers and the randomly assigned unique identifiers. 
Ensure that data should be backed up in multiple locations all under the same security conditions (See 
section on Infrastructure Investment). 
Where possible, select a storage solution that allows an easy way to maintain version control. 
6.4.4 Legal and Ethical Requirements 
It is recommended to establish rigorous approval mechanisms for sharing data (via consent, regulation, 
institutional agreements and other systematic data governance mechanisms). Researchers have a 
responsibility for ensuring research participants understand that there may be a risk of re-identification 
when data are shared. Find a balance that takes into account individual, community and societal interests 
and benefits whilst addressing public health concerns and objectives to enable access to data and their 
reuse and maximise the research potential.  
 
48 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
Ethics reviewing during a crisis like the COVID-19 pandemic is critical to protect highly vulnerable 
populations from potential harm. Therefore these Guidelines endorse guidance such as the Statement of 
the African Academy of Sciences’ Biospecimens and Data Governance Committee On COVID-19: Ethics, 
Governance and Community engagement in times of crises (AAS, 2020). 
Respect Indigenous People’s rights and interests and follow the CARE Principles for Indigenous Data 
Governance (Research Data Alliance International Indigenous Data Sovereignty Interest Group, 2019), 
that complement the FAIR principles and are people and purpose-oriented.   
Ethical use of open data ensures inclusive development and equitable outcomes. Metadata should 
acknowledge the provenance and purpose and any limitations or obligations in secondary use, inclusive 
of issues of consent.  
Researchers whose data have legal, privacy, or other restrictions should seek out appropriate alternative 
avenues for data sharing, including restricted access conditions and embargoes, only when absolutely 
essential. 
Ensure licences and agreements in data acquisition enable downstream data sharing and preservation. 
The way primary data have previously been collected and processed may have an impact on the sharing 
and use of secondary data.  Sharing and use of these data can be agreed for a certain duration, defined 
purposes and with appropriate guarantees for both researchers and data providers. Licences for 
secondary data (e.g. with universities or research groups) should be written to allow researchers to share 
data, to enable broader sharing for the public good, such as limited extracts that cannot undermine the 
data provider’s business model. Researchers should seek local support to clarify how best to share 
secondary data, to ensure and negotiate the appropriate rights.  
When working with commercial partners, seek opportunities to negotiate data sharing mechanisms 
agreeable to both parties. Develop partner and consortium agreements that make explicit each partner's 
rights, including what data can be shared and how. Ensure equitable partnerships. 
Using data from social media introduces additional issues. Individuals creating and sharing content may 
not regard this as a public space and have an expectation of a degree of privacy. Furthermore, social 
networks by definition reveal connections between many individuals; thus, an individual post or tweet 
may provide information on many different data subjects without their knowledge or consent. In addition, 
researchers collecting data from the web should ensure they have sufficient rights to do so to safeguard 
their ability to use the data; many websites have terms and conditions that prohibit data collection, 
particularly via web scraping and other automated methods. See Legal and Ethical Considerations for 
further details. 
6.4.5 Data Sharing and Long-term Preservation 
Disciplinary norms vary widely across the multiple social sciences disciplines in relation to how common 
it is for data to be shared and deposited. Some disciplines, including political science and economics, have 
rapidly developed data sharing practices based on widely shared norms about the replicability and 
transparency of research findings, as well as pre-registration of research studies. These have often been 
fostered by the requirements of top international journals to make data available for validation. Adoption 
levels vary considerably across countries even within disciplines, mostly as a function of the requirements 
and compliance monitoring of funders.    
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Embracing the FAIR agenda is now critical for all social scientists collecting data relating to COVID-19, and 
future pandemics, in order to ensure maximum benefit from the data. In the current emergency context, 
it is a moral imperative to preserve the data and share it in the most open way possible for each case. 
Where possible, provide immediate open access to all relevant research data. Open data should be 
licensed under Creative Commons Attribution 4.0 International License (CC BY 4.0) or a Creative Commons 
Public Domain Dedication or equivalent. If immediate open access is not possible, researchers should 
make data available as soon as possible. Researchers whose data have legal, privacy, or other restrictions 
should seek out appropriate alternative avenues for data sharing including restricted access conditions. 
Deposit quality-controlled research data in a data repository, whenever possible in a trustworthy data 
repository committed to preservation. As the first choice, disciplinary repositories are recommended for 
maximum visibility, followed by general or institutional repositories. See Use of Trustworthy Data 
Repositories and The 5 Safes Model for further guidance on repositories.  COVID-19 related social sciences 
data may be shared in a generalist repository. If you use a general repository (e.g. Figshare  Dryad  Harvard 
Dataverse  openICPSR  Zenodo and others), describe the data using the following as a minimum: the 
dataset’s creator, title, description, year of publication, any embargo, licensing terms, and repository 
identifier. The COVID Data Repository (ICPSR) accepts data from multiple domains (and formats) as a 
generalist repository, but because it is run by a social sciences data repository, ICPSR, it offers relevant 
domain repository benefits (e.g. curation by domain curators, restricted data dissemination options)  and 
ensures social sciences COVID-19 data are FAIR and in a CoreTrustSeal repository.  
To ensure social sciences data can be linked with data being produced by other entities, consider long-
term preservation of information that enables data linkages to be made over time, under appropriate 
security frameworks by creating a separate file. This file should be kept apart from the rest of the data, 
which provides the linking relationship between any personal identifiers and the randomly assigned 
unique identifiers.  
Social scientists should make available and deposit with data in a repository all documentation--such as 
codebooks, lab journals, informed consent form templates--which are important for understanding the 
data and combining them with other data sources. Researchers should also make available information 
regarding the computing context relevant for using the data (e.g. software, hardware configurations, 
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7. Community Participation and Data Sharing  
7.1 Focus and Description 
Public health emergencies require profound and swift action at scale with limited resources, often on the 
basis of incomplete information and frequently under rapidly evolving circumstances. The current COVID-
19 pandemic is one such emergency, and its scale is unprecedented in living history. Worldwide, many 
communities are coming together to address the emergency in a plethora of ways, many of which involve 
data in various fashions. For instance, they produce or mobilise data, add or refine metadata, assess data 
quality, merge, curate, preserve and combine datasets; analyse, visualise and use the data to develop 
maps, automated tools and dashboards; implement good practices, share workflows, or simply engage in 
a range of other activities that can or do leave data traces that can be leveraged by others.   
This section highlights and ultimately supports the work by communities who are collecting, curating and 
sharing data with the goal of improving research outputs and public knowledge. Employing specific use 
cases, we detail the achievements and outputs of groups who practise data sharing and stewardship, 
aiming to broaden access to the existing recommendations and guidelines for research data best 
practices. As described in “Principles of data sharing in public health emergencies” (GLOPID et al., 2018) 
and similar publications, such guidelines address issues of data stewardship, ethics and legality in sharing 
data, technical considerations in making data FAIR, or other similar guidance for collaborating in research 
during a crisis. 
These recommendations and guidelines ultimately aim to facilitate the timely sharing of data relevant to 
the COVID-19 response, and build much-needed capacity, including knowledge, for similar events in the 
future. They also hold considerable value for both public and science communication, informing opinions 
and understanding, whilst supporting decision-making processes.  
Although these guidelines have been developed with research data in mind, it is also desirable that data 
created directly by citizens, patients, communities and other actors in a health emergency be produced, 
curated and shared in line with the spirit of these stewardship and sharing guidelines. For example, 
community projects such as OpenStreetMap and Wikidata generate very valuable FAIR and open data 
(e.g. see Waagmeester et al., 2020), which can be analysed and used along with data from professional 
research and other sources. 
7.2 Scope 
This section discusses community participation and is intended to look at data management and sharing 
issues reflecting on the technical, social, legal and ethical considerations from that perspective. 
These recommendations and guidelines are both for and building upon community participation, and the 
intended audience and contributors are:  
1. Researchers undertaking activities along the entire life cycle of pertinent data, especially those 
not covered in the other RDA COVID-19 WG sections and involving broad-scale community 
participation but also data stewardship of the community-generated data. 
2. Citizen scientists undertaking research activities and in need of guidance (e.g. in terms of ethics) 
as well as a means to seamlessly contribute to a common body of knowledge and collaborate with 
other actors involved. 
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3. Policymakers who are involved in setting the framework for community participation, funding 
innovation, working on research policy or focusing on integrating data in decision-making. 
4. Patients, caregivers and the communities around them that are involved in leveraging data to 
improve prevention, diagnostics or treatment (this complements the section on Data Sharing in 
Clinical Medicine).  
5. Developers involved in the creation or maintenance of applications targeted at community data 
collection that are specific to COVID-19 (e.g. contact tracing apps or exposure risk indicator apps) 
or more generic in nature (e.g. health or neighbourhood apps). 
6. Device makers involved in developing sensors and data generating products for the community 
to use. 
7. Emergency responders, governmental or societal groups involved in prevention and response 
strategies. 
8. Communicators involved in informing communities and societies at large about data-related 
aspects of the COVID-19 pandemic, translating data into meaningful and easy to grasp 
information, and circulating graphics or key messages in conventional or social media. 
9. Citizens and the public at large, i.e. members of any community - including Indigenous - wanting 
to contribute to the COVID-19 response in ways that involve data and who want to have a say in 
how to balance that with legal and ethical issues surrounding such data. 
10. Other actors (individuals or organisations) who are involved in community-based activities around 
COVID-19 related data. 
This document is intended to provide guidance and recommendations to the groups referenced above, 
considering their roles and the data challenges they might face:  
1. Data subjects: Informed consent - including forms of dynamic consent as necessary - should be 
obtained from the data subjects before any personal data are collected from/about them and 
whenever there are changes to the data collection process, e.g. patients, citizens, general public. 
2. Data processors/ data custodians/ data controllers: determine the purposes and methods of the 
processing of personal data, perform the data processing, including analysis, anonymisation and 
de-identification, storing and preservation, sharing e.g. researchers, app developer, funders, 
policymakers, health authority. 
3. Coordination and information management - documenting decision-making, data workflows. The 
temporary nature of the disaster response stages that the COVID-19 context asks for often leaves 
limited time to establish a proper data management workflow and sufficient documentation of 
the data and decision-making process.  
4. Public and science communication - providing easy to access and reliable data and information, 
dealing with misinformation, develop a proper approach to engage the community participation 
in data collection. 
We anticipate many community participation topics to be relevant for the present COVID-19 context 
including but not limited to: collaborative data collection, collaborative service or software development 
initiatives, crowdsourcing of data curation services, data sovereignty when sharing across communities, 
citizen-led community responses, digital platforms, apps or other digital tools to enable public 
participation and/or offer open data. We particularly address two of them as use cases: app development 
for community-generated data and data challenges in participatory disaster response strategies.  
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What do we mean by app development for community-generated data?  
1. Symptom tracking apps (health monitoring apps where users self-report COVID-19 symptoms). 
2. Contact tracing apps (mobile phone tracking used to identify the potential geographic spread of 
COVID-19). 
3. Services app (including service volunteers such as healthcare, shopping, entertainment, religious 
services). 
What do we mean by participatory disaster response strategies and the related data challenges?  
1. Open government data for disaster response strategies - Recommendations & guidelines for 
community contributions & engagement, best practices. 
2. Citizen scientists and participatory disaster response strategies - Recommendations & guidelines 
for the engagement of citizen scientists, best practices. 
3. Coordination platforms & networks for disaster response strategies.  
7.3 Policy Recommendations 
7.3.1 Transparency, Community Participation and Data Governance 
1. A balance must be achieved between timely testing and contact tracing, exposure notification, 
emergency response and community safety alongside individual privacy concerns such as 
surveillance, unauthorised use of personal data and forms of abuse that might result from the 
identification of subjects. 
2. There is a strong need to establish appropriate and transparent governance mechanisms to have 
oversight of the data and its management. An open and transparent approach allows for the 
community to have a say and suggest improvements e.g. guidelines from the Ada Lovelace 
Institute (Ada Lovelace Institute, 2020). 
3. Policymakers need to adopt an active approach to bridging communities and ensuring inputs are 
streamlined, perspectives from communities are considered, and widely communicated. The aim 
of linking communities and supporting communication is also designed to help coordination and 
avoid duplication of efforts since many communities are driving similar or complementary efforts 
to help the response to the current public health emergency. 
4. Preparedness efforts should include provisions to enable web archiving of governmental, public 
health sector and emergency response websites. 
7.3.2 Inclusive, Incremental and Multidisciplinary Approach  
1. Consider data and data stewardship expertise as key resources for the detection, investigation 
and response to public health emergencies such as COVID-19. Encourage and facilitate the 
participation of data-focused organisations and communities to strategy and response networks. 
2. Inclusivity and diversity of roles - ensure developers, data stewards, healthcare professionals, 
epidemiologists, researchers and the public are represented in the teams driving the development 
of the data collecting apps, participatory disaster response strategies and coordination platforms. 
App developers or users or responders with data-related roles are not always aware of all the 
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ethical and legal implications of the data they gather and might not be familiar with protocols for 
collecting and sharing data. 
3. Consider the use of the data - clinical, social etc. This will help identify useful standards and 
disciplinary norms, provide additional directions on the necessary contextual information and 
harmonised metadata which will allow reuse and sharing across various information systems. 
Other sections of the RDA COVID-19 Recommendations and Guidelines provide further details on 
some of these. 
4. Whenever possible, aim to reuse and share applicable recommendations that already exist for 
and from specific communities and/or types of data. To this end, adopt a standardised approach 
to identify existing guidance from specialised communities. e.g. the Global outbreak alert and 
response network (GOARN) and its COVID-19 Knowledge Hub covers Capacity Building and 
Training, Go.Data, Research, Risk communication and community engagement (RCCE) (Global 
outbreak alert and response network, 2020). 
7.3.3 Legal and Ethical Aspects 
1. Ethical considerations have to be made regarding the two-way sharing of information using 
mobile-tracking apps or similar technologies when managing data related to the identification 
and prevention of infection. These need to be embedded in the emergency response strategies 
and measures. 
2. According to the humanitarian information management principles, information exchange should 
be a beneficial two-way process between the affected communities and the humanitarian 
community, including affected governments (Mackintosh, 2000). Therefore, it is crucial to also 
give timely feedback to communities during the participatory data collection and decision-making 
process. This requires additional control on data sharing and access management. 
3. Adequate medical, social and emotional support networks need to be established before apps 
relay to users they may have been in close proximity to a COVID-19 positive individual. Data 
governance comes with accountability and the need to work with the relevant local, national and 
international authorities to ensure appropriate support networks are in place and the app 
coordinates with these authorities in such matters. 
 
Use sensitivity to guide technical choices and considerations, such as a decision to only transmit 
anonymised codes as a means to alert individuals of exposure, tailored to the specific context as much as 
possible and with additional consideration given to wording, where applicable.  
7.3.4 Software Development 
Contact tracing apps should adhere to the same development recommendations as other software, 
particularly to build public trust (see Research Software Sharing for Data Analysis). It has been highlighted 
that scientists must openly share the code behind modelling software so that the results can be replicated 
and evaluated (Barton et al., 2020), and the transparency provided by open sharing can also address 
security concerns.  
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7.4 Guidelines 
In the race against time to collect the data required to combat the COVID-19 pandemic, there is a risk that 
data are collected without sufficient attention to quality and reliability of data (e.g. level, or rather lack 
of, any basic provenance of the data, quality of the sources, versioning, metadata and level of 
maintenance). The research data community has been addressing these challenges, developing standards, 
vocabularies and ontologies, workflows and various disciplinary norms, as well as a key set of principles 
to ensure data quality, findability, accessibility, interoperability and reuse (FAIR). Implementing the FAIR 
data principles more widely and in more detail will ease sharing and increase efficiency, which is especially 
important considering the time constraints we are facing. 
7.4.1 Data Collection 
1. Encourage public and patient involvement (PPI) throughout the data management lifecycle from 
the inception of the research question, implementation of the data collection and final data 
sharing and usage. 
2. Ensure apps and participatory response coordination platforms are developed with the research, 
emergency response and health care questions as the central concept and only gather data 
needed to address these questions. 
3. Applications designed to collect data should be developed as open-source, with an early release 
on a public code repository, and made available under an open-source licence (c.f. section on 
Research Software in this report), to build confidence in the public about security and privacy. It 
also allows for the rapid identification and removal of vulnerabilities. 
4. Protecting personal data is of the utmost importance when developing applications. Use protocols 
and methods that aim to protect personal data e.g. Decentralised Privacy-Preserving Proximity 
Tracing (DP-3T). 
7.4.2 Data Quality and Documentation 
Follow standardised ways of collecting and curating community-generated data securely and select 
trustworthy data repositories as a way of standardising COVID-19 data whilst ensuring quality and 
facilitating sharing.  
When collecting and curating the data, ensure detailed metadata are captured with the data and 
workflows are documented. A consolidated effort should be taken to include the following. 
1. Protecting personal data is of key importance when developing applications. Use protocols and 
methods that aim to protect personal data, e.g. DP-3T. 
2. Provide contextual metadata to help processing, visualisation, analysis, storage, publishing, 
archiving and reuse. 
3. Include detailed descriptions of the methods to aid verification of results. 
4. Include details on the consent and type of consent associated with the collected data. 
5. Metadata should also include any retention (and deletion) obligations associated with the data. 
6. Also, where possible consider including, as metadata, specific information on technological 
characteristics and their limitations (e.g. efficiency of the underlying app technology, e.g. 
Bluetooth versus GPS). 
7. Develop, implement and share clear and working protocols/workflows for managing the data 
processing, especially during participatory crisis response, preferably automatic workflows with 
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machine actionable data formats to maximise the data processing. Considering the diverse types 
and sources of data, structured processes for handling data intake and output allow all involved 
stakeholders to work efficiently.  
7.4.3 Data Storage and Long-term Preservation 
Consideration for long term storage and preservation of data generated from open government data for 
disaster response strategies, apps, other resources and response coordination platforms in relation to 
COVID-19, is not always apparent. For example, what are the retention periods that apply for COVID-19 
related data of a specific kind in given legislation? Due to the unprecedented nature of this pandemic, 
much of this is only being considered on short time frames that do not allow for appropriate planning. In 
addition to community endorsed best practices in data storage and long-term preservation (see also 
Section 6.4.3), attention should be focused on:  
1. Ensure that prevailing local, national and international legal and ethical requirements for health 
data and medical studies and open government data, where applicable (e.g. for data retention 
periods), are adhered to as best as possible. 
2. Ensure that provision is made to facilitate updating of the data collection, storage and 
preservation to meet any changes to existing requirements. 
3. Long-term preservation should be considered in the case of high-value data that could help in 
retrospective modelling of the current pandemic or in modelling future ones. See 2.2.7 Use of 
Trustworthy Data Repositories.  
4. Data should be available under an open licence that enables reuse, with CC0 as default, unless 
there are legal and ethical considerations indicating otherwise. 
5. Consider the benefits and challenges of either a centralised or decentralised model for data 
storage and processing.   
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8. Indigenous Populations and Data Sharing 
8.1 Focus and Description 
Indigenous Peoples around the globe have diverse narratives of resilience and adaptability; however, 
they are also acutely impacted by the negative social, economic, environmental and health outcomes of 
COVID-19 (UN Special Rapporteur on the rights of Indigenous Peoples, 2020). As such, it is vital that 
Indigenous Peoples are included in all aspects of pandemic-related surveillance, research, research 
planning, and policy. Systemic policies, and historic and ongoing marginalisation, have led to Indigenous 
Peoples’ mistrust of agencies and the data/research they produce. For example, Indigenous nation-
specific COVID-19 data in the United States have been released by government entities without tribal 
permission and knowledge. These sensitive data continue to be accessed and reused without consent 
from Indigenous governing bodies by the media, researchers, non-governmental organisations, and 
others. Although this type of data usage is attempting to combat data invisibility of American Indians 
and Alaska Natives to address gaps, reporting of tribal-specific data is making tribes more visible in ways 
that can result in unintentional harm and ignores inherent Indigenous sovereign rights. Media 
perpetuation of mis-information and dis-information is amplifying confusion and harm to Indigenous 
Peoples. 
To avoid increased distrust and harm, and to improve the quality and responsiveness of data activities, 
Indigenous data rights, priorities, and interests must be recognised in all COVID-19 research activities 
throughout the data lifecycle, and in ownership of any resulting innovations. We must also acknowledge 
that expressions of self-determination vary substantially across nation states due to conditions that also 
undermine the ability of Indigenous Peoples to govern data or enact sovereignty over data. 
The Indigenous Data Guidelines within this document have emerged through global collaborations with 
Indigenous Peoples and Indigenous data governance advocates. They outline obligations for funders, 
governments, researchers, and data stewards in the collection, ownership, application, sharing, and 
dissemination of Indigenous data, specifically in relation to COVID-19 related issues. These Guidelines 
reflect and support Indigenous Data Sovereignty (see www.GIDA-global.org) and are underpinned by the 
United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP). They do not supersede or 
replace existing Indigenous governance protocols or agreements developed (or under development) by 
Indigenous Peoples or nations. Rather, these Guidelines point to the need for Indigenous Peoples and 
nations to be engaged in governance on their own terms across COVID-19 data lifecycles and ecosystems. 
This demands proactive investment in Indigenous community-controlled data infrastructures to support 
communality capacity and resilience, and improve the flow of information for effective public health 
response. 
The Indigenous Data Guidelines set out the minimum requirements for Indigenous-designed data 
approaches and standards, inclusive of Indigenous rights to data governance and decision-making within 
the planning and design of Indigenous data collection and sharing. The Indigenous Data Guidelines also 
highlight the inadequacy of personal and individual consent and data privacy protections. For Indigenous 
Peoples, collective consent and data privacy protections, supported via community-controlled data 
infrastructure, are essential to ethical Indigenous data practices. 
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8.2 Scope  
The CARE Principles for Indigenous Data Governance -- Collective benefit, Authority to control, 
Responsibility, Ethics -- (www.gida-global.org/care) set forth critical considerations for Indigenous rights 
and interests in data. Indigenous data, in general, comprise data, knowledge, and information that relate 
to Indigenous Peoples at both the individual and collective level, including data about lands and 
environment, people, and cultures. In the context of COVID-19, Indigenous data include data about 
COVID-19 testing (individual and community, e.g. wastewater), cases, hospitalisations, health service 
access, deaths, and comorbidities, as well as related Indigenous Knowledges about COVID-19, and data 
on the socioeconomic and environmental correlates and impacts of COVID-19. The CARE Principles 
provide a framework for the collection, storage, access, and use of Indigenous Peoples’ data during the 
COVID-19 pandemic and beyond.   
Access to good quality data is a key driver for the implementation of the FAIR principles – Findable, 
Accessible, Interoperable, Reusable (Wilkinson et al., 2016). The FAIR principles are data-centric, 
supporting greater data findability, accessibility, interoperability and reusability. The FAIR principles 
facilitate increased data sharing among entities. However, they ignore relationships, power differentials 
and the historical conditions associated with the collection of data that impact ethical and socially 
responsible data use. The CARE Principles for Indigenous Data Governance speak to how data are used in 
ways that are purposeful and oriented towards enhancing the wellbeing of Indigenous Peoples. The CARE 
Principles can find expression alongside the FAIR principles across data lifecycles from collection to 
curation, from access to application. 
8.3 Policy Recommendations and Guidelines 
The CARE Principles for Indigenous Data Governance set a minimum standard for non-Indigenous 
policymakers, data stewards, researchers, aid groups, and others. 
COLLECTIVE BENEFIT: “Data ecosystems shall be designed and function in ways that enable Indigenous 
Peoples to derive benefit from the data.” 
1. “For inclusive development and innovation” 
Systemically, existing data ecosystems do not support meaningful inclusion of Indigenous data 
rights and interests, and when engaged Indigenous Peoples’ input is often left out of decision-
making, particularly when making data open (Rainie et al. 2019). Early conscious inclusion at all 
stages of data lifecycles (design, collection, access, analysis, reporting, storage, protection, use, 
and reuse of Indigenous data) and throughout data ecosystems (digital infrastructures, analytics, 
and applications) enhance benefits for Indigenous Peoples and minimize harms such as mis-
representation and dis-information. 
2. “For improved governance and citizen engagement” 
In many countries, Indigenous Peoples are exposed to a higher risk of pandemic-related harm, 
both to their health and livelihoods. COVID-19 is impacting all communities and responses must 
recognise the importance of diverse knowledge systems in decision-making in order to advance 
culturally-informed pandemic policy planning and implementation. By involving Indigenous 
Peoples throughout the COVID-19 pandemic preparedness and response processes, there is an 
opportunity to limit negative outcomes and inform both current and future pandemic response 
planning. 
3. “For equitable outcomes” 
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Repositories that include data that are collected or used as part of COVID-19 analyses or 
responses must explicitly support Indigenous governance of Indigenous data and include 
provenance for all Indigenous data. All surveillance, research, and data should contribute to 
addressing Indigenous Peoples’ concerns and questions to improve current and future responses, 
and to achieve equity. 
AUTHORITY TO CONTROL: “Indigenous Peoples’ sovereign rights and interests in Indigenous data must 
be recognised and their authority to control such data be empowered. Indigenous data governance 
enables Indigenous Peoples and Nations, through their established governing bodies and mechanisms, to 
determine how Indigenous Peoples, as well as Indigenous lands, territories, resources, knowledges and 
geographical indicators, are represented and identified within data.” 
1. “Recognising rights and interests” 
Upholding Indigenous rights and interests demands recognition and engagement of Indigenous 
systems of government and decision-making. Indigenous Peoples’ and nations’ governing bodies 
must be formally engaged with prior to the development and implementation of policies and 
agreements pertaining to Indigenous data that clearly state if,  how, and when Indigenous data 
are collected, analysed, accessed, used/reused, and reported. Permission to use and report on 
Indigenous Peoples and nations must be granted by appropriate and authorised Indigenous 
governing bodies. Disclosure of Indigenous information without permission is a violation of 
Indigenous sovereign rights and undermines Indigenous governance over matters that directly 
impact Indigenous Peoples. 
2. “Data for governance” 
Indigenous leadership concerning data collection, ownership, storage, sharing, and use is  the 
defining concept of Indigenous data sovereignty (Kukutai and Taylor 2016). Indigenous Peoples 
are in the best position to assess their own needs, priorities, and strengths and are informed by 
Indigenous responses to COVID-19 (see, for example, Māori Response Action Plan, also see AIPP 
COVID-19 Response). As such, Indigenous Peoples need to be supported to lead and/or participate 
in the design of COVID-19 data systems that involve the collection, analysis, and sharing of 
Indigenous data. Given that the identification of Indigenous Peoples in data collections has too 
often led to serious harm and/or stigma, Indigenous Peoples should be able to exercise 
governance over COVID-19 data that derive from them, individually or collectively, regardless of 
who collects the data (e.g. government, private sector, researchers), or where they are held. This 
includes Indigenous data that are de-identified or anonymised for the purpose of sharing. 
3. “Governance of data” 
Existing Indigenous governance protocols, including those related to decision-making over 
Indigenous data, must be recognised and adhered to during the COVID-19 pandemic. Indigenous 
governing bodies must continue to be involved in decision-making on data matters that impact 
their peoples and nations to ensure collective benefit and minimise harm from Indigenous data. 
RESPONSIBILITY: “Those working with Indigenous data have a responsibility to share how those data are 
used to support Indigenous Peoples’ self-determination and collective benefit. Accountability requires 
meaningful and openly available evidence of these efforts and the benefits accruing to Indigenous 
Peoples.” 
1. “For positive relationships” 
Systemic changes must occur at all levels of government and within institutions that collect, use, 
or hold Indigenous data to ensure that policies and data sharing agreements are consistent with 
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Indigenous priorities, are co-determined with Indigenous Peoples, and recognise Indigenous 
rights to control their data. 
2. “For expanding capability and capacity” 
Indigenous Peoples and nations have often enacted strong, effective first line of responses and 
defences against COVID-19, proactive investment in Indigenous community-controlled data 
infrastructure is recommended in order to support community capacity and resilience, and 
improve the two-way flow of information essential for effective public health responses. 
3. “For Indigenous languages and worldviews” 
Indigenous knowledge and worldviews offer strength for localised contact tracing - local contact 
tracing data are more likely to be stored in repositories that are governed by Indigenous Peoples. 
Investments into decentralised contact tracing applications and infrastructure is needed to ensure 
that Indigenous Peoples can control data as well as narratives over their own contextualised 
realities. 
ETHICS: “Indigenous Peoples’ rights and wellbeing should be the primary concern at all stages of the data 
life cycle and across the data ecosystem.” 
1. “For minimising harm and maximising benefit” 
Reporting of identifiable (e.g. ethnic, tribal affiliated, etc.) Indigenous COVID-19 data can 
contribute to racism and discrimination, hostility, reinforcement of negative stereotypes, and 
implicitly blame Indigenous Peoples and nations for the spread of COVID-19. Indigenous nations 
have the responsibility to provide for the safety and welfare of their peoples and nations by 
determining current and future use of their data, and how and with whom their information will 
be shared. This is to minimise harm and maximise any benefit that may result from public release 
of Indigenous-identified COVID-19 data and information. Permission to use and report identifiable 
Indigenous data by others (e.g. national and state government, researchers, media, etc.) must be 
granted by Indigenous governing bodies that have the authority to speak on behalf of Indigenous 
Peoples and nations before their Indigenous data are reported. Disclosure of this information 
without permission is a violation of Indigenous sovereign rights. 
2. “For justice” 
Indigenous data disaggregation is supported by Indigenous communities (FNIGC, 2016), the 
United Nations Permanent Forum on Indigenous Issues (2017), and by researchers (Kukutai et al., 
2015; Madden et al., 2016). Every effort should be made to collect data that enables Indigenous 
Peoples to be identified in relation to COVID-19 outcomes should they desire it, including the 
collection of ethnic and tribal identifiers. Non-reporting or aggregation of Indigenous findings into 
regional populations can disguise the urgent needs of Indigenous Peoples and is insufficient for 
monitoring the spread of COVID-19 for Indigenous Peoples. Whereas, appropriate reporting and 
disaggregation is a necessary condition that supports Indigenous visibility and decision-making. 
However, disaggregated data, without Indigenous governance risks: 1) violation of Indigenous 
Peoples and nations rights; 2) pejorative judgements from governments, the media, and the 
public; 3) improper extrapolation of dominant population findings into Indigenous populations; 
and 4) non-Indigenous algorithms being unreflectively applied to Indigenous data. 
3. “For future use” 
Indigenous data governance is also a prerequisite for determining appropriate future use of data. 
As contact tracing becomes a key tool to control COVID-19 there has been a noticeable shift from 
paper-based to electronic tracking, and to increased centralisation. Mobile phone proximity 
and/or location tracking is another tool being employed by nations and states to mitigate the 
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spread of COVID-19. While electronic tracking systems may have advantages in their ability to 
scale and include multiple inputs, they create an enduring record which in many countries do not 
as yet have an end date. These data, as well as other contact tracing data, can easily be 
repurposed for other activities. This form of function creep is of particular concern to Indigenous 
communities who recognise the immediate public health need but face deeper ongoing 
challenges associated with the use of surveillance as a tool of political oppression. Therefore, 
Indigenous governance throughout COVID-19 data ecosystems and lifecycles must be supported, 
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9. Research Software Sharing for Data Analysis 
9.1 Focus and Description 
It is important to put forward some key practices for the development and (re)use of research software, 
as doing so facilitates sharing and accelerates the production of results in response to the COVID-19 
pandemic.  
We provide here a number of foundational, clear and practical recommendations around research 
software principles and practices, in order to facilitate the open collaborations that can contribute to 
addressing the current challenging circumstances. These recommendations aim to enable relatively small 
points of improvement across all aspects of software that will allow its swift (re)use, enabling the 
accelerated and reproducible research needed during this crisis. These recommendations highlight key 
points derived from a wide range of work on how to improve the management of software to achieve 
better research (Akhmerov et al., 2019; Anzt et al., 2020; Clément-Fontaine et al., 2019; Jiménez et al., 
2017; Lamprecht et al., 2019; Wilson et al., 2017). 
9.2 Scope 
These recommendations cover general practices, not details of particular technologies or software 
development tools. The recommendations in Section 9.5 (Guidelines for Researchers) will not only help 
researchers improve their software quality and research reproducibility but also have an impact on 
policymakers, funders and publishers. The aim is that researchers follow the principles as thoroughly as 
possible, because doing so will improve the research environment for themselves and others. With the 
recommendations in Section 9.3 (Policy Recommendations), we aim for policymakers and funders to 
realise the--sometimes behind the scenes--work around research software (e.g. documentation and 
maintenance).  Such awareness will help them to create opportunities addressing, for instance, the 
acquisition of skills and the full development cycle. With the recommendations in Section 9.4 (Guidelines 
for Publishers), we aim for publishers to push forward citable software so it becomes equal in recognition 
to data and scholarly publications as a research outcome. 
Throughout this document we will be using software as a placeholder and interchangeably for compiled 
software (i.e., binaries) as well as for software source code (including, for example, analysis scripts and 
macros). When necessary to differentiate, we will make an explicit comment. 
9.3 Policy Recommendations 
Research software is essential for research, and this is increasingly recognised globally by researchers. 
This section provides recommendations for policymakers and funders on how to support the research 
software community to respond to COVID-19 challenges, based on existing work (Akhmerov et al., 2019; 
Anzt et al., 2020). National and international policy changes are now needed to increase this recognition 
and to increase the impact of the software in important research and policy areas. Additionally, given the 
impact that funding agencies can have in shaping research, it is equally important to ensure that research 
software is recognised and acknowledged as a direct and measurable outcome of funded efforts.  
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Policymakers and funders must continue to allocate financial resources to programmes that support the 
development of new research software and the maintenance of research software that has a large user 
base and/or an important role in a research area. By providing the resources that are necessary to adhere 
to best software development practices, policymakers and funders can increase overall software quality 
and usefulness.  This can be done by making it easier for researchers to move from quick and makeshift 
coding to creating shared and reusable software, allowing implementation of recommendations detailed 
in Sections 9.5.4 (provide sufficient metadata/documentation) and 9.5.5 (ensure portability and 
reproducibility). Funding for software development will also enable anyone producing research software 
to take the time to produce and document it well, which also aligns with the recommendation in Section 
9.5.4. After the software has been delivered, used and recognised by a sufficiently large group of users, 
human and financial resources should be allocated to support the regular maintenance of the software, 
for activities such as debugging, continuous improvement, documentation and training.  
Examples: UK Research and Innovation is funding COVID-19 related projects that can include work focused 
on evaluation of clinical information and trials, spatial mapping and contact mapping tools (UK Research 
and Innovation, 2020). Mozilla has created a COVID-19 Solutions Fund for open source technology projects 
(Mozilla, 2020). USA’s National Institutes of Health (NIH) provides  "Administrative Supplements to 
Support Enhancement of Software Tools for Open Science" (NIH, 2020c). The Chan Zuckerberg Initiative 
is funding open source software projects that are essential to biomedical research (Chan Zuckerberg 
Initiative, 2020). 
9.3.2 Encourage research software to be open source and require it to be available 
Policymakers should enact policies that encourage software to be available under an open source 
software licence, or at least require the software to be accessible. All research software that is released 
under a licence ensures clarity of how it can be used and protects the copyright holders. The use of open 
source software licences should be seen as the default for research software in publicly funded efforts. If 
that is the case, it means that its underlying source code is made freely accessible, as encouraged by the 
“A” in FAIR (Findable, Accessible, Interoperable and Reusable) (Wilkinson et al., 2016) to users to examine; 
it can be modified and redistributed (depending on the licence conditions). Through this process, software 
users can review, understand, improve, and build upon the software. As research outcomes rely on 
software, if software is not open source it must minimally be available for testing with different inputs, to 
enable understanding of the software’s functionality and properties and to reproduce the research 
outcomes. Whilst preprints and papers are increasingly openly shared to accelerate COVID-19 responses, 
the software and/or source code for these papers is often not cited (Howison et al., 2016) and hard to 
find, making reproducibility of this research challenging, if not impossible (Smith et al., 2016). Encouraging 
publishers to make software availability a default condition, together with the usually existing 
requirement for data availability, is an excellent way to greatly improve this. 
The policies and incentives recommended here will motivate researchers to implement recommendations 
in Sections 9.5.1 (make your software available), 9.5.2 (release your software under a licence) and 9.5.6 
(publish snapshots of your software in an archival repository with persistent identifiers (PIDs)) from the 
good practices section, thus increasing findability, continued usefulness, and improvement of software. 
Examples: The research community has been increasing access to key software and code, with a recent 
Science article calling for all scientists modelling COVID-19 and its consequences for health and society to 
rapidly and openly publish their code (Barton et al., 2020). High-profile examples include the Imperial 
College epidemic simulation model that is being utilised by government decision-makers, and was made 
publicly available with support by Microsoft to accelerate the process (Adam, 2020). The fact that it was 
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open also meant it could be inspected and improved. This is an important point that emphasises the 
raising of quality and the foundation of trust in results. 
9.3.3 Encourage the research community’s ability to apply best practices for 
research software, including training in software development concepts 
Policymakers and funders should provide programmes and funding opportunities that encourage both 
researchers and research support professionals (such as Research Software Engineers and Data Stewards) 
to utilise best practices to develop better software faster. In order to make research software 
understandable and reusable, it must be produced and maintained using standard practices that follow 
standard concepts, which can be applied to software ranging from researchers writing small scripts and 
models, to teams developing large, widely used platforms. As research is becoming data-driven and 
collaborative in all areas, all researchers and key research support professionals would benefit from the 
development of core software expertise. Policymakers should support inclusive software skills and 
training programmes, including development of communities of learners and trainers.  
The introduction of such programmes and funding opportunities will increase the overall understanding 
and adaptation of all recommendations from the good practices section among researchers. This supports 
the outcomes of the other three recommendations in this section.  This also makes it easier for 
researchers to align to all the recommendations provided in Section 9.5 targeting good practices for 
research software. 
Examples: There are various initiatives that link community members with specific digital skills to projects 
needing additional support, including Open Source Software helpdesk for COVID-19 (Caswell et al., 2020) 
and COVID-19 Cognitive City (Grape, 2020). Other initiatives aim to increase skills for engaging with 
software and code, such as the Carpentries (Carpentries, 2020), USA’s NIH events (NIH, 2020d); and the 
Galaxy Community and ELIXIR’s webinar series (ELIXIR, 2020). 
9.3.4 Support recognition of the role of software in achieving research outcomes 
Policymakers should enact policies and programmes that recognise the important role of research 
software in achieving research outcomes. It is important that policymakers encourage the development 
of research assessment systems that reward software outputs, alongside publications, data and other 
research objects. It is equally critical that funders ensure that data and software management plans are a 
requirement in funding processes. It is also important that policymakers work to ensure these systems 
include proactive responses when these are not implemented. Enacting such policies will encourage 
researchers to implement recommendations in Sections 9.5.1 (make your software available), 9.5.3 (cite 
the software you use) and 9.5.6 (publish snapshots of your software in an archival repository with 
persistent identifiers (PIDs)) from the good practices section, thus creating a self-strengthening system of 
incentives for the development of high-quality software. 
Examples: Policymakers need to support initiatives such as the Declaration on Research Assessment 
(DORA, 2016), which are beginning to be utilised by research agencies including Wellcome (Wellcome, 
2020), signatories to the Concordat to Support the Career Development of Researchers (Vitae, 2020). 
9.4 Guidelines for Publishers  
A key component of better research is better software. Publishers can play an important role in changing 
research culture, and have the ability to make policy changes to facilitate increased recognition of the 
 
64 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
importance of software in research. This section provides recommendations for publishers on how to 
support the research software community to respond to COVID-19 challenges. 
9.4.1 Require that software citations be included in publication 
It is essential that the role of software in achieving research outcomes is supported. Treating research 
software as a first class research object in a scholarly publication is a very effective mechanism for 
implementing this, as it increases the visibility and credit to the research software developers (for example 
by enabling academic and commercial citation services and/or databases, such as Google Scholar, Scopus 
and Microsoft Academic) (Smith et al., 2016). 
Examples: The FORCE11 Software Citation Implementation Working Group (Chue Hong et al., 2017) has 
been leading work in this area for 3+ years, and currently has a journals task force that is developing 
sample language for journals to use. The American Astronomical Society (AAS) Journals encourage 
software citation in several ways (explicit software policy, added the LaTeX \software{} tag to emphasise 
code used, etc.) (AAS Journals, 2020). 
9.4.2 Require that software developed for a publication is deposited  in a repository 
that supports Persistent Identifiers 
For publishers to ensure that the research they publish is reproducible, software developed as part of the 
work reported in a submission must also be findable. Publishers should require such software to be 
deposited in an archival repository that supports PIDs such as Zenodo (CERN, 2020) and Figshare 
(FigShare, 2020). These repositories provide PIDs that can be directly included in the citation and 
referenced in a publication, supporting research integrity (Di Cosmo et al., 2018). If the software is 
deposited along with data (DataCite, 2020), as recommended in certain communities of practice,  the 
selected data repository should provide a PID for the collection. Several versions of the software can be 
tagged with PIDs and, thus, if multiple versions are used for research, having different PIDs ensures 
reproducibility. 
Example: The Journal of Open Source Software (JOSS, 2020) review process requires authors to make a 
tagged release of the software after acceptance, and deposit a copy of the repository with a data-archiving 
service such as Zenodo or Figshare. This is part of the guidance from the FORCE11 Software Citation 
Implementation Working Group (Chue Hong et al., 2017). The GigaScience journal is another example of 
publication requiring the availability of software (GigaScience, 2020). 
9.4.3 Align submission requirements of software publishers to research software 
best practices 
Recently research software has gained a more prominent place in publishing and some journals specialise 
in publishing software and software papers. In order to make research software understandable and 
reusable, it must be produced and maintained using standard practices that follow standard concepts. 
This can be applied to software ranging from researchers writing small scripts and models to teams 
developing large, widely used platforms. As publishing is an integral part of research, software publishers 
should enact policies and adopt submission procedures, including appropriate software review processes, 
that encourage and support these practices, for example through adopting or adapting software 
management statements similarly to the widely adopted data management statements. 
Example: The Journal of Open Source Software requires software to be open source and be stored in a 
repository that can be cloned without registration, is browsable online without registration, has an issue 
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tracker that is readable without registration and permits individuals to create issues/file tickets (JOSS, 
2020); SoftwareX submission process includes two mandatory metadata tables that include licence and 
code availability (Elsevier, 2020). 
9.5 Guidelines for Researchers 
These guidelines aim at supporting researchers with key practices that foster the development and (re)use 
of research software, as these facilitate code sharing and accelerated results in response to the COVID-19 
pandemic. This section will be relevant to audiences ranging from researchers and research software 
engineers with comparatively high levels of knowledge about software development to experimentalists, 
such as wet-lab and other researchers in a range of disciplines, writing scripts or macros with almost no 
background in software development. 
9.5.1 Make your software available 
Making software that has been developed available is essential for understanding your work, allowing 
others to check if there are errors in the software, be able to reproduce your work, and ultimately, build 
upon your work. The key point here is to ensure that the source code itself is shared and freely available 
(see information about licences below), through a platform that supports access to it and allows you to 
effectively track development with versioning (e.g. code repositories such as GitHub (GitHub Inc., 2020), 
Bitbucket (Atlassian, 2020), GitLab (GitLab, 2020), etc.). Furthermore, if using third-party software 
(proprietary or otherwise), researchers should share and make available the software source code (e.g. 
analysis scripts) they produce (even if they do not have the intellectual property rights to share the 
software platform or application itself). 
Resources:  
Four Simple Recommendations to Encourage Best Practices in Research Software (Jiménez et al., 2017). 
FAIR Research Software - code repositories (eScience Center, 2020). 
9.5.2 Release your software under a licence 
Software is typically protected by Copyright in most countries, with copyright often held by the institution 
in which the work was performed rather than the developer themself. By providing a licence for your 
software, you grant others certain freedoms, i.e., you define what they are allowed to do with your code. 
Free and Open Software licences typically allow the user to use, study, improve and share your code. You 
can licence all the software you write, including scripts and macros you develop on proprietary platforms.  
Resource: Choose an Open Source Licence (Choose a licence, 2020). 
9.5.3 Cite the software you use 
It is good practice to acknowledge and cite the software you use in the same fashion as you cite papers to 
both identify the software and to give credit to its developers. For software developed in an academic 
setting, this is the most effective way of supporting its continued development and maintenance because 
it matches the current incentives of that system.   
Resource: Software Citation Principles (Smith et al., 2016).  
9.5.4 Provide metadata/documentation for others to use your software 
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(Re)using code/software requires knowledge of two main aspects at minimum: environment and 
expected input/output. The goal is to provide sufficient information that computational results can be 
reproduced and may require a minimum working example. 
Resource: Ten simple rules for documenting scientific software (Lee, 2018). 
9.5.5 Ensure portability and reproducibility of results 
It is critical, especially in a crisis, for software that is used in data analysis to produce results that can, if 
necessary, be reproduced. This requires automatic logging of all parameter values (including setting 
random seeds to predetermined values), as well as establishing the requirements in the environment 
(dependencies, etc). Container systems such as Docker or Singularity can replicate the exact environment 
for others to run software/code in.  
Resource:  
Ten Simple Rules for Writing Dockerfiles for Reproducible Data Science (Nüst et al., 2020).  
Ten Simple Rules for Reproducible Computational Research (Sandve et al., 2013). 
9.5.6 Publish snapshots of software in an archival repository with persistent 
identifiers (PIDs) 
Equally important to making the source code available is providing a means of preserving and referring to 
it in the long-term (Di Cosmo et al., 2018). For this reason, software should be deposited within a 
repository that supports persistent identifiers (PIDs - a specific example being DOIs), allows for robust 
metadata and discovery mechanisms, and provides more persistent storage than the code development 
and collaboration platforms mentioned in Section 8.5.1. Such repositories include Zenodo (CERN, 2020) 
and Figshare (FigShare, 2020). There are communities of practice that encourage deposition of software 
(e.g. analysis scripts) and data in one submission. In those circumstances the selected data repository 
(DataCite, 2020) should provide a PID for the collection. For reproducibility purposes, and if legally 
allowed, dependencies should also be included in the software deposition. When publishing research 
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10. Legal and Ethical Considerations 
10.1 Focus and Description 
The intention of these guidelines is to help researchers, practitioners and policymakers deal with the 
ethical and legal aspects of pandemic response and in particular with regard to key ethical values of equity, 
utility, efficiency, liberty, reciprocity and solidarity (WHO, 2007; UNESCO, 2020; European Group on Ethics 
in Science and New Technologies, 2020). In times of public health emergencies, it is appropriate to 
consider how best to respond in terms of increased data and research outcome sharing.  However, it is 
important that legal and ethical principles are incorporated into research design from the outset. The law 
supports research and enables data sharing (EDPB, 2020). Compliance with the law protects individual 
researchers, research more generally and the common good. The rule of law cannot be overlooked, 
therefore, and needs to be taken into consideration along with respect for overarching concerns related 
to human rights and dignity (Council of Europe, 2020). Especially where marginalisation or other forms of 
stigmatisation are at stake, these rights and values should inform appropriate research practices directed 
towards the common good. 
The aim is to identify and collate existing recommendations and guidelines on legal and ethical issues in 
order to increase the speed of scientific discovery by enabling researchers and practitioners to:  
1. Readily identify the guidance and resources they need to support their research work; 
2. Understand generic and cross-cutting ethical and legal considerations; 
3. Appreciate country- or region-specific differences in policy or legal instruments; 
4. Identify the institutional stakeholders best placed to provide relevant ethical and legal guidance. 
10.2 Scope 
The COVID-19 pandemic has created significant confusion for researchers in terms of whether, and in 
which way, existing ethical and legal principles remain relevant. The COVID pandemic does not serve to 
remove the basic validity of the rights and interests on which these documents and principles are based. 
In other words, formal protocols for conducting research are required both during a pandemic and at 
other times, unless otherwise modified by the relevant authorities. The emergency does, however, 
mandate a reconsideration of the balance between these rights and interests - in particular between a 
research subject’s right to privacy and the public interest in the outcome of research. In some cases, this 
reconsideration has led to legitimate time limited adaptations of, or derogation from, normally applicable 
principles.  
The assumption here is that there will be an official statement from WHO of when the international 
community deems the pandemic to have ended. This may then vary by country. Irrespective of official 
statement, the necessity and proportionality of any interference with fundamental rights and interests 
may shift as circumstances change. It will be important to evaluate the continued justification for 
particular trade-offs at regular intervals in dynamic situations. 
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10.3 Policy Recommendations 
10.3.1 Initial Recommendations 
1. Access to research and research outcomes should be shared with all where possible and in 
particular, thinking of vulnerable groups and the general focus on solidarity, encouraging the 
engagement and trust of all participants including vulnerable groups. 
2. Ethical guidelines on data collection, analysis, sharing and publication should not be confined to 
clinical and biological (Omics) data. Such guidelines should also extend to all areas of Open 
Science. 
3. In the spirit of the Open COVID Pledge (2020), organisations with potentially useful datasets 
outside the research communities should be encouraged to make those data available to those 
research communities during emergency, pandemic situations. 
4. Ethical and legal policies should be drawn up to monitor and regulate the impact of algorithmic 
profiling and data analytics, not least in terms of design and implementation. 
5. During a pandemic or similar public emergency, ethics review and other formal approval 
processes should be expedited in compliance with local norms and practices.4  
6. Policymaking should be underpinned by empirical research (evidence-based) such that decision-
makers are held to account. 
7. Provide guidance and support for non-research organisations to make the data they hold available 
to the research community. 
8. All stakeholders (researchers, policymakers, editors, funders and so forth) should encourage 
communication across all disciplines and all areas in the spirit of Open Science. 
9. All stakeholders (researchers, editors, funders and so forth) should lobby for regulatory change 
where existing regulation prevents appropriate data access and sharing. 
10. All stakeholders (especially researchers) should be encouraged to publicise practical guidance and 
advice from their own experience of working through regulatory processes in support of their 
research. 
10.3.2 Relevant Policy and Non-Policy Statements 
The RDA COVID-19 Ethical-Legal group endorses and recommends guidance published as follows: 
1. The OECD Privacy Principles (OECD, 2010); 
2. The UNESCO International Bioethics Committee (IBC) and World Commission on the Ethics of 
Scientific Knowledge and Technology (COMEST) in their STATEMENT ON COVID-19: ETHICAL 
CONSIDERATIONS FROM A GLOBAL PERSPECTIVE (UNESCO, 2020); 
3. The Council of Europe points to national resources from national ethics committees or other 
related to COVID-19: (Council of Europe Bioethics, 2020a); 
 
4 Cf. the Green / Amber / Red system of risk assessment applied in the UK 
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4. The Council of Europe statement on bioethics during COVID-19: (Council of Europe Bioethics, 
2020b); 
5. The European Group on Ethics in Science and New Technologies statement on solidarity (2020); 
6. The Global Alliance for Genomics and Health (GA4GH) Framework for Responsible Sharing of 
Genomic and Health-Related Data (Global Alliance for Genomics and Health, 2014); 
7. The Statement of the African Academy of Sciences’ Biospecimens and Data Governance 
Committee on COVID-19: Ethics, Governance and Community engagement in times of crisis (AAS, 
2020); 
8. Committee on Economic, Social and Cultural Rights, Statement on the coronavirus disease 
(COVID-19) pandemic and economic, social and cultural rights (UN Office of the High 
Commissioner, 2020); 
9. RECOMMENDATIONS ON PRIVACY AND DATA PROTECTION IN THE FIGHT AGAINST COVID-19 
(Access Now, 2020). 
10.4 Guidelines 
10.4.1 Cross-Cutting Principles 
In addition to following the FAIR principles, all activities, especially in times of pandemic or other public 
emergencies, should be guided by: 
1. The CARE (Collective benefits, Authority to control, Responsibility and Ethics) principles to ensure 
ethical treatment of individuals and communities (Global Indigenous Data Alliance, 2019); 
2. The Global Code of Conduct, specifically Fairness, Respect, Care and Honesty in research activities, 
to maximise equanimity in research outcome benefit (Schroeder et al., 2020); 
3. The Five Safes of research data governance (UK Data Service, 2020; Ritchie, 2008); 
4. Research Integrity guidelines (ALLEA, 2017). 
10.4.2 Hierarchy of Obligations 
Ethics and the law exist in a symbiotic, mutually supportive relationship. Ethical and legal considerations 
related to research are elaborated in four key types of documents: ethical guidelines; policy guidance; 
codes of conduct; and legal instruments. The distinction between these types of instrument is not always 
obvious. Regulatory agencies (such as Supervisory Authorities in the EU) do respond to requests for 
support and clarification. It is therefore recommended that where necessary, researchers work together 
with the relevant authority to resolve any perceived barriers. 
The following principles may prove useful for COVID-19 researchers considering the interaction between 
instruments:  
1. Ethical guidelines are often defined and published by non-law-making bodies, while legal 
instruments will be adopted by governments or other legislative bodies. 
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2. Many ethical instruments are de facto mandatory for researchers or clinicians, such as those 
imposed by professional associations or bodies, healthcare institutions, or governmental and 
funding agencies.  
3. Instruments exist in a hierarchy, with legal instruments being generally assumed to take 
precedence over ethical guidance and policy guidance. 
4. Jurisprudence and other official guidelines providing authoritative interpretations of legal 
instruments will often be complementary to related ethical instruments. In the case of a dispute, 
however, the rule of law will prevail.  
5. Both legal and ethical instruments should be consulted together to understand all the pertinent 
issues which need to be taken into consideration. Intellectual property and associated rights 
should be taken into account in determining appropriate uses of data and of the innovations 
derived therefrom.  
6. Ethical instruments are generally interpreted harmoniously with the law and can guide the 
interpretation of the law if the law does not address a particular issue. 
Common obligations in using health or health-related data that are found in many laws and ethical 
guidelines include the following: 
1. Research projects using human data must be approved by an independent research ethics board 
(or research ethics committee, or institutional research board) prior to the recruitment of 
participants and the collection of data, in compliance with local requirements. Research ethics 
boards have broad powers to approve, reject, require modification of, and terminate research 
projects. 
2. All research projects using human data should comply with local legal obligations as outlined in 
the following. 
3. The obligation to respect confidentiality.  
4. The obligation to ensure data accuracy. 
5. The obligation to limit the identifiability of personal data as far as possible - including via 
pseudonymisation techniques. 
6. The obligation to use anonymised data instead of personal data, or minimise personal data use, 
or de-identify where possible. 
7. The need to process for a specific, authorised, purpose and only to process for secondary 
purposes provided certain conditions are fulfilled and not processing for purposes beyond 
scientific research / healthcare; e.g. not sharing with employers or other agencies unless 
mandated by law. 
8. The obligation to inform individuals about the processing of their data. 
9. To hold oneself accountable to, and remain transparent towards, the individuals concerned by 
the data used. 
10. To provide individuals access to their data, and to rectify errors or biases in the data on request. 
11. To allow individuals to object to the processing of their data if required by law. 
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12. To provide individuals the opportunity to request the deletion or return of their data in certain 
circumstances if this is possible or required by law5. 
13. The obligation to ensure that data are collected from representative sub-populations and not 
confined to one group6. 
14. The obligation to ensure equal treatment across cohorts to: 
14.1. Prevent marginalisation of vulnerable groups; 
14.2. Encourage engagement from vulnerable groups; 
14.3. Display trustworthiness and warrant trust (The South African San Institute, 2017). 
15. The obligation to share data and the benefits of research outcomes fairly and without regard to 
discipline, region or country (UNESCO International Bioethics Committee, 2015). 
16. The obligation to apply legal and ethical practice to all stages of data collection, processing, 
analysis, reporting and sharing. 
17. The obligation for data providers as well as data users to validate and verify the provenance of 
data and ensure appropriate consent or other legal basis for the data’s use. 
18. The obligation to ensure that de-identified or aggregated data made public does not contain data 
elements or rich metadata that could reasonably lead to the identification of specific persons.  
19. To validate that data sharing respects the applicable legal requirements, e.g. conclusion of data 
sharing agreements and/or verifying the legality of a data transfer abroad. 
20. To consider the legitimacy of the further retention and use of data on persons collected during a 
public emergency without informed consent, following the emergency.  
Such obligations are formalised through ethical guidance (UNESCO, 2005; Council of Europe, 1999, 2010; 
NHS, 2013). Especially in times of pandemic, specific attention to vulnerable groups and guidance on 
related global justice issues are to be commanded. 
10.4.3 Seeking Guidance 
In times of pandemic or other public emergencies, it is important to be aware of existing and ad hoc 
resources and guidance. For example: 
1. Researchers attached to an academic institution may find guidance from the following (if available 
at a particular institution): 
1.1. Research Ethics Boards (REBs), such as an Institutional Review Board (IRB) or Research Ethics 
Committee (REC), will provide guidance; in some cases, they will review, require 
modification, approve or stop a research project; 
1.2. The Information Governance Board will provide support on data management; 
 
5 Some EU Member States, for example, allow for data to be held indefinitely when used for scientific and research 
purpose 
6 E.g. the traditional white, Caucasian upper-middle-class male. 
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1.3. The Data Protection Officer will provide support and guidance on data protection issues; 
1.4. Data and Biospecimen Access Committees will advise on sharing or providing access to data, 
as well as Intellectual Property issues; 
1.5. Technology transfer offices provide guidance regarding intellectual property and related 
issues; 
1.6. If such bodies are not available at the researcher's home institution the UN Ethics office or 
national ethics office may be contacted for further support (The United Nations, 2020). 
2. For professionals affiliated to a professional body, the latter will provide guidance on ethical 
research activities. 
3. For medical or other clinical staff, the institution (such as a hospital) will provide research integrity 
support, including ethical approvals required and ad hoc mechanisms to support emergency 
research efforts; or the appropriate governing body (e.g. the National Health Service [NHS] in the 
UK) will provide training and support both ongoing and in exceptional circumstances. 
4. Hospitals, much like academic institutions, are often staffed by a Data Protection Officer, 
personnel specialised in research ethics including REBs, and administrators responsible for 
authorising the sharing of health data. 
Researchers and other professionals should always consult their institutional support personnel as well as 
professional bodies. Often in cases of health emergencies such as the COVID-19 pandemic, fast track 
procedures are put in place, allowing the approval processes to be accelerated without diminishing the 
protection of the rights of persons. 
10.4.4 Anonymisation 
Data will generally be anonymous if they cannot be used to identify a person by all means likely reasonably 
to be used (Article 29 Working Party on Data Protection, 2007, 2014, 2015). It should be noted, however, 
that various jurisdictions define the threshold for anonymity differently (for example, the USA). 
Assessment of all the means reasonably likely to be used must consider not only the data on its own but 
also the possibility of combination with other accessible data, including by third parties.  
The consequence of rendering data anonymous will often be that certain ethical and legal obligations 
which usually apply to identifiable data will no longer apply. In particular, anonymisation will usually 
render data protection law inapplicable. With large datasets, and especially where datasets are cross-
correlated, absolute anonymity will often be very hard to achieve. Researchers may need to take into 
account the possibility of future re-identification, and manage this risk by means of a risk assessment (see 
Phillips et al., 2016). 
In the European Union, for example, anonymous data falls outside the scope of data protection legislation 
(GDPR, 2016). A number of tools are available which claim to anonymise personal data, such as sdcMicro 
(Templ et al., 2020) (See also NHS, 2018). However, there are a number of considerations when dealing 
with data which is said to be anonymous or anonymised. If data are not fully anonymised, then they will 
usually fall within the scope of data protection legislation (GDPR, Recital 26) and so therefore require 
closer controls and management.  For the purposes of this document:  
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1. Anonymised data refers to data where direct and indirect personal identifiers have been removed. 
Anonymised data poses only a minimal risk of individual re-identification, in considering the 
context of the data’s use and the means reasonably likely to be used to perform re-identification.  
2. De-identified7 data refers to data where direct personal identifiers have been removed (e.g. US 
HIPAA). However, there is still some risk that such data may lead to re-identification especially if 
combined with other data. Generally, de-identification refers to the process of reducing data 
identifiability rather than the identifiability of the resulting data (Phillips et al., 2016).  
3. Pseudonymised data refers to data where personal identifiers have been changed or removed 
(i.e., personal names and locations obscured). There is a separate key, index, or technological 
process which links the pseudonymous id code to an individual. The pseudonymisation of data 
will not reduce the data protection obligations in the data but can be a requirement to the lawful 
use of data in some jurisdictions and ethical regimes, where practicable (e.g. GDPR).  
4. Data that Cannot be Re-personalised: Some jurisdictions, such as the EU, recognise a median 
status for data that remains identifiable by law, but that the controller is not able to reidentify 
(GDPR Art. 11). For instance, pseudonymised data that the controller does not hold the 
‘reidentification key’ to. Controllers still need to safeguard such data but have more relaxed 
obligations regarding the rights of the concerned individuals.  
5. Qualitative data are difficult to anonymise because there may be indicators such as the 
combination of a location and an employment type which could make it easier to identify an 
individual or small cohort of individuals. 
6. Data analytics describes a collection of data processing methods which use large amounts of data 
(big data) to derive models and predictions about future behaviours or activity. Data analytics 
introduce some risk of re-identification: 
6.1. Cross-referencing or Cross-correlation: when data are aggregated or correlated with other 
data, then the likelihood of being able to identify an individual, especially an outlier, 
increases; 
6.2. Comorbidities: for clinical data, where multiple conditions may present for an individual, this 
also increases the likelihood of being able to identify that individual. 
7. Statistical Disclosure Control refers to methods used to reduce the risk of re-identification. They 
are encouraged when sharing or publishing data, and when publishing research outcomes 
(Willenborg et al., 2001; Griffiths et al., 2019). 
Our overall Recommendations on Anonymity include: 
Check with your institution, data protection officer or authority, and institutional review board to 
determine  local definitions of the terms (e.g. anonymous, pseudonymised, de-identified etc.) 
1. Check what the local (national) expectations are: a data subject will usually expect their data to 
be processed in compliance with local instruments. 
2. Check with the controller or data user what they claim the status of the data to be (anonymous, 
de-identified, pseudonymised, etc.). Nonetheless, as data identifiability can shift from jurisdiction 
 
7 Sometimes referred to as de-personalised 
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to jurisdiction, and relative to the factual circumstances of its use, it is prudent not to rely on any 
representations made by third parties regarding the identifiability of their data.  
3. Carry out a re-identification risk assessment before 
3.1. Combining one or more datasets 
3.2. Sharing or publishing data, or publishing research findings quoting examples of the data. 
4. In carrying out a re-identification risk assessment8 in regard to the impact on the data subject (the 
individual identified) before disclosure or publication and introduce additional measures 
(Statistical Disclosure Control) to mitigate the risk. The statistical disclosure control methods used, 
and the re-identification risk assessment, should account for privacy risks to groups and 
communities. The potential for sensitive attributes to be revealed absent individual re-
identification should also be accounted for.  
10.4.5 Consent 
Consent is the act by which a participant, patient or data subject indicates that they permit something to 
happen to them, or to their data, which would otherwise not be able to happen. It covers a number of 
different specific contexts: 
1. Clinical: a patient agrees to undergoing a procedure, including taking part in a trial; 
2. Data Protection: a data subject agrees to personal data being processed for specified purposes; 
3. Research: a participant agrees to take part in a research study or experiment. 
In both cases, the informed consent sheets for clinical or research purposes would explicitly set out how 
data protection will be handled, as well as samples or biobanking, rights to self- images and others. 
Giving consent should be informed (e.g. the individual knows what is going to happen and why), freely 
given (there is no coercion or similar motivation), given by somebody with capacity, unambiguous and 
auditable (the consent is recorded somewhere) (See also Parra-Calderón, 2018). Depending on the 
jurisdiction and the research domain, there may be an additional requirement to seek consent. This may 
include a representative community board as well as participants themselves. 
Ideally, consent should be sought for collecting, processing, sharing and publishing data. However, there 
are other legal bases for processing personal data. Some specific examples from the European General 
Data Protection Regulation (GDPR, 2016) are described below. Our recommendation would therefore be 
as follows: 
1. Where possible, use data where the data subject has provided a valid consent that includes or is 
compatible with intended use of the data and complies with the requirements on consent in the 
specific country or region. 
Where these are not possible, there are other reasons why data may be used (see Hallinan, 2020, Ó 
Cathaoir et al., 2020). For example, there may be a different legal basis for using personal data.  
2. If using personal data, check whether there may be another basis for using the data. 
In Europe, for instance, the GDPR provides other legal bases for processing personal data: 
 
8 What would be the impact to the data subject if they were identified from the data you hold. 
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1. Vital Interests (Art. 6(1)(d), and Art. 9(2)(c)): it may not be practical, feasible or possible to contact 
the data subject. However, to protect the vital interests of other natural persons the data needs 
to be interrogated and used. 
In addition, there are other provisions for both personal data: 
2. Public Task (Art. 6(1)(e)). 
and special category data: 
3. Public Interest (Art. 9(2)(g)); 
4. Preventive …Medicine (Art. 9(2)(h)); 
5. Public Health (Art. 9(2)(i)); 
6. Public Interest, Scientific or Historical Research Purposes or Statistical Purposes (Art. 9(2)(j)). 
There is adequate provision, therefore, in the current regulation and its derivatives. In other jurisdictions, 
there may be other provisions which could be used. Their potential applicability in a specific case should 
be carefully examined. 
10.4.6 Licensing Data and Licensing Software  
In releasing data or software for restricted or open use, it is recommended to apply a licence that clarifies 
the permissions inherent in the data or software.  Releasing data or software without an associated licence 
can create uncertainties as to the permissions inherent in the data that may discourage prospective users 
from using the data or software. Further details about software licensing can be found in section 9.5.2. 
For data sharing, it is generally recommended to use an open licence or public dedication to license data 
that is intended for unrestricted public use. 
Choosing the most appropriate licence or similar instrument can be challenging. Certain licences and 
public domain dedications provide no attribution requirements or use limitations. Examples include CC0 
and the Open Data Commons Public Domain Dedication. Other open data licences impose certain 
limitations on data reuse and can require the attribution of data authorship in a standardised format. Such 
licences include CC-BY 4.0., the Linux Community Data License Agreement – Sharing, and the Open Data 
Commons Attribution License. (Bernier et al., 2020). Further documentation to help you choose a data or 
software licence can be found at www.choosealicence.com (Choose a licence, 2020). 
Attribution licences foster accountability on the part of data depositors and can incentivise increased data 
sharing. Using fully open licences or public domain dedications can promote interoperability and ensure 
that data will not be subject to incompatible restrictions or use requirements. Data that are anticipated 
for big data analytic use or use in conjunction with a large number of other datasets, independently 
sourced, may be best served by a fully open licence that imposes no attribution requirement.  
Identifiable personal data and health data can require more restrictive licensing schemes in combination 
with appropriate data governance to best safeguard the ethico-legal privacy rights of the individuals 
concerned by the data. Further, it is a recommended best practice to ensure that the licences applied to 
data are compatible with any contractual or legal obligations of data users, including the obligations 
imposed by research funding agreements or employment contracts.  
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10.4.7 The 5 Safes Model 
The 5 Safes Model was developed by staff working at the Office for National Statistics (UK) to be an easy 
to implement sensitive data management framework (Ritchie, 2008). It has subsequently been adopted 
by numerous Research Data Centres around the World, along with Statistical Disclosure Control (see 
below under Safe Outputs). Research Data Centres using the 5 Safes model will typically provide different 
methods of access to data, including remote-only or controlled, on-site connection. 
The ambition of the 5 Safes Model is to achieve the ‘Safe Use’ of research data by accounting for five 
potential areas of risk to data subject confidentiality. 
Safe People - Who is going to be accessing the data? 
1. Safe People should have the right motivations for accessing research data.  
2. Safe People should also have sufficient experience to work with the data safely.  
3. Researchers may need to undergo specific training before using sensitive or confidential research 
data to become Safe People. 
Safe Projects - What is the purpose of accessing the data? 
1. Safe Projects are those that have a valid research purpose with a defined ‘public benefit’.  
2. It must not be possible to realise this benefit without access to the data. 
Safe Settings - Where will the data be accessed? 
1. Access controls should be proportionate to the level of risk contained with the data.  
2. Sensitive or confidential data should only be accessed via a suitable Safe Setting.  
3. Safe Settings should have safeguards in place to minimise the risk that unauthorised people could 
access the data. 
Safe Data - What does the data contain? 
1. Safe Data will present minimal risk possible to the confidentiality of the data subjects.  
2. The minimisation of risk could be achieved by removing direct identifiers, aggregating values, 
banding variables, or other statistical techniques that make re-identification more difficult. 
However, the loss of detail may limit the usefulness of the dataset. 
3. Sensitive or confidential data should not be considered to be safe because of the residual risk to 
data subject confidentiality.  However, it is often the most useful for research. 
Safe Outputs – What will be produced from the data? 
1. Research that is generated from data may form derived outputs; these could include statistics, 
graphs/charts, or reports.  
2. Outputs generated from the use of sensitive or confidential data should only be released if they 
report statistical findings and cannot be used to reveal the identity of a data subject nor enable 
the association of confidential information to a data subject.  
3. Statistical Disclosure Control (SDC) is often used to minimise the risk of releasing confidential 
information. 
4. Researchers and/or the institution managing the use of the data should check outputs (apply SDC) 
before publication to ensure they do not present undue risk. The intended outputs should have 
formed part of any application for ethical approval. 
 
77 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
10.4.8 Vulnerable Groups  
The overall motivation in producing these guidelines and recommendations has emphasised the open and 
timely sharing of research data. There is an important consideration, however, when dealing with groups 
and not just individual participants. Vulnerable groups may include ethnic minorities like Roma or Sinti, or 
others such as children, migrants or refugees or those with mental or physical disabilities. They often are 
disproportionately affected by unequal access to health and preventative services. As well as the 
Indigenous populations discussed above, such groups should be given additional consideration.  
First of all, these vulnerable groups should be considered for inclusion in research, clinical trials, testing 
and epidemiology surveys with the same opportunities as others; individuals in such groups also have the 
same rights as others to information, access to results where pertinent, and protection of privacy. Specific 
measures to be inclusive of such groups should be put in place.  
This is also true in terms of licensing as well as the collecting, processing and sharing of data (Taylor et al., 
2017, Mental Health Europe, 2020). Although a general recommendation would be to use a permissive 
licence (such as CC 0 mentioned in Section 10.4.6 above), it is important to remember that licences are 
not aimed at protecting the rights and expectations of individuals or groups represented in the data. For 
instance, advanced data analytic techniques may identify previously de-identified individuals themselves 
(Zheng et al., 2011; Bedagkar-Gala et al., 2014), or groupings among individual parties in the dataset which 
they were unaware of  (O’Neil, 2016; see also Boyd et al., 2012). This could lead to stigmatisation and 
marginalisation (van Aasche et al., 2013). Therefore, when choosing a licence or when reviewing the 
ethical implications of sharing data, it is important to consider vulnerable groups and ensure their 
interests are respected. This of necessity includes data which are not typically thought of as personal data. 
For example, identifying rare vegetation or animals associated with an Indigenous group may help 




RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
11. Glossary 
This glossary is intended to aid readers in understanding the meaning of selected terms as they are used 
in this document and does not represent a consensus of CWG on the best definition of each term, nor an 
attempt to necessarily include all, or even the most important, alternative definitions. The definitions 
provided here, instead, are intended to reflect the meanings most relevant to the context of this 
document. 
Term Definition 
Access With regard to research digital resources (i.e. data and software), the continued, 
available for use, ongoing usability of a digital resource, retaining all qualities of 
authenticity, accuracy and functionality deemed to be essential for the purposes the 
digital material was created and/or acquired for. Users who have access can retrieve, 
manipulate, copy, and store copies on a wide range of hard drives and external 
devices (CASRAI). 
Access Controls Given a data object name, access controls define access relationships between the 
following metadata: data object name, user name (or user group, or user role), and 
access permission. The information can be stored as metadata information 
associated with each data object. The information can be generated dynamically by 
applying the access controls of the collection that organises the data objects 
(CASRAI). 
Algorithm In computing, a detailed sequence of steps which, when followed, will accomplish a 
task (Coltness Computing). 
Anonymisation The process of removing personal identifiers, both direct and indirect, that may lead 
to an individual being identified. An individual may be directly identified from their 
name, address, postcode, telephone number, photograph or image, or some other 
unique personal characteristic. An individual may be indirectly identifiable when 
certain information is linked together with other sources of information, including, 
their place of work, job title, salary, their postcode or even the fact that they have a 
particular diagnosis or condition (University College London). 
Anonymised Data Data where direct and indirect personal identifiers have been removed. Anonymised 
data poses only a minimal risk of individual re-identification, in considering the 
context of the data’s use and the means reasonably likely to be used to perform re-
identification.  
Archiving A curation activity that ensures that data are properly selected, stored, and can be 
accessed, and for which logical and physical integrity are maintained over time, 
including security and authenticity. Web archiving follows the same processes to 
capture web-published data for posterity. (revised from CASRAI). 
Assay To perform an examination on a chemical in order to test how pure it is (Cambridge 
Dictionary). 
Big Data An evolving term that describes any voluminous amount of structured, semi-
structured and unstructured data that have the potential to be mined for 
information (CASRAI). 
Biobank A repository that stores biological samples and associated information organised in 
a systematic way for research purposes (revised from ScienceDirect). 
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Case Report The scientific documentation of a single clinical observation which describes and 
analyses the diagnosis and/or the management of one or two patients, with a time-
honoured tradition in medicine and scientific publication (revised from NCBI). 
Citizen Science Citizen science is the practice of public participation and collaboration in scientific 
research to increase scientific knowledge. Through citizen science, people share and 
contribute to data monitoring and collection programmes (National Geographic). 
Clinical Study Any investigation in relation to humans intended: (a) to discover or verify the clinical, 
pharmacological or other pharmacodynamic effects of one or more medicinal 
products; (b) to identify any adverse reactions to one or more medicinal products; 
or (c) to study the absorption, distribution, metabolism and excretion of one or more 
medicinal products; with the objective of ascertaining the safety and/or efficacy of 
those medicinal products (Clinical Trial Regulation N.536/2014) 
Clinical Trial A clinical study which fulfils any of the following conditions: (a) the assignment of 
the subject to a particular therapeutic strategy is decided in advance and does not 
fall within normal clinical practice of the Member State concerned; (b) the decision 
to prescribe the investigational medicinal products is taken together with the 
decision to include the subject in the clinical study; or (c) diagnostic or monitoring 
procedures in addition to normal clinical practice are applied to the subjects (Clinical 
Trial Regulation N.536/2014). WHO designates a clinical trial as follows: ‘any 
research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health 
outcomes’. 
Cloud Computing A large-scale distributed computing paradigm that is driven by economies of scale, 
in which a pool of abstracted, virtualised, dynamically- scalable, managed computing 
power, storage, platforms and services are delivered on demand to external 
customers over the internet (CASRAI). 
Cohort A group that is part of a clinical trial or study and is observed over a period of time 
(National Cancer Institute). 
Community 
Participation 
Involves both theory and practice related to the direct involvement of citizens or 
citizen action groups potentially affected by or interested in a decision or action 
(Springer Link). 
Compassionate Use A treatment option that allows the use of an unauthorised medicine. Under strict 
conditions, products in development can be made available to groups of patients 
who have a disease with no satisfactory authorised therapies and who cannot enter 
clinical trials (European Medicines Agency). 
Compound Library 
(or: Chemical Library) 
A collection of molecules that are synthesised with the aim that they represent a 
given fraction of the theoretically possible chemical compounds that have yet been 
made. Research is focused on both the generation of libraries and on new 
methodology to screen them in the search for new or improved properties (Nature). 
Confidential 
Information 
Any information obtained by a person on the understanding that they will not 
disclose it to others, or obtained in circumstances where it is expected that they will 
not disclose it (CASRAI). 
Confidentiality The duties and practices of people and organisations to ensure that individual's 
personal information only flows from one entity to another according to legislated 
or otherwise broadly accepted norms and policies (CASRAI). 
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Consent The act by which a participant, patient or data subject indicates that they permit 
something to happen to them, or to their data, which would otherwise not be able 
to happen. Information concerning the data collection process is presented to the 
subject or the subject's representative with an opportunity for them to ask 
questions, after which approval is documented. Consent should be informed (e.g. 
the individual knows what is going to happen and why) and freely given (without 
coercion or similar motivation) by someone with capacity, unambiguous and 
auditable (OECD). 
Consent - Clinical A patient agrees to undergoing a procedure, including taking part in a trial. 
Consent - Data 
Protection 
A data subject agrees to personal data being processed for specified purposes. 
Consent - Research A participant agrees to take part in a research study or experiment. 
Contact Tracing The process of monitoring an individual who has been in close contact with a person 
infected with a virus, who is at higher risk of becoming infected themselves or 
potentially further infecting others (WHO). 
Controlled 
Vocabulary 
A list of standardised terminology, words, or phrases, used for indexing or content 
analysis and information retrieval, usually in a defined information domain (CASRAI). 
Copyright A legal right created by the law of a country that grants the creator of an original 
work exclusive rights for its use and distribution. International agreements on 
copyright, such as the Berne Convention, ensure global recognition of national 
copyrights (CASRAI; Wikipedia). 
Cross-cultural Allows comparison of different cultures. 
Cross-morbidities For clinical data, where multiple conditions may present for an individual, this also 
increases the likelihood of being able to identify that individual. 
Cross-national Allows comparison of different countries. 
Cross-referencing or 
Cross-correlation 
When data are aggregated or correlated with other data, then the likelihood of being 
able to identify an individual, especially an outlier increases. 
Data Facts, measurements, recordings, records, or observations about the world collected 
by scientists and others, with a minimum of contextual interpretation (CASRAI). 
Data Analysis A data lifecycle stage that involves the techniques that produce synthesised 
knowledge from organised information (CASRAI). 
Data Analytics Describes a collection of data processing methods which use large amounts of data 
(big data) to derive models and predictions about future behaviours or activity. Data 
analytics introduce some risk of re-identification, such as cross-referencing or cross-
correlation, or comorbidities. 
Data Cleaning The process of preparing data for analysis by removing or modifying data that is 
incorrect, incomplete, irrelevant, duplicated, or improperly formatted. Cleaning is a 
continuous process that requires corrective actions throughout the data lifecycle 
(Sisense; CASRAI). 
Data Completeness The degree to which all required measures are known. Values may be designated as 
“missing” in order not to have empty cells, or missing values may be replaced with 
default or interpolated values. In the case of default or interpolated values, these 
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Data Curation A managed process, throughout the data lifecycle, by which data and data 
collections are cleansed, documented, standardised, formatted and inter-related. 
This includes versioning data, or forming a new collection from several data sources, 
annotating with metadata, adding codes to raw data (CASRAI). 
Data Custodian A data custodian is an IT individual or organisation responsible for the IT 
infrastructure providing and protecting data in conformance with the policies and 
practices prescribed by data governance (CASRAI). 
Data Element A unit of data for which the definition, identification, representation (term used to 
represent it), and permissible values are specified by means of a set of attributes 
(CASRAI). 
Data Imputation The substitution of estimated values for missing or inconsistent data items (fields). 
The substituted values are intended to create a data record that does not fail edits 
(OECD). 
Data Integrity The assurance that information can only be accessed or modified by those 
authorised to do so. In the context of data quality: The assurance the data are clean, 
traceable, and fit for purpose. (CASRAI). 
Data Linkage 
(or: Linkage) 
The process of combining datasets through code. Two methods are probabilistic and 
deterministic matching. 
Data Management The activities of data policies, data planning, data element standardisation, 
information management control, data synchronisation, data sharing, and database 
development, including practices and projects that acquire, control, protect, deliver 




An infrastructure used to provide data management and enforce data management 
policies, including resources such as data management plans, a data repository, an 
information catalogue, devices or hardware, algorithms or software used to store, 
retrieve and process data (revised from CASRAI). 
Data Management 
Plan (DMP) 
A formal statement describing how research data will be managed and documented 
throughout a research project and the terms regarding the subsequent deposit of 
the data with a data repository for long-term management and preservation 
(CASRAI). 
Data Mining The process of analysing multivariate datasets using pattern recognition or other 
knowledge discovery techniques to identify potentially unknown and potentially 
meaningful data content, relationships, classification, or trends (CASRAI). 
Data Model A model that specifies the structure or schema of a dataset. The model provides a 
documented description of the data and thus is an instance of metadata. It is a 
logical, relational data model showing an organised dataset as a collection of tables 
with entity, attributes and relations (CASRAI). 
Data Preprocessing Any type of processing performed on raw data to prepare it for another processing 
procedure. Preprocessing may include: data sampling, data transformation, de-
noising, data normalisation, data standardisation, or feature extraction (CASRAI). 
Data Preservation 
(or: Conservation) 
An activity within archiving and data management in which specific items of data are 
maintained over time so that they can still be accessed and understood through 
changes in technology (CASRAI). 
Data Processing A generic concept referring to all kinds of procedures being executed on data at any 
point in the data life cycle (CASRAI). 
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Data Provenance A type of historical information or metadata about the origin, location or source of 
the data, or the history of the ownership or location of an object or resource 
including digital objects (CASRAI). 
Data Quality The reliability and application efficiency of data. It is a perception or an assessment 
of a dataset’s fitness to serve its purpose in a given context (CASRAI). 
Data Sharing The practice of making data available for reuse. This may be done, for example, by 
depositing the data in a repository, through data publication. (CASRAI). 
Data Sharing 
Agreement 
(or: Data Transfer 
Agreement) 
An inter-institutional or intra-institutional agreement to share data according to 
certain terms and conditions. Data sharing agreements identify the parameters 
which govern the collection, transmission, storage, security, analysis, re-use, 
archiving, and destruction of data (University of Waterloo).  
Data Standard s The requirements, specifications, guidelines or characteristics that can be used for 
the description, interoperability, citation, sharing, publication, or preservation of all 
kinds of digital objects such as datasets, code, algorithms, workflows, software, or 
papers (FAIRsharing). 
Data Steward Manages and oversees an organisation’s data assets to provide data users with high 
quality data that are easily accessible in a consistent manner. While data governance 
generally focuses on high-level policies and procedures, data stewardship focuses on 
tactical coordination and implementation (revised from CASRAI).  
Data that cannot be 
Re-personalised 
Some jurisdictions, such as the EU, recognise a median status for data that remains 
identifiable by law, but that the controller is not able to reidentify (GDPR Art. 11). 
For instance, pseudonymised data that the controller does not hold the 
‘reidentification key’ to. Controllers still need to safeguard such data, but have more 
relaxed obligations regarding the rights of the concerned individuals. 
Dataset Any organised collection of data in a computational format, defined by a theme or 
category that reflects what is being measured/observed/monitored. The 
presentation of the data in the application is enabled through metadata (CASRAI). 
De-identified data Refers to data where personal identifiers have been removed (e.g. US HIPAA). 
However, there is still some risk that such data may lead to re-identification 
especially if combined with other data. Generally, de-identification refers to the 
process of reducing data identifiability rather than the identifiability of the resulting 
data (Phillips & Knoppers, 2016). 






A repository oriented for research output from one or more well defined research 
domains. All researchers working in certain subject areas can make use of 
disciplinary repositories – regardless of their affiliation or geographic location 
(OpenAIRE). 
Embargo In academic publication, the act of submitting data to a repository with the explicit 
requirement that public data access is delayed. 
Encryption The process of converting data to an unrecognisable or "encrypted" form. It is 
commonly used to protect sensitive information so that only authorised parties can 
view it. This includes files and storage devices, as well as data transferred over 
wireless networks and the internet (TechTerms). 
Epidemiology The study (scientific, systematic, and data-driven) of the distribution (frequency, 
pattern) and determinants (causes, risk factors) of health-related states and events 
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(not just diseases) in specified populations (neighbourhood, school, city, state, 
country, global). It is also the application of this study to the control of health 
problems (CDC). 
FAIR Principles A set of guiding principles for scientific data management focused on making data 




Data repository that is domain agnostic and accepts all data formats. 
Genomics The study of all of a person's genes (the genome), including interactions of those 
genes with each other and with the person's environment (National Human Genome 
Research Institute). 
Health Disparities Preventable health differences that are experienced by socially disadvantaged 
groups. 
Indigenous Data Any facts, knowledge, or information about a Native nation and its tribal citizens, 
lands, resources, cultures, and communities. Information ranging from demographic 
profiles, to educational attainment rates, maps of sacred lands, songs, and social 
media activities. Among others. Indigenous data comprise information and 
knowledge about our environments, tribal citizens and community members, and 
our cultures, communities, and interests. The definition encompasses both 
collective and individual level data (Rainie et al., 2017; Nickerson, 2017). 
Indigenous Data 
Governance 
The act of harnessing tribal cultures, values, principles, and mechanisms—
Indigenous ways of knowing and doing—and applying them to the management and 
control of an Indigenous nation’s data ecosystem. It is the decision-making and the 
power to decide how and when Indigenous data are gathered, analysed, accessed 
and used (Rainie et al. 2017; Walter et al. 2018). 
Indigenous Data 
Sovereignty 
The right of Indigenous peoples and tribes to govern the collection, ownership, and 
application of their own data, to maintain, control, protect and develop their cultural 
heritage, traditional knowledge and traditional cultural expressions, as well as their 
right to maintain, control, protect and develop their intellectual property over these 
(Rainie et al., 2017; Kukutai & Taylor, 2016). 
Indigenous 
Knowledge System 
Refers to the systems of understandings, skills and philosophies developed by 
Indigenous societies that informs broad societal functioning and decision-making. 
This knowledge is integral to Indigenous life and encompasses language, cultural 
practices and traditions, systems of classification, resource use practices, social 
interactions, ritual and spirituality (UNESCO). 
Indigenous Peoples Indigenous communities, peoples and nations are those which, having a historical 
continuity with pre-invasion and pre-colonial societies that developed on their 
territories, consider themselves distinct from other sectors of the societies now 
prevailing on those territories, or parts of them. They form at present non-dominant 
sectors of society and are determined to preserve, develop and transmit to future 
generations their ancestral territories, and their ethnic identity, as the basis of their 
continued existence as peoples, in accordance with their own cultural patterns, 
social institutions and legal system (Martínez Cobo, 1982). 
Informed consent Consent given by a patient, data subject and/or participant as a result of being told 
the risks and potential benefits of taking part. 
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Institutional 
Repository 
A repository affiliated with a specific institution. 
Interoperability The ability of data or tools from non-cooperating resources to integrate or work 
together with minimal effort (Wilkinson et al., 2016). 
Intervention/ 
treatment 
A process or action that is the focus of a clinical study. Interventions include drugs, 
medical devices, procedures, vaccines, and other products that are either 
investigational or already available. Interventions can also include non-invasive 
approaches, such as education or modifying diet and exercise (ClinicalTrials.gov). 
Interventional Study 
(Clinical Trial) 
A type of clinical study in which participants are assigned to groups that receive one 
or more intervention/treatment (or no intervention) so that researchers can 
evaluate the effects of the interventions on biomedical or health-related outcomes. 
The assignments are determined by the study's protocol. Participants may receive 
diagnostic, therapeutic, or other types of interventions (ClinicalTrials.gov). 
Legal Interoperability Occurs among two or more datasets when: the legal use conditions are clearly and 
readily determinable for each of the datasets, typically through automated means; 
the legal use conditions imposed on each dataset allow creation and use of 
combined or derivative products; and users may legally access and use each dataset 
without seeking authorisation from data rights holders on a case-by-case basis, 
assuming that the accumulated conditions of use for each and all of the datasets are 
met (RDA-CODATA, 2016). 
Licence An official document that gives permission to own, do, or use a piece of intellectual 
property such as a process, product, data, or software. Commonly used licences for 
open access works include Creative Commons licences. (CASRAI). 
Lipidomics The study of the structure and function of the complete set of lipids (the lipidome) 
produced in a given cell or organism as well as their interactions with other lipids, 
proteins and metabolites. (Nature). 
Memorandum of 
Understanding (MOU) 
A nonbinding written document that states the responsibilities of each party to an 
agreement, before the official contract is drafted (LegalDictionary.com). 
Metabolomics The large-scale study of small molecules, commonly known as metabolites, within 
cells, biofluids, tissues or organisms. Collectively, these small molecules and their 
interactions within a biological system are known as the metabolome (European 
Bioinformatics Institute). 
Metadata Literally, "data about data"; data that defines and describes the characteristics of 
other data, used to improve both business and technical understanding of data and 
data-related processes (CASRAI). 
Metadata Schema  
 
A labelling, tagging or coding system used for recording cataloguing information or 
structuring descriptive records. A metadata schema establishes and defines data 
elements and the rules governing the use of data elements to describe a resource 
(Zhang & Gourley, 2008). 
Metadata Semantics Encompasses controlled vocabularies, taxonomies, thesauri or ontologies and add 
an interpretive/translational layer (beyond any that might be provided by the 
syntax), and enable complex hierarchical grouping and querying of the data 
(FAIRsharing). 
Metadata Standard Metadata schemas adopted by national or international communities, establishing 
a common way of structuring and understanding data, including principles and 
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implementation issues for utilizing the standard. (Clobridge, 2010; University of 
Pittsburgh). 
Metadata Syntax Defines the representation of information from a conceptual model or schema, and 
the transmission format, such as XML, CSV or RDF, which facilitate information 
exchange (FAIRsharing). 
Non-Design Data 
(or: Digital Trace 
Data) 
Refers to data that is collected (often through webscraping) from naturally occurring 
data such as from social network application. 
Observational Study A type of clinical study in which participants are identified as belonging to study 
groups and are assessed for biomedical or health outcomes. Participants may receive 
diagnostic, therapeutic, or other types of interventions, but the investigator does 
not assign participants to a specific intervention/treatment. A patient registry is a 
type of observational study (ClinicalTrials.gov). 
Omics High-throughput data from cell and molecular biology. 
Ontology A vocabulary with hierarchies, meaningful relations among concepts, and their 
constraints that allow classification of data models and data items using the provided 
terms, concepts, and conceptual structures. Ontologies provide a way of expressing 
specific domains in a way that enables interoperability based on semantics and logics 
rather than just formats and agreed metadata (GoFAIR; RDA-CODATA). 
Open Access Making peer reviewed scholarly content freely available via the internet (CASRAI). 
Open Access Journal 
(or: Open Access 
Publishing) 
A journal that makes its articles immediately available online to the reader without 
financial, legal, or technical barriers other than those inseparable from gaining 
access to the internet itself. All the articles in the journal are available open access 
(CASRAI). 
Open Data 
(or: Free Data) 
Data that can be freely used, re-used and redistributed by anyone, subject only, at 
most, to the requirement to attribute and sharealike (Open Data Handbook). 
Open Format 
(or: Open File Format, 
Open Data Format) 
A format with a freely available published specification which places no restrictions, 
monetary or otherwise, upon its use, and can be used and implemented by anyone. 
For example, an open format can be implemented by both proprietary and free and 
open-source software, using the typical software licences used by each (revised from 
Open Definition; Wikipedia). 
Open Government A governing culture that holds that the public has the right to access the documents 
and proceedings of government to allow for greater openness, accountability, and 
engagement (CASRAI). 
Open Science The practice of science in such a way that others can collaborate and contribute, 
where research data, lab notes and other research processes are freely available, 
under terms that enable reuse, redistribution and reproduction of the research and 
its underlying data and method (FOSTER). 
Open Source Referring primarily to software, open source products include permission to use the 
source code, design documents, or content of the product. Distribution terms of 
open-source software should allow free redistribution, modifications, and derived 
works, include the source code, and not be restricted by specific product, software 
or technology (revised from Open Source Initiative). 
Patient Registry A type of observational study that collects information about patients' medical 
conditions and/or treatments to better understand how a condition or treatment 
affects patients in the real world (ClinicalTrials.gov). 
 
86 
RDA COVID-19 Recommendations and Guidelines on Data Sharing, 30 June 2020 
Persistent Identifier 
(PID) 
A long-lasting reference to a digital object that gives information about that object 
regardless what happens to it. Developed to address “link rot,” a persistent identifier 
can be resolved to provide an appropriate representation of an object whether that 




Any information that can be used to distinguish or trace an individual’s identity, such 
as name, social security number, date and place of birth, mother’s maiden name, or 
biometric records; and any other information that is linked or linkable to an 
individual, such as medical, educational, financial, and employment information 
(University of Pittsburgh). 
Portability In computing, the ability of a programme to run on different machine architectures 
with different operating systems (Coltness Computing). 
Preprint Publishing Preliminary version of an article that has not undergone review but that may be 
shared for comment. Preprints may be considered as grey literature (CASRAI). 
Primary Data Data that have been created or collected first hand to answer specific research 
questions (Data Tree). 
Privacy The ability of an individual or group to seclude themselves or information about 
themselves, and thereby express themselves selectively, the right to be let alone, or 
freedom from interference or intrusion. Information privacy is the right to have 
some control over how personal information is collected and used (Wikipedia; IAPP). 
Proprietary Format A file format that a company owns and controls. Data in this format may need 
proprietary software to be read reliably. Unlike an open format, the description of 
the format may be confidential or unpublished, and can be changed by the company 
at any time. Proprietary software usually reads and saves data in its own proprietary 
format (Open Data Handbook). 
Protected Health 
Information (PHI) 
Under the U.S.'s Health Insurance and Portability and Accountability Act (HIPAA), 
protected health information (PHI) is considered to be individually identifiable 
information relating to the past, present, or future health status of an individual that 
is created, collected, or transmitted, or maintained by a HIPAA-covered entity in 
relation to the provision of healthcare, payment for healthcare services, or use in 
healthcare operations. This information is often sought out for de-identification in 
research publication (HIPAA Journal). 
Proteomics Proteomics refers to the study of proteomes, but is also used to describe the 
techniques used to determine the entire set of proteins of an organism or system, 
such as protein purification and mass spectrometry (Nature). 
Protocol The written description of a clinical study. It includes the study's objectives, design, 
and methods. It may also include relevant scientific background and statistical 
information (ClinicalTrials.gov). 
Pseudonymisation The processing of personal data in such a way that the data can no longer be 
attributed to a specific data subject without the use of additional information, as 
long as such additional information is kept separately and subject to technical and 
organisational measures to ensure non-attribution to an identified or identifiable 
individual (GDPR, Article 4(3b)). 
Pseudonymised Data Data where personal identifiers have been changed or removed (i.e., personal 
names and locations obscured). There is a separate key, index, or technological 
process which links the pseudonymous id code to an individual. The 
pseudonymisation of data will not reduce the data protection obligations in the data 
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but can be a requirement to the lawful use of data in some jurisdictions and ethical 
regimes, where practicable (e.g. GDPR).  
Public Health 
Surveillance 
An ongoing, systematic collection, analysis and interpretation of health-related data 
essential to the planning, implementation, and evaluation of public health practice 
(WHO). 
Quality Control (QC) The operational techniques and activities used in quality management to fulfil 
requirements for quality (American Society for Quality). 
Raw Data Data that have not been processed for meaningful use. Although raw data have the 
potential to become “information,” they require selective extraction, organisation, 
and sometimes analysis and formatting for presentation. As a result of processing, 
raw data sometimes end up in a database, which enables the data to become 
accessible for further processing and analysis in a number of different ways (CASRAI). 
README File Along with a repository licence, contribution guidelines, and a code of conduct, helps 
communicate expectations for and manage contributions to a project, typically 
including information on what the project does, why it is useful, how users can get 
started, where users can get help, and who maintains and contributes to the project 
(GitHub). 
Regulatory Body An organisation appointed by the government to establish national standards for 
qualifications and to ensure consistent compliance with them (NHS). 
Remote Access Ability for an authorised person to access data on a computer or a network from a 
geographical distance through a network connection. 
Repository A digital archive collecting and displaying datasets and their metadata. A lot of data 
repositories also accept publications, and allow linking these publications to the 




Published results that can be replicated using the documented data, code, and 
methods employed by the author or provider without the need for any additional 
information or needing to communicate with the author or provider. This can also 
apply to software and software code (CASRAI). 
Research Data Refers to information, in particular facts or numbers, collected to be examined and 
considered as a basis for reasoning, discussion, or calculation (European 
Commission).  
Secondary Data Existing data which are being reused for a purpose other than the one for which it 
was collected (Data Tree). 
Selection Bias A sample that is not representative of the population. 
Self-Determination All peoples have the rights of self-determination. By virtue of that right, they freely 
determine their political status and freely pursue their economic, social and cultural 
development (Charter of the United Nations; International Covenant on Civil and 
Political Rights; International Covenant on Economic, Social and Cultural Rights, 
Article 1, para. 1). 
Sensitive Data Data that must be protected against unwanted disclosure. Access to sensitive data 
should be safeguarded. Protection of sensitive data may be required for legal or 




Personal data revealing racial or ethnic origin, political opinions, religious or 
philosophical beliefs; trade-union  membership; genetic data, biometric data 
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(or: Special Category 
Personal Data) 
processed solely to identify a human being; health-related data; data concerning a 
person’s sex life or sexual orientation (GDPR Article 4(13), (14) and (15), Article 9). 
Social Science Research on human society and social relationships. 
Software A set of instructions, data or programmes used to operate computers and execute 
specific tasks. Opposite of hardware, which describes the physical aspects of a 
computer, software is a generic term used to refer to applications, scripts and 
programmes that run on a device. Software can be thought of as the variable part of 
a computer, and hardware the invariable part (TechTarget). 
Source Code 
(or: Software Code) 
The version of software as it is originally written (i.e., typed into a computer) by a 




Refers to methods used to reduce the risk of re-identification. They are encouraged 
when sharing or publishing data, and when publishing research outcomes 
(Willenborg & de Waal, 2001; Griffiths et al., 2019). 
Structural Biology The study of the molecular structure and dynamics of biological macromolecules, 
particularly proteins and nucleic acids, and how alterations in their structures affect 
their function. Structural biology incorporates the principles of molecular biology, 
biochemistry and biophysics (Nature). 
Structured Data Data whose elements have been organised into a consistent format and data 
structure within a defined data model such that the elements can be easily 
addressed, organised and accessed in various combinations to make better use of 
the information, such as in a relational database (CASRAI).  
Transcriptomics The study of the transcriptome—the complete set of RNA transcripts that are 
produced by the genome, under specific circumstances or in a specific cell—using 
high-throughput methods, such as microarray analysis (Nature). 
Trustworthy Data 
Repository (TDR) 
(or: Trusted Data 
Repository) 
A data repository that has been certified, subject to rigorous governance, and 
committed to longer-term preservation of data holdings. 
Version Control 
(or: Versioning) 
System for documenting changes made to files that enable earlier versions to be 
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12. Acronyms 
AAS The African Academy of Sciences 
AAS American Astronomical Society 
ACE2 Angiotensin-Converting Enzyme-2 
AI Artificial Intelligence 
AIPP Asia Indigenous Peoples Pact 
AIRR Adaptive Immune Receptor Repertoire 
AIRR-seq Adaptive Immune Receptor Repertoire Sequencing 
ALLEA European Federation of Academies of Science and Humanities 
ANDI-MS The Analytical Data Interchange Format for Mass Spectrometry 
ANSI American National Standards Institute 
ASTM American Society for Testing and Materials 
BBMRI-ERIC Biobanking and Biomolecular Resources Research Infrastructure under the European 
Research Infrastructure Consortium 
BMIC Trans-National Health Institute BioMedical Informatics Coordinating Committee 
BMRB Biological Nuclear Magnetic Resonance Data Bank 
CARE Collective Benefit, Authority to Control, Responsibility, Ethics (Principles for Indigenous 
Data Governance) 
CBF Crystallographic Binary File 
CBF/imgCIF Crystallographic Binary File, Crystallographic Information File image 
CC-BY Creative Commons By Attribution license 
CC0 Creative Commons Universal Public Domain Dedication 
CDC Centers for Disease Control and Prevention 
CDISC Clinical Data Interchange Standards Consortium 
CDM Common Data Model 
CERN European Organisation for Nuclear Research 
CESSDA Consortium of European Social Sciences Data Archives 
ChEBI Chemical Entities of Biological Interest 
CIMR Core Information for Metabolomics Reporting 
COAR Confederation of Open Access Repositories 
CODATA Committee on Data of the International Science Council 
COMEST World Commission on the Ethics of Scientific Knowledge and Technology 
COVID-19 Coronavirus disease 
CRF Case Report Form 
CSEWG Cross-Section Evaluation Working Group 
CSV Comma-Separated Values 
CT Computed Tomography scan 
CWG Research Data Alliance COVID-19 Working Group 
CyTOF Mass Cytometry by Time of Flight 
DAA Data Access Agreement 
dbGaP Database of Genotypes and Phenotypes 
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DC Dublin Core 
DCAT Data Catalog Vocabulary 
DCC Digital Curation Centre 
DCMI Dublin Core Metadata Initiative 
DDBJ DNA Data Bank of Japan 
DDI Data Documentation Initiative 
DICOM Digital Imaging and Communications in Medicine 
DMP Data Management Plan 
DOI Digital Object Identifier 
DORA Declaration on Research Assessment 
DP-3T Decentralized Privacy-Preserving Proximity Tracing 
DR2 Disaster Research Response 
DRA DNA Data Bank of Japan Sequence Read Archive 
DSA-WDS Data Seal of Approval World Data System 
EBI European Bioinformatics Institute 
EBOV Zaire Ebolavirus 
ECDC European Centre for Disease Prevention and Control 
ECRIN European Clinical Research Infrastructure Network 
EDPB European Data Protection Board 
EGA European Genome-Phenome Archive 
EHR Electronic Health Records 
ELISA Enzyme-Linked Immunosorbent Assay 
ELSST European Language Social Science Thesaurus 
EMBL European Molecular Biology Laboratory 
EMBL-EBI European Bioinformatics Institute of the European Molecular Biology Laboratory 
EMDB Electron Microscopy Data Bank 
EMDR Electron Microscopy Data Resource 
ENA European Nucleotide Archive 
ENDF Evaluated Nuclear Data File 
Epi-TRAC EPIdemiological Transnational Research Action Coalition 
Epi-TRACS EPIdemiological Translational Research Action Coordination System  
Epi-WIN World Health Organization's Information Network for Epidemics 
ESIP Earth Science Information Partnership 
EU European Union 
FACS Fluorescence-Activated Cell Sorting (registered trademark of BD Biosciences) 
FAIR Findable, Accessible, Interoperable, and Reusable 
FC Flow Cytometry (See also: FACS) 
FDA United States Food and Drug Administration 
FHIR Fast Healthcare Interoperability Resources 
FID File Investigator Database format 
FID Free Induction Decay 
FIPS Federal Information Processing Standards 
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FNIGC First Nations Information Governance Centre 
GA4GH Global Alliance for Genomics and Health 
GDPR General Data Protection Regulation 
gelML Gel Electrophoresis Markup Language 
GESIS Leibniz Institute for the Social Sciences (Gesellschaft Sozialwissenschaftlicher 
Infrastruktureinrichtungen) 
GHDDI Global Health Drug Discovery Institute of China 
GHDx Global Health Data Exchange 
GIDA Global Indigenous Data Alliance 
GISRS World Health Organization's Global Influenza Surveillance Response System 
GLOPID Global Research Collaboration for Infectious Disease Preparedness 
GO Gene Ontology annotation 
GOARN Global Outbreak Alert and Response Network 
GWAS Genome-Wide Association Study 
HASSET Humanities and Social Science Electronic Thesaurus 
HDX Humanitarian Data Exchange 
HIPC Human Immunology Project Consortium 
HL7 Health Level 7 
HL7 FHIR Health Level 7 Fast Healthcare Interoperability Resources 
HLA Human Leukocyte Antigen 
HTML HyperText Markup Language 
HUPO The Human Proteome Organization 
IBC International Bioethics Committee 
ICD International Classification of Diseases 
ICPSR Inter-university Consortium for Political and Social Research 
ICU Intensive Care Unit 
IG Interest Group 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IHME Institute for Health Metrics and Evaluation 
imgCIF Crystallographic Information File image 
InChI International Union of Pure and Applied Chemistry International Chemical Identifier 
InChIKey Fixed-length format derived from the International Chemical Identifier 
INSDC International Nucleotide Sequence Database Collaboration 
INSEAD Institut Européen d'Administration des Affaires (European Institute of Business 
Administration) 
iProX Integrated Proteome Resources 
IRB Institutional Review Board 
ISA Investigation/Study/Assay 
ISA-TAB Investigation Study Assay Tabular 
ISARIC International Severe Acute Respiratory and Emerging Infection Consortium 
ISO International Organization for Standardization 
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ISO/TS International Organization for Standardization Technical Specification 
IT Information Technology 
IUPAC International Union of Pure and Applied Chemistry 
JEFF Joint Evaluated Fission and Fusion File 
JEFF of 
OECD/NEA 
Joint Evaluated Fission and Fusion File of the Organisation for Economic Co-operation and 
Development/Nuclear Energy Agency 
JGA Japanese Genotype-phenotype Archive 
JOSS Journal of Open Source Software 
jPOST Japan Proteome Standard Repository/Database 
JSON-LD JavaScript Object Notation for Linked Data 
LC-MS Liquid Chromatography - Mass Spectrometry 
LMIC Low- and Middle-Income Countries 
LOINC Logical Observation Identifiers Names and Codes 
MAGE-TAB MicroArray Gene Expression Tabular format 
MassIVE Mass Spectrometry Interactive Virtual Environment 
MBAA Multiplex Bead Array Assay 
MD Molecular Dynamics 
MERS Middle East Respiratory Syndrome 
MiAIRR Minimal Information about Adaptive Immune Receptor Repertoires 
MIAME Minimum Information About a Microarray Experiment 
MIAPA Minimum Information About a Phylogenetic Analysis 
MIAPE Minimum Information About a Proteomics Experiment 
MINSEQE Minimum Information about a Next-generation Sequencing Experiment 
MIxS Minimum Information about any (x) Sequence 
mmCIF Macromolecular Crystallographic Information File 
MolSSI The Molecular Sciences Software Institute 
MOU Memorandum of Understanding 
MRI Magnetic Resonance Imaging 
MS-DIAL Mass Spectrometry universal program for Untargeted Metabolomics 
MSPepSearch Mass Spectrometry Proteomics and Metabolomics program 
mzIdentML Protein Identification Data Markup Language 
mzML Mass Spectrometer Output Markup Language 
mzQuantML Protein Quantization Data Markup Language 
mzTab Tab-delimited file format for Mass Spectrometer-Derived Omics Data 
NCBI National Center for Biotechnology Information 
NCBI SRA National Center for Biotechnology Information's Sequence Read Archive 
NEA Nuclear Energy Agency 
NHS National Health Service 
NIH National Institutes of Health 
NIHR National Institute for Health Research 
NMR Nuclear Magnetic Resonance 
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NMR-STAR Nuclear Magnetic Resonance Spectroscopy Self-defining Text Archival and Retrieval 
Format 
nmrCV Nuclear Magnetic Resonance Controlled Vocabulary 
nmrML Nuclear Magnetic Resonance Spectroscopy Markup Language 
NSW New South Wales 
NUTS Nomenclature of Territorial Units for Statistics 
OECD Organisation for Economic Co-operation and Development 
OGP Open Government Partnership 
OMOP Observational Medical Outcomes Partnership 
OPIDoR Optimiser le Partage et l’Interopérabilité des Données de la Recherche 
PASSEL PeptideAtlas Selected Reaction Monitoring Experiment Library 
PDB Protein Data Bank 
PDBe Protein Data Bank in Europe 
PDBe-KB Protein Data Bank in Europe - Knowledge Base 
PDBj Protein Data Bank Japan 
PGD Plan de Gestión de Datos 
PHI Protected Health Information 
PID Persistent Identifier 
PII Personally Identifiable Information 
PPI Public and Patient Involvement 
PRIDE Proteomics Identifications Database 
PSI Proteomics Standards Initiative 
PSI CV Proteomics Standards Initiative Controlled Vocabulary 
PTAB Primary Trustworthy Digital Repository Authorisation Body 
PUI Persons Under Investigation 
QC Quality Control 
QuDEx Qualitative Data Exchange Schema 
RCCE Risk Communication and Community Engagement 
RCSB PDB Research Collaboratory for Structural Bioinformatics Protein Data Bank 
RDA Research Data Alliance 
RDF Resource Description Framework 
REB Research Ethics Board 
REC Research Ethics Committee 
ReFRAME Repurposing, Focused Rescue, and Accelerated Medchem compound library 
SAPRIN South African Population Research Infrastructure 
SARS Severe Acute Respiratory Syndrome 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2  
SDC Statistical Disclosure Control 
SDMX Statistical Data and Metadata eXchange 
SER Serialised/Serial Spectra file 
SHARC Research Data Alliance Sharing Rewards and Credit Interest Group 
SMILES Simplified Molecular-Input Line-Entry System 
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SNOMED CT Systematized Nomenclature of Medicine - Clinical Terms 
SPIRIT Standard Protocol Items: Recommendations for Interventional Trials 
SRA Sequence Read Archive  
TDR Trustworthy Data Repository 
TESSy The European Surveillance System 
TPM Transcripts Per Million 
TraML Targeted Mass Spectrometry Method Markup Language 
TRUST Transparency, Responsibility, User focus, Sustainability, Technology Principles for digital 
repositories 
TSV Tab-Separated Values 
UKDA United Kingdom Data Archive 
UMLS Unified Medical Language System 
UN United Nations 
UNDRIP United Nations Declaration on the Rights of Indigenous Peoples 
UNESCO The United Nations Educational, Scientific and Cultural Organization 
UniProt Universal Protein Resource 
URL Uniform Resource Locator 
US HIPAA United States Health Insurance Portability and Accountability Act 
US or USA United States of America 
VGAS Viral Genome Annotation System 
W4M Workflow for Metabolomics 
WG Working Group 
WHO World Health Organization 
wwPDB Worldwide Protein Data Bank 
XML eXtensible Markup Language 
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13. Additional Resources 
General resources on Covid-19 
Description of the resource  Link to the resource 
COVID-19 Data Portal brings together 
relevant datasets submitted to EMBL-EBI 
and other major centres for biomedical 
data.  
http://www.covid19dataportal.org/ 
OpenAIRE COVID-19 Gateway https://beta.covid-19.openaire.eu/ 
LitCovid curated literature hub the 2019 
novel Coronavirus providing central access 
to relevant articles in PubMed 
https://www.ncbi.nlm.nih.gov/research/coronavirus/ 
 
Resources on data sharing in clinical medicine 
Description of the resource  Link to the resource 
Database of publicly and privately funded 





















Trans-NIH BioMedical Informatics 
Coordinating Committee (BMIC) 
https://www.nlm.nih.gov/NIHbmic/index.html 
Open-Access Data and Computational 
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https://www.egi.eu/egi-call-for-covid-19-research-
projects/ 
Research on “Sharing and reuse of 
individual participant data from clinical 
trials: principles and recommendations” 
https://bmjopen.bmj.com/content/7/12/e018647 
https://vivli.org/ 
CDISC Interim User Guide for COVID-19 https://wiki.cdisc.org/display/COVID19/CDISC+Interim+Us
er+Guide+for+COVID-19 
International COVID-19 Clinical Trials Map 
(based on the WHO Clinical Trials Search 
Portal) 
https://covid-19.heigit.org/clinical_trials.html 
ISO/TS 17975:2015: https://www.iso.org/standard/61186.html 





































Standardisation of clinical trials and 
evidence-based approach to clinical 


















































Resources on data sharing in omics practices 
Description of the resource  Link to the resource 
RDA COVID-19 Omics group https://www.rd-alliance.org/groups/rda-covid19-omics 
 
Resources on data sharing in epidemiology 
Description of the resource  Link to the resource 
RDA COVID-19 Epidemiology group https://www.rd-alliance.org/groups/rda-covid19-
epidemiology 
RDA COVID-19 detailed Epidemiology 
supporting document  
https://doi.org/10.15497/rda00049 
 
Resources on data sharing in social sciences 
Description of the resource  Link to the resource 
RDA COVID-19 Social Sciences group https://www.rd-alliance.org/groups/rda-covid19-social-
sciences 





Best Practices for measuring the social, 
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Social Psychological Measurements of 
COVID-19: Coronavirus Perceived Threat, 




Resources on community participation and data sharing 
Description of the resource  Link to the resource 









RDA COVID-19 WG 





Resources on research software and data sharing 
Description of the resource  Link to the resource 
RDA COVID-19 Software group https://www.rd-alliance.org/groups/rda-covid19-
software 
 
Resources on legal and ethical compliance 
Description of the resource  Link to the resource 
RDA COVID-19 Legal and Ethical group https://www.rd-alliance.org/groups/rda-covid19-legal-
ethical 
Global Alliance for Genomics and Health - 
Responsible Data Sharing to Respond to 
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